ࡱ>  ! `n ;枚"pD0PNG  IHDRXdsTsRGB pHYs . _IDATx^]XUMiIA;;PQ[P$zQ.)9w/wμ5444UՁ#F@@@@@!8Bs O#8z#         ~d#D>4#<@]]}wwmD_D 0G8Ԑ6@nn==##ïܶm/dTTTf~ݻwccMI#s٩kA4 @tr???\/ٵ+VNN蘘QQSϹ8vt,ts$#%a`衚/// ;;kG* ::ڄJOUDDD?QQQ :;Šꢡ `ggyƩTPPۃfRRK]]784DAA cyuC}=//ED}|Ha^888rsϟ!"E\s6 l^,624bbfy[<|UVsrrܑ! }+qHAWÐ AA`Z (U:; QFՍ Ͷv9>}i  C""&6.>:""""3oAcIXwvttbn6C~DyD>$ÞGf rr_{A 1#H/Bw &ڪ|X[ۿ.(jsBf 07@Vsc+~Ȋ7t 07@ܘ ߄HspnboE#5-#33sQCCCW@Lo@M]d/vur2B d/Y0n|o9@!w/A޼i\ /Tܻ5^&ڞ `Nm-ݝ*RbY9yyW\^0485Iw[*Hȅ 0 "Ʀf /Z"I !o`8ZQJpQӃ/Y  {[أ:WWt~XܺyM檽]Б.#oJ)iKJҌiIRR"9%7vBw M$xqϞDs9 #b3V r+V, ۶ ]]L Q,,,\\@0oh<@ِy9Q@0)@ z{2+prsx;hȈS{]UMLoRRRXdA"|EZqq_|LlLGKkŋ̼o0uU+ ={'ۻw@闕 Jnܼxo1tv@V3oCy%45u8aNN}m 0.)fN.$ zxrBM[ /2cBI j]k1 ݡ[by4MUA!]][W L.YDM]#==&rrr*xĸGOL9HpEַԶ2%wYF7@~MKM ^ꩳkYA[r \_<~, g8Hd #ֆߜ2jK-gΜbgg매iij@;BfΚ␐3g^8#"&HMMyMUUMffgϲ2$-#B:viQqppi`+-ih }t}A"AG9CjZjJRb{sSqY[s-)IGO4uuqQ1{`S-eE6XnN8t-`aa^R?!!¥K{vRTT|!AHH{999 %EgΞRϻmlhoblÀ+!/xyD\"755w7])))6r|ŕ/^޹o-5 ^`xw\z RWEɫkm{ $Fp UT$$ԕY>WMLoOorZ-Q2=l鵵@nKK+ՠ%!bGO53gW76߸IYAow$ \aiqDKF\уlL6s Y8pT -Xf` zˉ鯂-SH+aQ uvCCaj5uۛ75u3o+((&5FBBttP~LYUՅDF)*ؘ2=~~k֭ClXSUVBID;Mv7-dea_)(!+O221[s63th@=@sKɺOgOJAN9 ^-,)B>躀"f߄Hӄ$[lDͽ@NYedTduuՊ+áI) ۺ{Z[[5kjk|>x&|~dODL(*!]_[KH@HH)|,4t9-=9*S6+-Y)!m\ f`a㈋-TPjik`aEIn࣪ "$ ,,4M j0BqA`ȼ@op(6,XFIYk)1*䡽‰cF2#a?/5!VIs[g***L_ڨh-Z(! \c2 ,63޼z5p/2RSYS'#5Ob= 13So=pXA]KRD8.sKmͮm55 I%#+Tcc:²* ]=ddee/UYbRCuBB?恁LQyˇIȄ%.'"$aHEA1q 2hfh\1Qnf6KHMquuuylݦ%zK@ z@W VswCFHu⅝GjUmy={w!G@#0q?x$))# ,7\uM*p.j|>O>& -#UM-3II)&ޟ(()Ƞ9#o{bcK绷n ;f 308whijpu 6%.vwJ fFaqኊi 01G81鹀dzEDDH B8 {/)/iil*JW%#%;{{84=>twwUWzNG2#e&5 2y >ba`f!] PX^^v\aEAAD߈M=3|SPSqE>7-WpBHI(-&F #6  [CkwWZA 58Ɩ򲜜f)z.=[߂KW(0RqM$PGCE ٝ,yx8H!j:Z;Zѕ QDI}1"v7c pp9ϝ~_;#X1֯pKl,^&:r"B[;ܼcA.6dDܱQR111Qai9MM,ؘٹyxEE 6E|Z\RFkUuMhE+v㹃oځWnmocsÞ5>2|>'%ݝ_ AA`@C()[VZq x)Rb"`Q> ޵q|-D89ط6ƵKJAr\:丸{7W6bts^7 5ftIpx*޵u8w_gWW{ik}nپ `cGIFMG>g bD/?5ON9hXr /Rk&ǃ󹞾ާOvvAAt$=&|)w.[zb#$pxG<=}ՉK?=.>Q~|RW5cKD% ~P^~ 5kסdPlBh3ꛚt,_8yؘHhYl9usziKm9$_u "B}Cntpr|=ۅ%%Wӣž]8 'y{f_G{[ldBI2b^QOM8 XXx QiLL޽E x-52x[֖pں>mkh^qsoᦕVGR2Ps_x G(vCKkTjGnRRP(hhI((/X ,((0j#.8?V ?[? !5s8܌Rt Tt]}iqDsml/,jsbU@ s "|[s ZՋJH=}pS.ޔDyo.dD!rFo7ꍛ.6HKK ihU fd;$|h7n.!#)7SZݹЇC2U580ٴV_|*e_[XJoάkWA)i2J^?~ghBEE w^>{Ҵa6 2rᭋӶlQuŇ k.M!b1\EYՙA/v/^dfrQ! )4,)"LT_BjJM-7SS\ rɉ}X8Dߙlmiٻa}VE .<ۃ] L?s' 8!)%'(9-'蘸Ԕ>^^M7mKB/p@=Лc ~Bw5zxOH\bx,7,D>pDTUյl#ZeaboBh(:c{>Q~]o//syY)Ұ碘}䂅O.8ub=k-Z[wE;:$Pν]d*:ˏ@ NSR$ˈX]cK{{CKKwoo_?ؑ=,1S@#zIGON6ڑۆP˾^`SHŃaU7AȊ!96ꪗx757A&6Fax>co,WSR/.߶={!~L pf7nxddGG:OY;1|RXQSg?Ǐ|<464 k.k&A`N#89==qhFcܾu l?rq_{@J~U11 _WO%eJbz+4ݺ+"#*`o|fu64ЇT|w:`ŋY# pS\LiLU4ٙ uG;q`ϊeKX9èRr5@@b";⨩ $Blڶ mn8xX&v  lz 1q5- f`X<9py͏_*po^_gQWSk` ¡9ѿBhZv6 H7l\eWG^ܱצ&'f75yw7߅KG*X=4d$DD4E %]WYa٫}=OSk ){$(8S^/DUomз0[<< J*Ύ,l 07 }}wh/ccyпBب/?f9;̫ϭ++mdccSCts^nn=5ܢԿta!6Hl#792h));{Fj_sG=}ie8-KURILI).*FB:.-"oU>'7;Tݺc646+++7@Eyޒ?1 {6~2Rϟ^}'ĻDG~JʪJ(=KHH2(G6N`~ot$r ]016H+ y@ୋkMbm2HɾqGFcܾv (6;L 11D$$8$=4$4 w><2l|qqU)(( iW^5 [XfMWRU)$l9x2psO?NJe`U^srs>cGD#ܤ[@DtG/h7LEFLHhnlgLb%Fqs{~@З/iekuG|6~hl}~m;2kCSv4@ UfUU$$Č4,Ɔ _f(>\YglX0312JZ p/9~8(** Eefevcټud)B(( xxhC*Q.bap 46v0)k/RWf\oj8BA`Z@(q&[,5(341޽mXc>*9$uuܴTTTBP $Foܱ*?z~%9 h{ ;}ģ{wl*ۺ j?ׯ{%#'[ ')pM*JAJ.&!.>'1^PTDHT8Ǐoۂ8! ߘ?c @`c{טڿw="c 467?{t_P\ vd‚FR Jڷw7ݷDx T۴eWHIIBBBc h.@VZZ~-[[H?eu[PdhO b"drb{jkkLNbfaYoj{;*?~?HLhokwp\ %@I3G12C810D%J[zzcB|<܉iXP` ! ߲+זS8vSMJ!!)(*9~E>9v;8ښKDJuC;I6)QPvS[\\Rh0[iiS?yuUDAA@!13VOc ~OVA)!&3;/) ɨmRZ/($*&!.+-'W旚ꪨ'O.)1̩8fV/x`uX^RRVQr2 ln,%/޼}[ZF""2hBKgg2R&FtvrplJwQT ڲq ƌ"V"G8g1PQQrg/d pp<oh/ϫ(' !nD*ZZ{p$dR _ _B|HH᭏^dUWyedX(73Ha$oܸ]\񚊒vi.V昘Dey<|6<|ҕ\܍Mihhؿe(sgUSg! LN4oC -= M ;uhh3p ⼜rRD'&2n>77xDRRR=Ύ-7mvm]u +1!6vV{dab OOK716m{ѓg))u|-/ʪ(5-3<*.33_TTXEINDXiTaVVh_ zMYI:rh22糰eGJl*#xy`>?kL_.!̻@$fda)gg`f_ gŷ8blًN]|ӵvݿ}UHˣP^U}  JX䬲ENFfaS]@? W5Ct+&.)s~FFW,DyJpCյU4^~e?3L_ej;PZ30mf_vg|WP}*G5G=^EdXjUַvuʨ0˟ -6rQ%3596(069u󦍸67׬[_YQq۶XI=+/}yCc3,9Xn 2zu~ڍȨز*-VE$B"|8[Z+*OΝ;<$'[49tG 9+-*颧sjvȨN>3l잞׭! ʜ>s- ʜ={im}+#=x{'O>||7o_osx=%-ܽ{_FFn۶_/\rъ*xk}}GP2C] w!;I.=+' z1) #V:,\̼La܆>v6T7zvv/>سko:y$NTXxAhP!qNNDD;rϞ-/-@!l޼~rβJJ @@HqtrMLHQPS^ @DI >\@Dt,I";Μ:==#8,2 vAAkGTUYW>>߹LSS#&#c">|E&r҇/]چE@q퓓ۿOZZCۤ斨H/OlgǍ@9C,z{zJIH[88(iq2Sb[kkXHHiQQ_Ow| 6CXMfrBK}BYy t:I^lȰGwnWm;\O>~)Ue.kPU iBLD9} IȖ.գOMI6_gY55 y: pJv36m-Rd$Pp1(]pn^&'IMCieeVWU]WUi0$#23[y#ѱ oaYP˖-1_ZFF6зBTٳg!JFVAKSƍ[yy9KKΟ; p]Ww|ܒR1я?qww'&!~==3e< .]r7o_9 5EֆPϴ@/?7~^EaaY9DDT-G[03=$`׾(;By"b jXY5u2bbjwhavjx #[be-ۉQTnjfb#G^>kuܺx|'SSӎ>\PTkj:Ud" D`'DH&!70X6 ~\HJJwiݽoނjjϞ= [bELLQTR*W[wPQQ~}s9(B FhEɗ_!F muuvzzz~ d6 h\X-P>|1wR3#̶-ĉ(H׍XII>e%I)i}頉~vFZ<..vNK.} '!"&RR?q쵫w‘;M=]4T}seK3H_7Ȁ~@`wpnD䚓WЬyβui!}尶=k^/Q񄼂B~[6m@njnPՉ' tC/߳[M^6!:g޽7l:; .[GJL>^^piiᑕ:RR]D>3g[D\AY/,|.2CDp7Ϟ>~[zXw Ә@J[KG(s6mų1QQ2qR}}=Ee`\k("",,"TVX[~@; 3渝yc""YYϱ0Զe\X +q3GEx#1=sjZTڪ%h xdHHQMf$| H>z yTT999֮;|hgBrPMbR32`|T2<\D=y uu12i$طkr@ȮmoS98uuAq?Oǫ |u3¼p1GX:Ȋp" EOb3s52sp< ^g'ƢG"&Ϗ~ Y#YQ }hxى hecȀU L޹s%Boݱc-,֚8t!A-7 (r2b fff޻|To‹ ?S E }Bpm׷vvM G!y0[m۷!d1ZfXImp.&tW"8¿rZA؃S>ɫi"gUQQ~ 8ѿ ټݻ;~ x`g˽>>>IU]U]]97V[vl++2&+/{N<$}]<؄$u%;wxj~nn{7YPr Ç44` PJ)*@§O"b D$HNn^@3gD>a0"b ĥ`x]--e5-gΎΕ+ @>66vC>E%EŤBC~ H%#+@wk*7U  V\z%k{ Lqm@0GqcH e"MW>OK.AaNVnzrSK)j++Q4";HDT?\mbcogPѽ/ FƆ99𢶮>HPtW7|\UQ]c}-9!EׯsuvS6V զ͛33bma%8U e w_$yTGJOK3Ye1:LiB!@!,{=Y_a$hobþ?B}ѕ7];+[}gŊ>x~_BLPPRP>| ,*. -OeY\<3r"ʊ"/_Sش<~S@ tho?~u0BWV'O>wS'i]߽?Ϻ;;Ճa=R-~oߺ~B\Ӆ5:  F1e[{;Ch>Z*`atM*88qb#Wic[sKNIfadbbsxoootQZY^V~;g:3Իʚ+*ʡTaytIoS4oT%"1Z\3 Gp <}NCCo`+K,¤&07ocG-]˨(E\[["!6XVsprVsmM"--=酜\\Fvvw㬭322`b " ̯P[c& sRSW ͪ)-=.~Ms;>> 5cu{p{V ^ ;vm%""{~pP#|fꃇ߹ZCJIc EL,P0..#5/7)yFR1I?tv'ݾ|^]]uZ "(QP[WCR hhE ۷n8XϟSSSkmm'ݸypS/_$!! 9t00=xHHIiiw ,%%,֒e53h7Ψ@k-aerux%( u]}P*ӣ ᅠÇW2hy ͛#CB KKJԴe+>9NTzaCmmEI 1)  MMIAgk3^G+RCC!!>}Zk&WI!&&~䣄 !5VǭD%LW uuuі&~gϞÉș3>|-)qq*J PYΝĤ;wl_z1l^))L'%" c$ʒ;w@)""t{qȑ{{C 653""3{bJ۲29ĤTTTIUde faV5vBB2##c s/grڐV#tC3 ͛Q˕Mpk䞞n~Ax'wǎ,/47_k()@r<~ ETT4\]]G8G6l 4eG#&![JxiGk&ߒ |}Z_ad O8JITWV7b$'(n۶ 8_ y rjjODAGqxל>ԍhooH7n{eE####]vHKC9!V0+;)ʃ&P?t{ LVݺi.4 6K3 ]^xᖍ[[Z^ڿ73[dE&j2s:Ꝧg= @ 1D&K!H IqQ{۳g/77FP  [J :< #{` 8Y<׬|⅞&jdg9s TVU:9:S\߽ۼiӆ )Z;wPNHH{;: +ll}҅V K4--Vw\Dҥy;c>% s8'9-(Aȹ?ـvWv/($"HD=sxa͓ tiQQFF̈́eu ޭNJMMM kw̎HIHhii` JF4HFKk}܇_ VnxxDCBF]fz6EEEH\tʕKϟ50ԇu6'1H !:¬lşX(3&JOG>wܷwoAasgB?n##qAv$ ܺcǶ'N=r>P\[ߚI?k\Dh/:!B@W7CC#`h P-/,< B5DWT% oAyh׋JP 5546۷qpKfhe%}ZjCO@?Z^@?*={dņM@0k۷oAM;tB_#:Yٿe}t=S8"#!ܜl//OQ!q I •\]^S;ư{mr=' &F&Hd H[E_qmm54lr}W=z:>70pr͇ź \\P5//OSSCB\tQѠSKK:_[;[܍\?Sa'O^ #?A ,;݅KZ::V7B CTUU`kl,v^Pl ~bcS`FIE %98iP/ < /$ʇ/nki{tl,lem~izzQC/("HsiD_E#_ "+O> dEEEn!_5|}SRR`ahPUYI Boށ0@} n=vtpYcp]tISS VuPjg˦kg [ oߺ@xÇYcih,,ܱ̅ɓ]B3Gɞ*XLc 1,?8Fw*o9i3 Iy;o^}}@n(팚 ނMZ&3/;b.BBT=^d r66eP#!%vIPÑקO~=ۅM׀ho#O ?~""$Ԛ*Si 0"o:^-x!!JJ78-tUwnaK'+ mYYv@s333tf&Fg /޺yׯ?zx:33S-Ke70p!HMNNٴi1ё!e V3t %{!&s.|R Vk ߽w߸bS %#E{A20‗Zpch/>r2 )( khpׄ:]yxG x2x ݁fAۏ^/^SS[\SU~vV2:iD_YN#dP!!){T5UllJJ8N`XPaS| jSS3]ѝ9s U57m/6V֫ׯv[7tuuG8+q3C{.hh]AՑ (n#[SW2751$%-32"|-3d'AA`++‰2>}TuՊ?C t~RKCKO߾s;yz@,\\BII!Ԉ +/XAeϟQUQFG[|puߖҎAE!xꯄgc`mbiR}|aK3Uk֬CSC ">+_tj+*kE~;!sFx%KO5fvvQTF쨄/(gX?9 bgo.]>u꜕#GOX73?D }_ě-\_e#J6J@z}fccsqq:u򤽽]; *>|3 MD?[m756;xՋSi 0] p'YYywvA1ʊN(EEI vhֽ6 &x Z2/WfOEIsCC]7lRM/[ tK`ILwyx-]˖{zaB\7ޑ&C/ A`ZIϑn9|QeR%C ~Ɉ χNOih<{>p.[xee?"y;(e(-+Xkll ='NΙzG#NPc=**CDVj41]&qq&&&J 㦖'oh1JӾ80W}O@!"*H̬ov5 B.ErZW@a#qIW^ܻk4nY_!SǴ+?r8BӮQ 0 pDT@wvj vj}*&ӯ]>C=^SSUǏ0;"&'"u6D?⺙>77Fdkq--{X_Wq .*4#fQq};?} ml<´5GZAwEk#bc㺻J'R[7o3^`:z,+rF8HgN:UQQ%(١J%d#%%۰a}GG3?zuu50xj˖Mi@@GGJ#>j3S<<|G( *)%),`t7&Ȋ`LG:|Сׯ_9 DMUwtiIYQ}[[[_|>iQk֯ |ʕ+7lJd/^o `@{{w7lZeftثLWsu>vЂi[HkT\Wlwommhɯ_qB;OBDB Ze {AOϸfYxDteeeff֖-[=|HMM#//wffj꽽p"(,," (Jʥ\-_YQQl_$XfNM2b>}8oh%z~F !~Ze=b_I JN]ݻv100 :³mooodaf*>ƊOz>KpLBGCKBJJFN5 M%#%ik;Ν7'%%Þ! !ᤍ.Ge];Nڒ—RDDJ%Egg991U!p#fdkt4gg1YIbbӧO^t8M N#d$Ĭ\w!ّbv[ NQkj,QURVQڇ3(%<21^~\ի'Sr6"8vQxn}CϟKJJ:yH~s AתG=|p;T/^#GMyj~y;Ъ,88"5$'9(΅Gdͬx_ / 6mJjjmm]EEUBpaQ : FP) #QO>Ъ H RRZ "r!CE@GTӌOL: H=?z&c`PP0TEx91Cm[73 qS -a? jSL/HHHTlh& t&&&_~*};QVaaQVf0;ve۷o[Hlh`…\\{g'GG ꢣ^K.rr||,;;<}vƭ֖&)xQ]}CFzzrr*G''H9߿Ks2>yu^q]OFF^^ib6c|^=]]66~kr}Ci/c2CBI м!eŋ , ~ZaY&g .(,AFF:immff/5sg\$@kk{gPQIYss ޟvs@sKklLlww[w `74$ ׭%!CSSHU\ߺ.>~PS[onfe˖tuu __ʪRܸBUU-++ 9Y_oߞ7x&vMEI}tL"ԥ=cAb5 JLIIMWݺmg@^ۿ 8`ZztiC!%!ɝ%wgNOm/$$#{e$(\w[TPI~_feuB]]'pp< 1j}%ApPPPQqpq`9"N5F@ܭ0TSX`۶s>s;^8yeumۊ +o  = ]r)KܻBP888k>KC}7ovB %KVTV@1WW-[02A ,&a# +>~>uG߫O߼~ilʻ4URT7\rϩ}0ط$'((,hnmomi/A>xD/**'4(_>ӱveeoH:mT}wph^nn>,|>y>rC||qp))(&j@x`O ԯ% ;̌% /c?BcEe`KFF ]@E9A:r|NXkSP@ -rr0HZZzzIuV8/' (ƪpyyy)#+;[;`%]}{A8lyE9?/yy# ȳ5Po 2(@9h n֭}c겳{Ϯoݸu?GHCTGo?6RK1!7bpi)$1m`Hhii^bZ7w>77$Z2>{Wi 0 pbnذQTL߳KIxp.$E9.-uxxy_' >>X_~> ^|~9\pXa[k/ hkiA,ԓ1?}ecl,xǮʢ 'Puiq~PG~1&b"ciڵk0%#,,Zoܸ :S@\t)6ƥehhIOP317C. N`TU qJ\B*&:22*!!Y[W'+-ekwųn=D5zBB<>}?냊 rcH-Z|l7MB]TWG򭫳Ƶ9NBm#rrrP}/_ VB=Ҳ2C×/b|'0GɠM[Z?1zoݼ:!mYY@@0 T=LT?"zDP(3֦48>7WtlBrRu eB/ip"' >@=82..oAUDM;L g|:hI Ԇ,̟*+CſQDpSP-PSS I^/A0)ނ0]VZn?Eq"_=;<l슊JYy?c27mO>{q޽w1޹:^rQUE wVi gْ%\:PcS'gZ $T'i{$!Ϻ}bu 2ZRRx/8::ʕ{Õ#+#-333¼}mx,m,F@= >tޏ٣G~y062 x\[ޝK޸a#uvvpTKJJ]]=~bLCG!]ZRv\CeK¯ZllǏ7VZRz81w-֮Ox0tiS$:t\]],Yb}!LwZ9Mre5bAj E?*u3-,,EDŒߢ1/KMMxjҽ=]99Aa DƫV9|] Z(-sYV@ EGQw%Ѓ̓ښZKK8WV{BTc# TgO.KCIFA4)P9r0|Epo޼322Z~+%6a gSoZ'%&SRQq?B}NF o\! UGFȐ@W6-g'Od'3),, 6R vRR UT*sB ݻ!~Zz Kի@׭aEKK{6QQ1GNNs{ ذρ,|tt }ǎ ggl>9B+C>Rnn6;' NE%ꪰq-!`:zAG5}V3ki1:|V7(DrlZ4pCAAEcc~BG9-2P{HwIHHQXPx/11q^hjj|i# <@6}eE1u֎;!KUDT }<8g%S!vPy#:TTTAxPTt¤אɅyJH@0ѺKPqlR31 羒_8|8F'i?/##=i2~ YP$kFѱDE\\TxG?|Lzv6>uPSod}cO*CɑQJɓ7yмNNNϞ=Q6nNJJFߜ?+:K$$et=&&&._YX\L \3rF aiQ[WYTOPj`j\B?/; mS?#8}L:1ϟ`cVTJ@rNfDC5""Cy'Ggz0GfdE aWPPZ( q" }~IɅjZetqH(4115%Tft\*+PUYt"DWW*_$ ;:qTQy3*((NN5-[#54]RR2cr244ATL[[ഛv|0A@MpΞ=;پ ` v eƀF N ׯ[DNF 9@P6 R yxWprt*(ȇ#>>^X=BJB̙P7P|-8wђS]r+5%֭[,)##-/+ kĤDxus.HW Y9Q*K.}7r6 /@!wSb 8oSHHh7ԔOBD\Cx@"JOOWd#Rsm~9ڻoOPV05#OSm6fD65ue*W.Yuw 1B:CH49T]'$ 6u wu|Kk >^.-!+%8 q4#==۫WVVFŦi̼?՚G+6$欻N ˞zȨρPK&#\7A]d*tTh _^Xm] eI%Tl-dk?K g4^6m|CUwY9?*6SR-66Not_\׮[߶5^p#;igF_Y]C҃F"tdxA0XG򤺥s)O8X!  |e+X6Qdywtz<7:"S'`HЌ Р7u A.Nx\YCk*DЖꐒ):66wf'2Fq'z%DY 4F /_~v$ZXu<9@Z*v*ݻ=<~alllNZM#߄@JJ~ggGU֒M`DD{U!#eO7UBq.%)>PLMQ-=m}}亣n 'ըUU5)zwn_@"OPl!̜H+4t'"*&Û!d z Q܎95f#D/@?񈌎ڷ99?jBml:ǵUw6T7MLVb5\\\sk!"#vk7->@K:GwZ}Z^C9c"?k)))qJ8R!_eߢ*Aa](Y-- ffgѲ--7J/㶅qeߎ%S0Vec8D=t֭;P k{C?AR37N u  K~F*"dk;, ?3SCcOnΞ=6nLqDߺe3$"}3#4,Pdj-!' 'r`Úu@n<=":Z'l9w="$%zw~&%v}+MUs֠05eU~/#&U"''WMMUFVfLRS_x4Gwܹkgw (92ssh 7o"RN{ LE._X3SWhb,=¬fԌQPS'E} a$b'))EQysߪ%Q >wqWM6 }"1[^5:8Q̓ +++ook s9"7[@7Nq?:2* ㋳3+sCwӣ6EiNkta Ϝ  ]99plw[Z=KH@n +ӸSU9\RJ<|8^}fL!9R{sa HM U55gj`'/`Xf?QF W;rШe(((Z5S= ׭w5 U5 iAJ=!:IR\^X_ECXXL4İ18o8)ѓQM-wyDIX4AV35qs"MMRhӦ qqq1=By94Z;k^&&!Oaz0.m#G_z<_߼y#`eVbv֭[8FB,¦Q `iM(\tw!T-Hm At _&sN~8"=qŠTۃ+&sMa033302޽wYNB d&œ/V M$Y[wa_TJz4J訞ms[臷~>8ysջ)\Z<%y4wq4ұ1 "3@D`{;wnۿz𺮾!/s vD.\o*`&CYPj*ʉ6<\KwŢ쒑9 q.Lɓٶӝ_- ھI^ F1-q{n\1D` pMUرcZ89$0QŅgu#b$1RIw͗cBn9{COݴGwESѢSU#?CTTTݻ|*D#HDӥ5`qSUUek(k}tg>\FYU#$##`*Cc+*&իIɉ?]DRJ涝߾EnWT[(-w>ӈJg?{SGJJ E-7Z~FƃҮ^!ZvrVE'B+[VZ5`3u}HJNQ߉XOZyO?>s挋䓴³|a"yU!!v[P&:uj6)1n\,r/`a,8B l/Hikm!AC[ljl5))ޞn@B *|֍rr7o޺rMdz{߰.#=_@u u545|w2X}O?`-"9 &S/(KZ)1U8&$0J޽5pKGVTTߩl߾YԱ) iY\d>2z憙kvAā#"Y) Pzzڴ[+DL}hhPb$@4Nu,**޾^_?^QQQϵFQرx935 66ԱR>9~w#:`滈ͪCI+I*fz%uL~x2u]f5!!޽)Ο?7'-}69/W'*Cc3CF-뛜={.;;{=urxhѻ E"R3Tr2(f*ڦ^Y322C&'ą!qhGFF۰nAy;6..co&.AEE ;VzFFE*xROW֭NN.%paM[VQ6ՉqoNM"%$ IO˼L\if͕T*#uvrzv<֭[aRxy1o[$t{\i!^uϊM;p~r>Ko[ N 1:Ma,֚!tu9s1邝)F T9{Q.>>^]]ݬˍxyyrk>.27Bs)=J0A!HդIPSU[D  1vQq 㜜R&o0qRR2JK+{ۻvBڳJ{ j*;]˛k5yY9iIGf $ƫmY#YlM,-79ӛ23!ssu-HHRRQh`_RRnHnȗb͋8X؎a&kVq L)X^^S閃Ejp ?I{auKcUK+E % vnbFƆdpg$Efr:^GCIRR\RXTlkgKOG,E޺u!>>gsY|ݚ=ѸK+AQ0‘^".uO TMVF;wstc]r?U a@yMG?q%@!XɢOak466Ãe(&~_`Y G8fBaRSuIRRѣ={&PE3a޸:+z_}߼`c.ϭ\o4U>X}˛΢w;[;;be5?,PZ_RG-SNhW/S&*cN _;ž;'Cž9Yn#%%;}]cMPU{ #}aYIIG~ŋцWw!ӧ 6<;(6U9hnn9HDk[g.:{T<}4ڀB| UW6 )z{ZZۨ(wڵdbnnnRRRvv:\lC#`hi$?4:=#5466H/j7(?~q)JD\RyN`@ޏQBEvmI56 t6Z = Z:w9<|f92fwaMq!id!GGgVVNs篯-IVN5^ ibF}A5 MזNt@DCq!4/_SA~.?_/88Gۿ_TD N`gii _4j""B} t۞$0|pRjki>3W/^Kcc#4%=]x>y%aÊ`GB͍iBL4 }KI@JFH(ÊQh4?tAbh"6~l Փ (۩&: T fGVp2~ةi &:[!":VvFQ6P@GB%=_H{͗qj9hwlUM ̭ a\&gSU]]vי`I=S3 efjo>dfڒI_ڴ<=N0׿L9Մ4<,djSUJA4_)/\]wuWFF_~! 7]-mbrPi X&.]0"9H XM@k6Vlg~w&'>)Ms]_䉉_M'%&$ʩ)h+ZȰwL|K))iO&?ĕfw3jθ==[x-2711aB5B!z,pjayvfֱ;>}z3,mjj>#U\%7ٺx3t['PKCK_]Yc@xeNvŘx04tneFDYN'úkf:6IIJeK_6-vu./C>~mm+n).r 6 f7T,~ _$MD椩P*.@?SgJJ޼yr2 gzEׯ߿w.%Pc[WQ"akF8??{A@q%芛j0DgI:l tF<-3ԛ]w֎M 2R<^^^P&ҥ+O\\{;逜|qAyll%an_#lSDBL퀧 :;W\|w/F>hήd'PX-=F8xfY1bؔK*egnIfV#t[ׂN1љ*%%%-[~d|B^6ozXv^?"{4_3Uݳ{ר}(SV^a8ٳ/KiƎbL+rq A Qyk-U^.C#NqOZ`pր4k<{lSL"<-du54N{\:6eu׿|*##kXJ;vmQ5 }~ȿ Y7F'A7{F } ;j]\?.B1/ث^=@[Pv0jZRTДrRBg|؊?%;FSPyTuC-y8 P>诈Ol "3嫒Dz (F# a%1ue]8ŵ B|,R bMbu3[0a†s _9M`#wG~~J?|} !CY;f&DTxDXHI9 [!]U0_z$(; jʻ{5QP'pi7ի7gb#..oMS`nCLLuBZ˟/GK^DØ `/,2QQ?xa[㣏O3zr>xgHS^$ķ/03VOTqV.l$ dܿ@!\Ϲ89ТqTTQ+***'':r˖m \YATЛѶeMvP?q^-=7Z:J^j?#N c|}(Rx/ {\3:$˄}HY% û*boc4hI(ZGȨ+IXqfuuxC)P6ttz5ZldM*F+9%Wͺ#G޼yۓLW"U_<~*{lć9DIL*&D@Bj37;T$@3I/f xr@#5cQQg͜P(1)TDM?[Do"|{_w*` )FG0WƇ%_{f >}YQY@Hp2^ZH򐕼&佐Ho8pСot$,nes NEBU`1UcTWWgf~/ =NBs!! ccmxH`NYW8?rZq TqW,[_XSQqL-3+Gd7-K16jz#i 0䨑OŰgilYID/NZnBH@! &(cǏN"Jll\cLB'7P ,g̩|q+r2O|,,0NQ[o(+SWoG>`) p\"$sNX54WTw(7s? 9u99ߎ~ &Bigq,4s23O!T}>-)2b 3Sp$) 4`L2RXl{}*>]vQ'dInټ8 &4khbfmԧr3bB]ӏP+$$4! SE0ɓ';vl[[^Q c`6H۷hii޽9{wB=B1nwuv-g_=y򘔌,'7g\\,9(}HQTP8AA[n_v- T1łK[:WNT/ ^c* m1D_\W{f!6yE͞6ǕO\~B`-4T#Ɨȼ‚W0"%3\Q\_YR+)H{zۨmncWZQrUPtl>[AM݅;?{lxlٽ::i *} 0N\z]{/!!&z1r|ZPރ7<|ڵP/2*GZڋvڹg^U"2#CF;ˆu8d:vׯq+.Z+>Y֩Sg+;+h lT8qvW~ϟ aSn[7of&iv/:Ǐؿ~}JC kCpg RR z>pJ=gjp`#? .L(Uѥ/EMFSmG7$6:pSV*QM ˡ$E_;WME[g)E7]jl_mOHF;+BEA_>JHKSRR+8o(uW@SSr`p@WW6 ,%XOWzz!: ET4 II0^^24N3,,l|a8rÆ{G }6V~魯cKFw"k_tW]_Hkjfs}(bbjtM]]]OO/BZ #c+ w޷t $323-6c+VYvzK%e5v;sܲzzK_waRNNʕFΜ9!@teT% )^Ԕq%1GHL=Kw wQ6MXCRnA0QE$PFQc_;ޛ}vyww~G&yX @+pv|yYA))WvJK3[ߺ>]oǷpO\s}񄘔i)pǼ\r^C] ݻwI gfNj/*.Dʰչ}CaH/3ҐrrruxRRJ pAA!9`g椹TOr)ıy>eg(Wr3`)Y <mVa{VD`*BEyLV+s2,^0: JJ3=~}}#7444cۧ &ޒcbss35F9ѝ򑑑c>衴c ))۹/jnn/e` ps׮7d;vgwlcccYmgwd5pm)}3sѾ}{>|p716.f]22Ү~nT+$M\ ~:;@ T4\ ǣGmKJ諪*agfXfuA[ KgϞ9ܺse333sikllq3xxjN>k{LԴ4yo߾cc/xmb{6m03 gB`Cl=ie;% L" ^?z.4c]X 0bb` }#SS  s+ zYg޷>;e&);%#6 )mWWLaO7\)2 Y?_II&׈ktñj՚eˬ4aa+W|J Ŝ '( ($аu&;.Zi$db0pUPFaIq9UE? ާvYJAٷIU Қ#h?X: n ݖdf!q2{[ϟtw\plin!"0Ɋgg~ȫ,na`#'xSRSYqa]SCfu^EcmI4J)Ei-M-p'I2z22Ap8""Wd$g<8Z$JK~5 w ;H`i $ddep@IJLBB;T)Mu2ۭ4,--lg=5D`'C|*̂Ăl|%)=--\ !!& $cd.""b0Դ p j**XAª$_f3p" F|}$xcY2~JwB>yljQa.˲-*2Òf kvv`_߈H$'űr~l@\sUV5[޹38XYYۮ;Zڷn|RG'/QwS kkX^l*Wa{p^8\5~ vȨh0`QU]S[]SSYQT14 poԺXvv.Fjb"V6:jJF*b""|<R|,B@{dt4 vS %U=e0t6͞QlJCN;ϓ0l9hIhY̔y3EjRB{k?FNNW@}Ǐ,\t?d4m2LY.^3SB*-597_|luIIW^!''766,.˗DGEpp)5#cT4bAvn 8ed010Spgg h7#'0JiY/,,䇂𥜙CNN [)LH!MMU\ vz#c# @|8"A nB3+x(ܿtsPlbHIH4y &HvPjkmYdaAwi1R< ѮkihFs]ScucCMsCCGcKK\KOF3 8b:;;(I3RAZ87&Rrb2bjL4!)))98ppW6*&ϭ6>?? 9QrWccO_~_뛚xD X%i%&$ D>|!\di9CEǏ6(uvC.(v"#±ĉHKK #8HB`l1!0 ϟ?XYInQ3=-Ahϝw)9|Q@=իv112=Һsii`4.y̸Owt|il2RRR|,ͭcpOmimu{TߪQZV^Y] Tl,`[=1}1߭$.sC3 0ݎxL榶V״޷G%,H[lgSs϶N ɋۦ빥kyEQ?Q:GahBx䒐|99A_oCxaKtO K!|䙧Ǎ_멻{oCn Nɱo!#S1|⦃{W͛7ꍜ>[~gB!cbw܆f99y*!!/_晙EEE# wiܻwo g@S' 3,,HV,_\gDL% jI. aJ 1Beg -l l}& ۺu $Y/5K++;G]MEWGk_;T9S<5=cl#X={|Ͱ%9 } m쇘":N|d fvG\cBBxx&'JJ!\p} |}f[yDqR>~ QtS8q">.'4/!s\>cq +++ϲ);Q K-Yj7!Y(&iHI`B ee:*-> pء9knD& }i PRb|u|؍WӾO s[ H^~ٳ2U `휜W`>A Q_jsF.K稨+.-hl3 d52 >mÇ>k8?XeeK.tvbrY}h@&a+]\.:=v4?/)(嫏uga Lx;+-oaZ%VA, @׮^۶u N5 kx)+)kj)@rF ࡽ}箨ԆN;f1 i]‚/TVVNzj"x{|V)) ,U-!)3+[YEMHXM5xCavv.Xϋ$&yzz&$G8#=%,0<%$|! XZaIIMWexw# \o޼ ^>S\Ja-,z0,6b6RklL YWp}dJ/{h I?!?2X5\PY*.-;4??_YEu0zRj4NTZZZp׮]a1Ӻ:N:pm;l+'HSewԡC?^tNMMxY}۲e\SM[_r z8 'a&+/NOKCKG/!1i444 #QC`*LKPp̙o A=tpS@ \XU$## d$#-?ՕA*ac \P2VuN#0!,&IKC]AwIMEFI[AhAܺޛQ YPP ^QË 6x9 Y3@Aϸf|QL OEy|Ox;؃.^8daaaL!U_>ᣚ/+W޶}s|vp*‘ }}h-jʊh}ù&IwW+*0H4rͳY;<,G2J͜9g}GyH$C >>!4, ^Y}#/*& vQ@ yy`,{PPKJ,Xhn2Ϸ G!(?N\w?rps!=p5;;;#&cBWMJ-ʏI/?"Vf۪GzHCA,agΙ?+1uMtؘhۄW}]Cl!M-o acs͚Ul,nnn3gJid]b9  ug !v6{1ޜ9IDD5ᨁ;BG7Gy9iLz^xo%_ljz3Ga_PY&1gfsAW&>`wBgc<!0 hkt@Ɲ$VfH8j( MMh 8!ɋ)bsG BE>qpTT؄}_ʎH!C!CYu{ۏ 9=]oOJUCBP+B"b"C *ʄ9Gᙉ{.3P280m_IBJ9]B C8&FG珸nOTʾGK>WPh?w`)GwCiXLNʲh_|7|lP?wy vTox{fffM0 C8Ǩo ~-()z|R쑾~ST__ LP5p(\utD=\=H'BNISEGT.w/{p(9kFj"pıcxx0L1Yfͺںӯ |]裩X±B~!;קAù0"*ZSG 1N%T$98kA "Fl&&[Uym"B"$ cc/#($*qm7n8HHisqqZfCqq, ).nUumE%[30=SJUFdGaמ {/mB"aB+6WA>neNON ^3k91ѡA~4 _xpF-阈 W o36 `d/!.%׃k]ynR2>kw~uLTρn-%%;d>^QwNB8&&PtSrjkFŎ !Tڇq;$4l#-`&Zc=6h:;?[li"y#mlg: !L@)HY؁L6$&nSSCT!5/ג%<ʪj# 4@I^MK+ ASYY'X)`n/'/>(uւ=b8BwUUUFrkr556\d:w^||< ) |pVCNN z/" d a-*fDօ@)NDqtusUcaf̻Mgp<(I]ߓ ׎A1o@Rz '\0?qceC/3&&׮_]vzúc AvCl LVF ,3bЎ␰(vG^~"d:GE FEFpqKw џ(yrʊneAK*mі\udz}Ϸ]1,Q b"8B`@#h݆z>mlj޺Z>xyKHHKq[D$f+0g Kn8E ;:C.fJ?,#%Ɍ2lt8+~CMM_ @ IMNQWQpE𴌒GVJ6[AG H ! C8~t~ +s^~3\W;/AJLXQM,MD  J16Nisk yĎR99D2o1i[W[kPVPX+O_))I[/I1A)S⿦%g5c5̶4n7͍t+%TL~1& @ C8f1q8lԔɩi#o))+e߫a{WGau#ϒ mML]Uԝ4a?(Td[<(mR<<J;eה0ټLB N9})9Sd'޼{kjPHrS]o$LU0Z#+Z).˚rut^ew(;/9])z'(S0B!0e@+‰7!}\ʊ CRpJꚲ5bٴqK i|_~d$Ss X~W6v{´O{]%ZZrˊýKYXlYJK3"߃k!*@sP8?4/%5_p}7֛EBB746~ lomCC;+r2ڂ:^&km,NU"Coay?@7UrV:J22rRR22`hionkxƖF(.kmmk`h7Tdfc\]G8~!d'ޔ @gZ6oϰohH:iꪊ}s^L]p!;) 1IucS -A)Y"Sa!FjrzsCSC}c] є>2/~RRM -^2Gc+ jG2rz8xji!3-=#++zxR@V^Q s Oʟ`Ѱ2J!i~@gn,  %$yxRQ,^p0@f pX;\Vtx: q=.+\$"d2B9ɷuQǴ)XB1Νt g]$@ 9Xo/әV.\8GIQk 9Ͼ?#ڗ[o|)G FdGEIQ::6zK]߿l/_j"5KϜ9rՆ@+fD8I6GB &#+Kvvڊc 31y-" H~~?LK,D 'qUFDy""b #oLDT$- U up*?BqӦw\XI[{Xꨩ8&*f׮ SlUU,"'\_4g&'%۠ZW[nF}srp s~8sx^FvOQssk7섿x yـ"P@+¡3ggiT25ZCQe0+=-=%%~A@EE,ÇyxaS B2h& ?Q1zO<5K5Llj#'+Xɥ֝ȨH˗[:{|$g``hllbbc\W qrss/Y?Oj{***ٰaH5pDS54 ؞sqqy?`A@Wgm&,=k珣' ӱѩ'{>ܚ:rү-cb`֪՞Ç]|#ZZDnn脤]9%U5EUrٙiR.n?M%8$qt97,]5uRi{LSӹ,#s666=Q7  3;t@e99ZZZ͛:kNii)D+-\hz^شi0TOCޝڵkR5ŘLE%pVW._mnn7AAo߽ex "ږفI 7S0xx톛p iw;"jdFp2 HJJ;vLRRj߾}hA{A?vf9Ga$G`v؞v:+?Gtڥ Cy>~qryOBNC--= ׋/53ԳٰgϞ{oOAqw ;w_8w))ŋ,ধۖЄyʺ\],[坧[ڳC((*?f…ޞ:}8-;dk{-jkZ[[{Cݻ.^TXX NIYsDD5?526ի׮_^RJ:88a-%hղ;v+C7:4o’R)iǏKK˂u6g|X|k4-{# !Ì“޽͊z`[f'&ldlea50MIuk`bkcsSRnA$iĤEL,~?ljhjVUV+*,P>=''GUM_SS#55y֭O?7aVv,'{ZZچM?Ǐanmidgeggcff>X le SsKKrrOK7(f`zC#ًA6ظ4^>Ǐ1K[vvw[nݸ݄%#vx|g6_kll=KOs x۷N:T׀{#Ȉ7 l{X_FFON#CøFM" (!,, FIY]bJCGO_xƄ11d%iifW8tv;4DD= ҹ?~LPRTҞj˗߾} Oi=HJB,,$m&#}jj*([$$-mϟx]eU P\Wlߺ>U>ޟ20߮O F E^p!58߱zF^]+&&&15v'X3xga.*4\BVyἉ{rYF=#3[}Ej}}C{G/ׯ_889MMRSR3D1[QLZ88#""YXXL8/`ǁ £䙁'H`?cNHmgbRpAA99ݠr/ a2>ZLvvvpsM}l!샕i77!&"BEK 1#!GQ)HJܳiOhI'ܴy30ڂТE/hktB Tn$qzq׬Ӡ,pb}FҪ/_51 ]ߢgfLӳs0Sᒖ  72X۶mǾnݺ ѵk U yy;8.Qv1ϟ7w(x~Fz0zstTTAEesKsqa ?<! *pueeMC烱:?ׯ_koogbb޳g0KE%x ijgϒSR VMO a9uCߟ+;g1~W /yEdRVR8o\6>Bp:1SFJNYzLBFZV)`5<" xh… (J9wrr7n8@%%{ݷ+&&G[n|G{|Ⱥ0F0c맃ѷsQB`UZؖ_ΡU` B"sN ]]@B(.-AECŀ[ZNBplyœӹ֮Yg TY֏8iw`k{S+^| y݁P a6os?yjN}%5zSZ^IRИ 'U54 $dDhhb<;) eHkʸi?~~ ^#2#"1bMMy!7ndggBajlh:sL̘ vv$¾րݺw.ݏg&@@?M6ܱcНۂ@Kk}dac̈́x ?;{3=>4{fnbBZlaWgmUuzT*3Ýkϝmefj=-Ɂ2cU4PFOG'==ᣇ41VK%#7:rܲyc~A>>^l Ɖ7v8tx*Ggckz+O4<-t5 ٧ JN(y5-}{%I/,)g1mjlb`emzhiE1QٻY[[ڬYeF'Ͳw &&>Uhki9v.++ýv$#(pO MY,,?ogW"x@@^^ "\qq&gHKAX.;{VV:1Geeeb!5FJDH8d^'G#=E`68W38^cG'n[v֗TPe } r׿G1ow^ D_iEEűr x uqiSGo?6&Y9m G ! .ZZ* !dk KxrAܱ{Ckzep}E'BC}lRT)>qMɪoj1 <خ&'/NK5TIڔ$SST!F00ҕz3~z=丝z [&%ܸ}xa%8rlU}BAN| h-Љj=|3 C8YGvœ6Hs3. wI[7/_:ZGJ3g[{Btm4M XQ^TG)jᡴ8|A {Fήր Ne!Y:<-٫_9ݹ}Ogrr..l?4oOOg`ȱZlyaQqȈ(UU E%ոظKJ* LBn{TGd[T`R^6OWiv:t`?!3‘RK_.۾hEk9޿hϊ% X v !Ǚ&7nܺ{zfZzajj{iƕKnCx8RR҇ ij C8%FҥU޽|XÛүAX֘vxyyEyFʸa >{i陥`C"r Q{;|~1@pëihx 13Qҵ? XZSc2~\>}_-2t2zVfB+6<ޅ1As}ui~;+CNC~o߼̱34ԟ5 Z9S\45-ÆH$G1ɍ,tXVZ͛v#%-#rj.nޚZqq,5 <<=ٳ__|jZNoqNnӳ_~9e+ RͿ0=xx,0o߹C5߈|i{ngGGYyųsZnF_ L7c2p`'z=cUҗ玻Os1Rm-#} #};b֭uvytEsEU+W^[[}7o}&-%yGzFTtfvvAA]]x9Y6oxNLLٳgvmdhxĉW^*(*ee4LdLw  HBB2>\l'F.Q}a)hkHH;;\hE"{=cCûqX|vgO(bŅ%dcC -_!އOJ]8g{a F ]>p`|.ȳ4Xx<HWO!4C׎enذkϟ?~F_?$dG*..ɲ_|}ykj"Ň; kHCKG_Ymv{xnRR8y 66H2o]JKll)&VBsKnt/CMmۛ/ V2Sv͠\nmeGg}Ȋ )1sDW;ܓ"Nڜ<%5u\W|v霏˰?a(+CAt;W8{,Yoۃ nBP l[Z|A2"l{QSSu⅝;wB~% m`:J564x 1pic3l޼濦`c*eFCC###&&itt ^u`‘37芬PW;O~7o q_j 2k)q)-d_~ ㊥nSh TX"B 5ul@+±j/XjjS.LT l&OAAD3 EVVl+% Ձ{g'xMu '##+f#444Ԡ##dwaG$II)(OqѢO%8\M[k+x5X![>/_TS\%~$ a@g5UpwLG:TфF =|6ȑc#&gj`mR⌌?#33߾s޻7BxcSsgEkphyW,޺'gn;x:\ }ﳦªԴ 5ѫq@"dLfA;`TWg v= ԋyW!]\2S߿BahƐyx33A 'N1E=q`Er̈4`axʉOH1+%te3<;== >}O!R3>q+Bpj!щ=FWVVNQQAKK+rB8>J 24P a?pH(G:'?/Q@ڵ_@%pzQR&@cNN>~fV~LJJ/腬\I͇Œֶ6-V : hmiFFp8f((,NF&ņP;.T x UT\ I@ē 1 ))& 4|78f&Ɛ1 @CKKu~3Iҳ$Eo8SWU1*0MP-d'ء:[nܺmy<\Ӂʎ"BZ+8tL d񅵗===ÍEE_}.GEDFEFFEGE{y~ws KINNHLrp!=y <=gΜmwaiI$ιmNkhp^TXxͺuq6VT YZVV!ĕjkk[/R701f* I)K/Z )*.sjhjO u;wJJH}=1ڹs/={gݷ_JRwtxG;BmHdFG|$Pa30G~Cheoha_\psEzc?U) gg`||`o+N0Y__+XHK8 JQy2OGԷ!# !R0{~3w~ʃly-gҾjm 6Oc>eC5 buN'bdhLZđ ~7CQ "74B`puu۽w?))ۼiÒŋ/0(h XWbRѣ:aWv/ [YuuDĤW. GʢRSd@nN`?Y]]qÆ1(o0$4}F7)OJJl VTV%dZ(%0JE#;; Mhx ffFptIIIp{O22W655رc^9bݛnv5^^nl]rrr(^9ѱWT) C8G yj!099rqqI ´ }9;;[LW@@".\ƍ _z5knDD߼y `s,RҪ*j::tuugg|3;w~y< (-dy skoҲz!7o]hS$0>@gs\P F...DDpzi\HOOcaf |hnn~!;t蠕5رd:գ֔ Y9JnrOz_ @Iooy:0#0 GUȨ PXdw\|hʱ;8ܜ?0tt?~^bg ˯22/Ճ![''766vuySȐ}Z 9x45fQў8~,+3s׮=p KO1QǗρ:}.]/144Dy4I݆:̨! E 0wnzC}Yiŋ=< 0` `ɓw!!W߭ OWW',,tݺsjK@9QxsHN^Po&+ LfMfc,][/]¾l sZZ+7 驇:#zcz<?L!z; N1{zeed*))<<\2 x699ٷd!MHL1`@aX際0QӕU2C"-kdů_~|woC;`!锔JPEĨv1EB49G`m66;zRN!VV%RU02ёiE ,X!cs˰ 壃P(3:AH)B`,-W_ ᳼>=}699@SKwk7\~ݕu~eff #n ")2SnQ'"`,,,aǒ\K{VG{D?} //Ν564^?olb21 qq׬`g^SNl ?t7ӹMM6>>~444gϞ4h ]L4Z-&*0 C8eu|"! 665FFDB=h:?]v.]4'7;;wn9+wlvxxx@(='ϞC`7w g{A$^;;FDDU|rk#CA}b3 bКq)$ C8G} 0WWS]jѐl۷oY^^9--~ԝk##mޛxuݻ-OX%&3tahP-yQf@j'NqDцMnPR{6vN3ʕ+ gp6o\&&aQ  s NmR"VrXQ6;wdd~SeU[/_G VVUӢ6k{Њp jB`R pggooy)P1r]iG'hE8Fe )^us :s@;ہe{@~vНPEw(t!pBB`BBQFGjijjhjJHbcΜп̲+%$'+;ls_[I Qm}>hhhHdBv2!09dI~>EDF@]* Ȩ2 J!!^'66̣G*?32@g==?Azoo_5uﹹO< <<55^UUBB7nLKHH^\R!/0(٥A@`F@GfoI KFox\\\ܽw_TTMM-||zW@Pg۶m.]NNISPP<} вsp߸EN^ALT R::嫺}A5ڣؼgフ̌[ <>B.nj 6˸|qy]O_`!wbbNC%4g*đ $ C8Iuc!YvR39bdd\ xt.X0sSQQ䠥⚾qڛ7lXUSSS129zYZ8qӧ MV_@A^VTT,'"KŋSW!Pg,yC_\0olj#> ;1/7ƥmH!EM4vܿGOO D08r}޽{gΜ1@;P55%_MO0߿}ȡ?o6`).* JO<8&|T\I/%_2]H$3@pOq|_LI TIYEEYeݺK7nڨC@ \nmuήcڲeVݗ/)ưz ̀lK.ѫ#|DDDLL|죞~T! !)@}]CBBB`PpoVZ5ĸ禁JQ/L˹4Ld"f|\o/yD+SPX䪡Ά{)$#pNnhhÕrQ#)>=8(Rn;Jmz."֖E%@ ځCf(8  *)-ZbvDn#C8܈"} uϞ7oߑWP,A$iV<|< )*" Ւںڭ[7QB_ [[{v(KPs`p $ Y B!0H._ܺm+xvZWɃu566' wvtSq@dP1o C&B!0\v֝Pp¹F;hk1C% $$<8edbƹ(DШD@FVwv6V!!xFmAmC GGbTB!@g!ϣچ@ #2#1!@ 3AmC GU@ d蠶!: IDAT#'FbTB!I"""C}]11Q1 /,\d"}$++wۖ?*++*++w|flXYYyy..͛7(-hE8n5 !0yK>>pm.YTTrph~A3_6Dϟ?-,*2~@pj B`2#ɻ,4$TSS 2Au v%%%}Vgg{g.XXbj:o񒥦f11:::sC22˗ضm{ssvĤ5khpt|-''/++jk{j֖f ~䩂'Ylَ:ң!11ySh} ]ƕ qcqId)7d .".. XY-Xox`KKsv~'N [w޿k>mk|ss+WSWװ^륋\ &HXYU٣۷o;kkjSR-_~E/((( r6=s =o>>{>UE>>v }VV.X8OJZv) ֬Y5*Xnm4>.:dddshhjӤ6`U* 0cbt֬Z t̉in4!=-yѢ%r 11<YTTeqqkWnr06DRhFfzDd7HHHf4O_X rw=/*2\RRrӔ84B!0zSP/**Cjժ7o͕b:g6dv꼼xH]}}G{ )Ƚb?A-MMMp?==v ܸi NQ-" 6t1 yYi1 uii"&$Ԟcaa׎$$x>gd ax^ ㇏a CGG.6/={ p%߯oduZ$@ ~Ayڵ{>>+VNIMqsw'OOϭ[ˋV\ ֑_@XDDdΛ[Xrq^OҲ<}}hΝ_>֡qB CB!0XZZoڴ[pݻٝ޾-.*#!!/ݧA2w>UUUo࣪ʊyffaa^>AA!o^Cp3gї߹8_S]D yTF=>uɂxr޸qýu>\\\x𤤤 329SBOO>^ga:&ffQ'cc5@^S|# OpN\Lx7(n8!)B`"#DDҒa?i'rPۇ"N4.B!p2`B!N!N4.B!p C8 5!@ dM !@ &N!C F DDB  2nPB`8@p8DB`!?acIENDB``!f$i,c6Hj44xfuIb"< (4rA P:ȑ8&<ɠ3p:{Htp@=Ѓ@f"nk]+zggU{UjZwO?OOܟǟ?7__;w???_yzʿ7Z&Bۍ7_oj{.-mk4 ߏ{].>ʞszyyc_+K P^ P?+< +yW^m=ϛ~ӧO;Çϟ?λwz{{n|m߯_٠ :͛7]|Wr%.˗k3A?~߾}sۈw=ҽCpl]Pr<.g( 6!X?Ȏv }VPn;}]uKg|w|?mP>p,n'0BSXԽ%j3 >tHC.msN<fHoT6x7-q=Xs* )⛛{AO4=^ʛ#> ^}C|^+~k'ӫ~rtq}2Sy|q-Zs|vH9߯q̕RxM7W>yϵm<qW^.OGyK~mI骼FڨMT>~AuL:Q]-+ѷFri)/\FiֺG|?_R=Kf6ٸWP9m}X1a{Eݪ A|9g#G~Է'ݥt}'ڂ>d|ULdV\+^ j[:Wr?ks?בFz\W6o.Ytk׺nkƈ_򨜫⹚3 qxTٮ堰ȇ8^$Σ4Ԏ݆Q6u=۾ڬګtM奦3j#_ꃣ8[ \4jGuܷr~~[_T`[XkUYn-Υ3k(y:}k\s]F#p[K:IɧѸy UGq.1䷼/MqiFgT|ʫ$W>ӭ:5ꗗxmܾ׶2sqKz\jMx?=~T65߶O_Vq\-eysK~Ͳq2\(9'x{WтwMwIg;p#,峦k]Fv*w uEV6m:%5gsF9DgT|u']{\fyktm_rqmMh.osu<*ZK|O9[3ε%uDK(ͿoUHsڨMVg%K߶TWkrlq[gZUgfٸK{GW?:پKe/އsFmRgM\\hs6>} ".㕖ݽORm[}3->ޫsztg&2zyxFcI[,YMT|'+_ {GU5.|ɜ sx=9>;w$W\/Ջh.}/1j7K<.Fj|#;f\.1nռJʟ|<}}GmPޏDL{ZկX]Xi˭o{ח(T* qlk(m{_2gqQFu<*Q9r|2 W^^s>oFyl1/ʫZGv?V6Ig uyL0jCrw~yZW6/k߮&SsmkummceIlxӬu3wkSy{Zk(Ȩy17 z?Щ/:F۩a!w=e<9kwzGݜ--\R(ϫ|~:gfqs4v,ut]7qo%5mf߼ 9־[ʁ}|[<6w!:_4kݜÞcr& lϣ)_t}?p/KLkq*'s+sZ۾0VM_=so?_j9/7fKյ\7Wl3U?AtBWG%9:;q:Qp?+H.o޼9r(yWRv޽;j:AanJ `9gtF|Wv9÷17>w ĸމV^~6ˈ'ܴމ8~誚+w߿̗W?ʑޫt90}1HSƵ%wBt:(g"=E7i^ǷQ 7 ;웆ڄGԹ j/c?οf'~jkSãU'Qv3㩿~4DKߓN!Cx6dYutΖ}Ի%{Z2Jzc1'33u7=yNaKdG$t==|\,ٽ=b4F<9thǗx50STzt%]Zc,#3xtRKzK'zkUֺMPm:U'_9z'ҖMud\\&ӕtO# ]E&OJ7"Sa65Z˫>c0/_6=Wg=+~ѪzUJFE\.7/j&ܺtkwtLr. im=EWr}yrj>_{j-SkxԷ|$}hWܥ8%ykTs#O3kqOy]=W>δFgK>>(5:Z=i4XkᾶtFsm5男(C Wc%[@NUשH\qhGQ.?e3*nTgGy5"}G9KJߋj#si˧}ߪ9>n>7iW*]:qoRpH^: j \xO3xdTyeSQ?*Fj]۽4u+!#^+ hoQk^wȗ׆j6Y.svQzUZc _~陳';4-8kDKCcjshرǝG VăS뙣9o7Z} }Z[f.}NeQmܟ,-s/q[#{lJ|OQm]/Oڭܾ4%Oaا,|R:> =lkPq+|r DyE}.b:f=)rc)5*__< oO bn{K猰Wg|k]yKhϝ5ᜩpu1(Ƒ]/"|kc:C!&t9gq{f|AUxGygj?o~:L̶y3z\H{+ODYu^~Fb.Ú9yϑm3@._Vߗ?+jERRٺhD?#~$ג1j_s!OtVUTޞ2v/pϢQ}OP}tYڣ[c'`ϣzR]9uF>S?*}y)sճe8/(.R.T|UZ%Q5=tFIWsZQ^[[~3jϵ?9:Eֳe߻>DG]Y[~_ee5WKO/̂'[4FOt }6sʛJ]9upu턯1~OSeeQz_]GS߮u9MZ'2y+!3uHg8iy^䣨:rxNe/Nso^?*}Iըk9̕+1{B:M=ҭy>_yu";|)u1#9ݱPSg>5@kAzj7>wC>5nИ΍QJsklkCHԵ|j'+*(^Fw]sؑX|Z򓞮{/j}t]u-ϸZ%q{_Wק̵S鎣~Pyn. Mr{Ě~uYCvMDݗJrG:~-jTkk>0Q51sssa$k>Wm eXo֖cGX{ﲗiq]2Psg#Jf^/g$]im|)po|^\aϛw|1݋ww ߾}#/sy H3t@/;RZgc^R(#h.1G'Ն<g^w[߻eq6y+3 ɣʋQ m dύI^,Qm"ڐOJI I׊x:υs㹚Go"RZƥ/x^,?;x<]ucϫo:uvu8HqhwK~Y+"d\?v1PɚxVv A)SH6RLɂ:v{fhKqthA۩4oλJtY=RC/[ ye}%Cg.Lv*46򺕜S%@v:RUg _zi[_{.#u=QEΥDU8Dxq*h~lI]C6nT8]Dsv{I Sߩ9{n"ssDvj}a,?~R~Eڗc׺k4oIn'NR;mⶣQ$Og7;k%Xm$4<5oE;1g.KXnGso܅+vڙֳDmZR5KԸ/t8PyHS[HǪX:V\Ԛȑ'JקuZ־5I5%+]Rcp' *N6mcA澢נܽNY?si\~|͏977h}S4JS˕c~Or=ܦp^kxkt4F9έՏגʹν~Ҡ~.vYF+opznrWۢ.oi?SUw9Ψ}/=^o}oWS-e߿QW4GlhU?kӠ_f,QoW|.9<~)%_;{ 7+=C |Pc GBqg,AW,D9mEA:4,J7T-YAݱϝ {&e < Bs=s??C0a܏KJaT\_veunZDq?O͕;o˫oHU:qqFGsgZ:r;F:q3"țމu/( xׇwMCm#\||{j(j3?~"O*皶)5W]GO.g{ҩ:x>>U,`:?gZq]W_ZגaG`dtxWסYGͳtwE\%#-=RUyS4bɖ]~ƈg48߯ڦu|S=sB&o5'GX+3KWS.8^ϲJ/Fr퇲=nӿj<6_;S{yZO{ siJC'_ޢ1c'5Vk"Nh>NӚQpIQ}/:q-5^~GUQzWթBq{<茚 EgTZ=f.n|jn]0:8{Z!=EWr]!#?::W=IIQsW2y]o|jgζGշ4kgTs#N3qOy]߫vodY3ΥVgq>5GkC~S~mΣ#~>Eی>K6AHg'$?+!#dr֒[u&F~^ST>FV%Rqߥҕ d<;sȡ0/gɷRa_zs}b. x~[=7[.Z˦xůvaٻKmӿ+~2#Z.餣GGGzki[rRkF!qq0t{F)3_M>Q^\CW"/O]:/9ޟ +Onwi[[#=+4 ^\'\?46phرyɏyU/}k\]{|:V%/}ʢQϽ? oZUHYomilC+G]8k_v5sq-5}~WvI֬;<<ڱO_[>O)~Js}V{2Fؖ(Ghǚ}⚫klv-o^+@gNS>:~ǃIӹM{^Kp:o 1gJ/[WZ|s~#;{~X:"´GϢ{w#u/ng]}?uV1Y2gKmko"ӞP ֌3|I;5 ,r3u.Vio\KiwC63׮\^F379{ڃZzdڌt?a{tdtx.Oѹ\\sJ'V ssgb;W ,C=?3ok<;׳Ln/)[5>@ʼu ]܆θ/МlhW\zW;üq9K=1uFOS#Qg,Cv~p [#U (m3.SELǩ~F>qͅӆQO1FmP|Kpi8Ռ4]WT4V%9R۳ta^O+/z^H/0/ŏWs_FitsvuC_߾FO:9e15tsqꌚ/;+1s:m`v^Y洴4y:csԆގS7JsP֮^YB61d hžsMrG/Z'5Nn,w+A/s#%}r\c3<5U"e_C-!f{G[tM?7\Ep ڠ6bwqͅwkKJEϮ}cߥo5;v_|~Wx(_W|Ζ8S^͛ήׯ_?zjۍH_njkDg'_V!Psѣ0O????~~+˗/^ݻ:6NdzoPa7+މD:>}ڤq]{QW(L:yҳB? {eܗ(}1>(kΎ$gq빈Ҏw3$q.ntu:c\U7_r.湸-2'd}FP3_/C&]l{y-/eόs:`ҁ?#}KyqD/1}C/r4psʲ#V}Mز^<*zןN4StF팡I ]/\~ұW(deִdNqGZSq/>*=Ӯ3ݥ`g___L,C/oeZ6F5Z#Å^y=+[tV{i?KwKU/=-nGΑ$5~u5\°j˱L+ 4'NYpf_W'|_qЎs߽{71y}~WǧO6:ȗ/_~AAo޼}{dc~? DU4jqÇ4q?Wc[\*aG{/≰ CAΫkg 7c!?@UH;髯6{QY{yDe}z~iu^I6,:{yKC&dsjWt'OYW>#D`ɑ:. ]+ D΃7;o~Fi>zj2H.i%0GJה>UǵƵkt/M:GV]F]MƲo/ܚ~1S|,RiOV:/#1GyC/+|>vd׈}Ҩ2uS!.o{4|2< {M=Wps~~ΦX緜d[q&jeCgs}[M:Λ[F4dO>vTX:cId~]\߇B?r_SOMg;#@g|4G#QŵZ=O~^ޟW;ڼƈk -Jg }"Hg\+{֦qt+ɶ~9`U"[+ݺ}GYd1vN}Vs^M~C2!^_$eo.FѵER:=[V_ֵ|DOW\ 6 >=B{cUY5LCD.:PSjkyU/* HkOtÈ#%bcxraG®qy_55\n4VsU94vLok|ԟڏT~0M r_[|~Wx(_WG|۷ox_7oldW{^~=&,"o߾̻w6}if߿D\%O_(A.މ6vq߬oў ދg>k.U?*[a JnIѻW_|LC"Vr0G;(NoߋҌumzuS!W5.T uo޹Gz:|:Co}mPd`Թщ4AoWJ(ۀ{OAUտ~[]kWn:~)ێ)u ]BQ|#&m"xs>3_mA:ۛ~_ƘNvKpm'w2l PxX5,6Qwy&@t:l-s_ G5}G$6Vglܢ=2x8Wnش"=MD95:c/;θkDBOn|_|l} }\_G(:Qծ/R?QsjxM? yޥX+ \B pcv,"_m%I&} [!^u/h>66ú&6tFp#_*~͇Uc ,yˬ'KЩm"GG>6#=k }o. Xu?ٿϝ| akjzػNWkAApy|_)/Ͼ# P?+F?-kWG|G@۷o) f~իWO_\GXzÇ}ǏֽfNEϟ7n:ߢMkӛ7o,ƒ;Z_+|||i?@<~wg(O\.U/?=ۖ e@z] v۷M[jc%'-oo=e]cWV}cd_/rx/Kuܻo j7k|a]?[/zjXb=L_|q-FGܾ:#w&hMW\W!wzvX+VpIgw| 3 s yUuzNgm:/tFpuCnC_ }uBmWm:cBgܥ~g{Pwa+pu/-]Nv|5lK6s[#~ nZsd)lv@k݆nyme|옧/wSQR= Ψ9)/~Tk^ܞ(x^L~#}N=c8tFp͐!lYt%yqT*޵5mʞ"u/L> ^S??'37|߯|[{*_N~9 )K$9'9v^Nk1>1#6~ ni~{K(>yj{EvvRfՏe}#ý?2j#^l.vY+jSF}[FrUքO7Q\%z MypE |~?_  pB;} _|~W)| )_͟{O_|_6V??_??m_'- $|:J&k܋S?Aԅ#~G=P+t2Qu]\妵>羋ԏJxܴν^FcGϋ/FkOJK6Uߥ@I5Ce E\ n~G `MzڇQne0`;tt'ָWg|g٣eBz&lφ.ug{ ?E;?K}Oz2.wVp;z?N"ݢmN=o+zFgbXl~M>4*Ցω2ԼIGY y!j>.SYFݹK?Fg3:F*9%|,]f9ַT>%_tngKglI.ͨOYL{u&= Uo~u{j zS@{sm_W;3~5r^~N.tαw|vԡΛn$ho.╾(Q_!8o}fGy>͚>\z}ਭ-K/֔/V}=}G'?$ցk5[~ok_Wۢ^uQe(z=]̚~m/Wߚ]-Ku'>.59UgY3},ͥklϔߤxvͻ\kro]tcڹַo|>q׿MRuV[sTէn[Zຊ|5t yj|{:YKmߗ1ߤt6"^(ͺ`[kCK>gцoD?ac{z_GZ#Ark 镾6ɿ5ת[/Cg?FuijnUύkyר RtLqU6 vK}K量>^vX^#=;bϞ瞺 kEz7[8++gFeq(gFǯwG e+ߩyy+~o7kvMc=q?Jmiبx:Fuan^xdy\k=Ea^xD0!\^HF?#H:HV~K$[iINHFG!G {xGTa?osF9Q^/Bf+\ʻ򊸪sq/ҕqI*ȇʼ[j<-LouU=b^^vj*xjm{ ;陚66ﹲ^ϻύxBiFNx^˥z5޹U]~mQ>sVبnKv?cy׹@s2 :oe]􏮛t*p,QvHLjέ3FH6!Pa)l#?QdGiײӷMg\|-ˮ.%߻[SK:\Q3TKcn7.= :oRe?錡׸:lsH|d9uFNס.e5ŷE3}rIoSc˷ϋGڲT#Q>KV;]˛x3.ſ&mu_7#[66Wߣ[=|mףFQD߅3V %tEɺIjV8lWޥHgGvz}t~lG'}B~>8|w)kXk]J'Ñi;(ʇ6)x7~QszJA_hkl+åzYw~)}LύlaK/[SQmLkQ"Ϊos1E;y}X+sϏ  c}*7|wBYVLNOV%D>Wdq٧Y ktY#=C |\_ιTe\:X}WGcߨ^zYbՋF^_so[}#JgN%?ww-;}yw<:_Q5P+TkG8>n4n1e۶mssۮv;9Cʲ nw~Xwk{1K\ # |8Loύ|αolګmlIhOFz?+й>~X+/5O|LZJuHY;nO{OwCsy;E_CY hXik^ڋhk n|sGe%ESx̲.;i~}.NQ-A{{zz_^ߍ}O`spqt ?^܉{w{_?~z~{W%61ӟ{AAеr A!! 9 AAr A!! BNCAr  4A!! BNCA  4AAi BNCA  >^z..疁ׯ_i+>|޽{Ѷ$kb8}ׯ4RZuPk ͛7M*rJ V_|i׭./[<|1߾}nhe;!6{Acʁ7{j59lM|X)[HTq~T`ѩ ~Ci|֪'VlQe Izknc eXJ:=??[&[l]Hcu~H&ޝ[`{8EE{Tsf031L˧nO%#zC,^wՌ!)bkOo/1˭质|+Wd`W3 [Bc/)ͱA+f:ǖ Mcs/L9e/9N^^2}33ڒ,ƽ3{YC&,<Ln4< Nla_]ⲴS--qS8hQfg [)gj]t8}+{Vʘ?%iםorlY0o59n]d XIL$s_d\Dg被h V데-$;K 0;afV[<@pb3]OV_,E]ǿb6|EldpNc.:''΄:}+_)M.-Md2ffuN.|7;@W'XEe193~8sesǻXWBmnR]B gĊڐ=ؠԬǤʲsߘv/O˲4);VK <3m9._dY $ˋS,ÄCHy{O9evR+_#}bMC9 SSXy`!nJV΁ќ.}1`iICS7ĥl'9yFf᧑^}٣Z-sv r;'}@6MtZԥ|+|Jlrڐ zUvh9n/Mijge۴v*I,) tg 39,]rB)["K.9}Nu+#wӭ2R]FNBtYaTݰrLDzYqh'|P0mș3gɪmjn̋|'z`NSj/n'oR3͜[:/N[)o'] 3oA9r׳r{ҫ>KnŚvy}sh)iWW͞Xb !R)6d^F46|)n\3N>jVi'ڕۮ rBEOw8dޖ xC9]jvˌ҂'9;宯蝦g;&䰻]tɔ0-+55L7gSMϙJfk~oQ=0%^y{Tz]`- =^} *н\G>t*#Ͽ=%}S-E]ʧ|E͝kY.JLC2YYuN xUfl7G~؜;ot~̽'g`RiNŎ%33/x&KN&ݲzMpe+dMO$4Faz^hf=vgT[&>yʴqV;i V_Lm8WEGlm+-!m|vl>bž裊ڬoөnN6#2eeX$;+խ1/pDCz9ݽ)?n_ds\;1eڭ K GyNc)v׻5pmULcsSc?u ;S++t) \]SޛKoOwǛdvmSv1dӝ&zOOKNCA  4AAi N.  4AAi BNCA  4AA<ݏފ1;Aޓܙ6Ϟ[TIA>SГ?d-BA#9 9 A!˗7o޼zGik9ac-ܷi#|[-Xx|_mϕIdl-g#̼e*lhv_cMEh)xnkQDy~]zX~^V=TGZUS<9('fUf{_6Pgce!|5A=ֹdӚ}zvggG8dypgoZγw~23yq^O{*'HŔ-vb?{lدQ=4׎L#صWGU)5#ʪVU j=ZBJ摺`o;#A7/{O<E#.qgHG=??7]k*SO@y2E]34*tgVe5$ҰSj:uQdgTkSكr6 !{Z0ݭc>t^)]5){ [k.omi**3̶[lVO=d亲4*t^w{.<9*6jnON`C-%Ÿlb{}.6ٚt W\(fgZ?e+]d T<-.ۓ= jݟڂF27YoݞoathHf8Js2&(Dn hw3яZ_ݶi6WC.c4vg#, ?m(3"stN7GH)݇r:#ss9W(h[ O#aN||)tO9Iϴ Ө.̧N+e:Nƌ!y %eUzzusN+[ҙ;#A-k9f)_H>vLs\z{nd'v?{K4cmzPu9P,h4Im'|zoNzMIL&ׇգsHy)mhRmC4]v.=F>ۖsț95_fC|?wIGz(\}ҺBJu.2xM;G醣թ(b 䴏@y_\Nw;㕕e Tl>Э\Tɱ%ZGcwSb qhXW/ {o}xUZBr|'er ats_:\6KW@Ik Ai A!! 9 AAr A!! BNCAr  4A!! zp9'h_o=a6#oys{%ʹ|:NȏwZϩ uα>tG(r%vJ/+^4-ب6˗c{G!w&?5l-lrDlo%n|;ktλyL0”SHvP(t~Z3KTcVC"9=uL~KEx C.^nwC/Jbo6[U{ G> uN!w[ތqm6>yE=L*6mpg߼ۢmH#E2-"K5_m.uO grzr\C5Tz!go!Y#B'4%4ڤ Xwۓ9*EpveN#E]&!xd"WXgrm}sUܦ6 yr;5%yrwƺ`ܶ!o:FHCt6li4AAi A  9 AAi A!! 9 AAr A=ׯP73d8 %9'k˗5 –< n@N.9p>Խ"n9 s< *t(ךH$ؓ-v|jxQZm2+G%쥹3=0S}АclhXn+BNVQv4]:f`{`9w $R%PŐkt$9=[R}N!o|C0oiNN;AdSso8init+,i{4}ДcFJ[r"ti9M1CR^wKQ}鸪,v>1}23R+rzE>~N!o դv]E.9r:FF}u=|f9{4poX[mZ) rzJug3v9qCT˙d&;Ѹ$NQ×'zNɜλ|,m/꣱:S˛y8ږuO䰦LMXظ3y&iCϬ6Dv42r۩R ݝȊ!r gߔt).W9H2[j3 "\ sF,ZH><".KcɛκyULjHC~Kgty^2;]un MWs]QأܦQQmJcJnKֹ4>\$5+R̜v{`68juε)>R D}rǖL7gn0y.SzwׇC&#͐t_U ]jҙV_(^rbb?~%ӋkrFurrl1zT)rzi<]|9JrTM X]y. '@>V#iYyӨ+^iIO#25[.&q[(aTQn')ǺۚJEu 1Ml =悐E`N -s-VS}8#R9HcI%8yT^r%c~?8ǖme@L98M)wzF- 8BNCA  4EAAi A  9 AAi Aݕc rS~O<  9}ʳbIyz~Qɕe+] BNOy~Q٤![pϝl AA= m@ܮ9.9 A!˗fVdi4*tżQ+¦=4R/Аp;/q\j٘5g9iCtru=9йS짙˿>Ca9_[yg*EQ1{#(r:#ssvI9W(hX OkaN||)tϞIde4*䴛%̧N+e:6ۘ1$*Sr`F9lׅ7^bE*&,q8A7/i){M>vL[z{nq[X^~Oͩ뜭sS!#K ̮j&A4o̤Iݢ=?5u3\:{Tε#SJ݆v*UԊ B-ѬtqK;^2^\k^8A7/w<~4{Ȁ=S,?C2WsQs92۝nHż y 崏ChWܛ>qtjj0,E]CmӦ\K>sQ%ǖnvWE[!+_8A7/WqrpHܭ߷Ar  4A!! [9G| Oc Ǖӹ cn|Rb57|9!Ǖ}wϔP,qO1ꔻA龭R?qE˂sϯIgn~ }We: K}r vKyݞܽ!7~+e5t :}'/v3Ӧel6f9rzmn];u(;/,onvjJv Xu*[sg˞8} lKvsto芸4O&yҹ;Opt9zDjh ۤN&Fr꺼s%J0E]I& \hC9o'S6o89}󧧆"|st|J {&\ދaإci91Jwۓ9^#a|{i?0kZ3>! OO^9;MH)s`}DNN'vwvqC9q1[{OO79a<}rO9Ο./NC`]^,N;D 鮆w'"{8_IQj9-88eyQt=єEN{G.EnNNq=- 9z:^#e9FĩDr؍Crz=vCxgNAtН;Pk( NL =C,_wtt:9z܉Ю4 +,!Nʶ>r=iyn"왽b~:܁N}t'/ΝH L{EёDNȠj-4lNovFW(9Wip-ts;YCLΟ8w"5Y)S 90u)4rV1"W%ů,~'u|΀ A!! 9 AAr A!! BNCAr  4A!! BNCAt~9j< ׯ_ۆgJBAt9~%r -S)LsϷAvU_6GI{=4𡅴ZH~ =b{,nTl^6Yo'! MLm&8 N!6aq:n?shj^γS=iVJ8o)@AН6`킰Uw<9BI"-yawcr z,9daJE'SgL,sݞs<MH(2ci >tMd7ќ~i:C?؅hڽs4g"6t~+wF}4 kVQr[HgM'3L>#)nv7p>CL1EAA-8uXԝz& }kd}ܝAP8sAA>J9UA!! BNCAr  4AAi BNCA  4AAi A}-Γ+ٿ HN7܄ssֈj 9ӧ&|r:! rdG;Ϗ?uLP^Qy<-Ç7~gV_}&цi~o鶷Ofk}լ1ffxBǕyc?y ʱsp+'Jqv<'gb4akJUrKe涒!}g+-?H8^N9byR+EцddfCZg-1,2,zYCߦќo4'^p#t:{EWӝ֤3h|sSj|̹Ϊ9J\ʽhzSyv2֓CT4oitz`iBn-\z{r} B9Uut:&ۃNoGCQ~čS|ܑ>ƽ1M98+Wdy^!2$:}4 NdD4?.ɉ+_ʃ2`J:;H6BO׮ſј-u.sa)aCR-8ŸFPVU1?rvIQmOI]:M=4:}bBE bMbS2$ `!]zôdKȵ#")jh>R^.IqcчI"orǁ-ss~A__3y|xy^hyW]_Ǐs<)?Sl-y=ׯdy](.ǪA&[\zbS-Yߚ2`**9SN?Ajn,][DBb {bբN|7o1Wq/Dyؽ8hV8, GU5 )#g vUH6y1`\B92Cs؍4Ia#*'E?5'BhNz*pJ:}$4x‘Utf_USu:{k `ȤPH[—@KNӊ~oۭaf<;:M_8IsuΜxLu9%Oӂ*6tÎrlS$L+yM:N[ (RJ>ti<,ܣRu.tDU@ԀTA0@^Iӗwsu,ot|NbjL'sʙ.HrU'wkQQTdCF0LNܔkBܡvOlN947f:M3ꚗaΎנ5yvxNUذ&U}:kW9u㴛:}N5M<,VuMkW Ld*lRh2΁AE .\r"/x)g>zH5U>t8=}WeOg 2~!Z6QL+UGiB[XS+=tc2)W1ȶVoj,5e:©^ E^ KM1͂C>װ"@wG^7/0No>7ꢳ\ZF%4:}$2f杓z5:-"""괈"""괈"""괈"""N"""N"""r:͚0}yEiV"""괈:=o߾}]6jZt:䫞@g8KM"kVy%&9~T?Ⱦl{#O> + 8IRQo$&['9_yX=%c6eN*9Sl|v }Mҭ2hqǢͽ >GA +%Ÿ׷oa O婵] Jijkl^W 9xDəp4$^yR *)*Pe|zj>9a7<9Z#;m]4}O+TVpf#Y&u5^ q8'ٱ/6tE#rnuv[tf{:MX4}_ HrD( NOυVN3uzozFJVCm]4Pw=7#*R!=zi$œSi;jMSZCӽA[I]ӴK4ȒǞ_8(qe6M57Be^Ju>aߚ,A3t͋s^Zg"[$FkVIb122𜾸Pg{:Th ڙm{t5:! Cɜw;6Aiպo;z:Vq32roL>"TsOՖZ[}Wt:=ܻ 'DD>I&Vbx?䩾N984#Հ+I1o|$\i<՛Z1K=Wg`vѡewAN3FK7.wOܴ^ej<*.@iY8ypX6}ƺ.+]ܻ /<+!.=5r8 SߚBDuZDDDi7"""iQEDDiQEDDiQEDDDQEDDDQE^?ebg_?_}˗s?ݵMDy_1q2g_ɩS$0m [e;~&N7?c4.F#Czv1cuZnPlL՛JL "%>f_N5 ͯ>Tb嬫޶}nsP捹b4:l$b|[d\gL""VO1눃d;K!<#uZdvE7CD#z8?{Ͳxݐۙ旍?kUbn|tQ1;s3aݠRH~BiuZ -CV뫶۹u׊Ζh"]nG}ؿ8/aC5G{d[iWԞX=HvW6jULďngT0_4ӺӴSжvv{uBj_iرB:Y]}) Pki99?'BiufPzlQEM |5+ d^pLo>n1G@Zng-bƙ]:̝b#Xώeb&B 9 St"MGB 1( ^{Y{͂BDDٿ5q۹u:$D=wpFv5p^spҹ}Lmws{S;sAzsZfC~ߟy]==L+hj> cG}QQE&O8HVc+ Ӌ4v5e_=gት$Ci*SҞNl~bΆwۭISJAx{ 괈:-"""괈\Nϫ?6{~:}^jr8XGUk%;׿xgE|TU">'?(W _0JyH5vzT%=V?UoڔO[喇u|kYw?K9! ]\jKh1f5NE(7xl?Y?@M i{ g?Y{̏\H 3(@\-' yJj՞y- @^P.DJO ""^%Sɋ lMKo`0M/ԏd:<{9-$g ;U!xh:ӏ i{ ŰUNS5S+Ǎۙh^swgfgf\xB5)4aZp1%C}l - N:pOv\Xs_z >0n/ ã*iBC;:=:VZpcro"]pC7/!6ۇ[龪Ryu>Oh}w2N/z,{tcm>0n/}C48"@3 a $ߠGSw\ 18M%ϋ/CWO ]w1uܢVuuH!:=?z…tz37Z+ΫskTL-!mCG ӑ,5zWkBU ՘kI2DLes{+K9^[2 }l ָ+v0Ľ0=5]tr[kAu-(~`^ {!ZhGՀv!8$2cn +>.V|4zrpxF RͬyjMu.5W҉ Gk0/fνs%$(tp3:]"Ǐ:Ssw!-zlf_zqi'QG՘v cjZF_0Uz!uw|BI}:] &b^ާVNô^^哸O}E{uZˣ/*rkT Oӕ]ڧ^S܍mɵIjK.:߂>2_N\ukd℗܍cPx>D괈"""괈"""N"""ta{ZDDDiuZDDDiuZDDDiQEDDiQEDDi Q6"y"N"N?}?+X/_$ݻwo߾ϟ?'_|!F|8Z> 9+%!sʇvϐC'C:_ۑz&[NQ%'%pX.*s'9ӧOdW9f/CW2D8$)+bWHowpYR nJx̃.yb6w+pV$JA\C?B+"?T^R*,tTuj Z0!>+CCEPw( M(ǜw"^١ev^b:hC0W\Km,u*}i[,4Y +EnJ`j:ݣq:M3($fst_|@SvUD@U,w8њT)9#2$wf= C.|,k:h3.Z#,-!_7̮8|Ctz8,YQ y.{DvtM 8Um4 wz,"OD۪sMJ3)d2jy/J<{wC;%>|,sm_8gYEmt! ;IAq5*]bzWm>\s&'n=|x1ly.t]W N3Fɀ)B'iO L`7T !T C'5Sm5F^=\cv~<~Y;!}>Tj( g Ol3L|. t]h!-,&n=ݫ6()+6.6Bm-ܦG;?C ) wADO1{P$`Tr(L!7:#M>ԭ>B*z3L}Kj;E(Ly5B9aO~K UI F,kbkfEwBcH\3~NF?uNwbN?v˴>%$iqqŻ "WյXsU}*Oj®7xt ywP}҅w٤m#F۴ $:WS/wҞŗ@e`4}N<ԇc(G~yEIl8;ϤٺeIi \I<3^ gwqH Iq/N2}5/Ꙗ9/?e3$"괈:-"""괈"""괈"""괈o/ϵB`!*[,<3@*?qvMؕdWxXYkwww"b &v`a؝H b`؂`w 320Cry~ʼ̝w{O} @? * eKЦ@ɚ_J~W&mmCZwhCgc~"0YzzMgyU^K%m/m$]YxJuz-4ч_0 0 0 0 0 0 0 04}r_(_n/aaaaaaa$+0 0 0 0 0 0 0 0W}aaaaaaa&S La_aaaaaaaTWaaaaaaaa2N |gϜ?t"BoT˗8v(ݽ}{*C7lE c Tx}ߞ=Xh ׮_S's;2ij'OЬY3sg5ha6rV\ŋa`ط7LS'Q ԫ cGCA}TXo^ѶmT\cGϏkWʏwCOccnKQ޿GfuX~[\tI謑7^ݻ)l˖,:Gԭ] _>6y-h+l/YQ;?Y*V [+ 9T,߫-""a7oJTxGXgFM=zIU{֭hi:˾}Jp^ҭz#DkM7Wdz&3L\2zX9y8k2d"*W,?}'DzQ,\0_ᵷo7 ϞYnt 4%ŏ?Xg&1}T5oO>;oe%}*nA&&̶ge2=3آjX e[M<~@~]18ud1V2Lf۷o9Z X:5bN8CqC鵦]Lq@VѼiԨRI[ʊt[nW&Aaq ~>,;1w0WZ \a2:h 5n__ &y?ʺ5STgѲy3t`mQ G  AU,_S'N4߽ӗۃT>yk֥ &Ïl1rcٽ6nD?{|: , jjp{7hB;o`2ΟOj`ܹmeJDn5& 4w_ãFH[hmˤodΟgNzjXj=|v$[w)?{n F jm0z=:a~Eh溸-Ϯ7!C&my=sZԼ`D3stx{mHI_\ r1 ח"!~:I{ erx,]" P QnKnkWp[3W,$xDpZCeV ~mIWs2 gOjU eZӌ5r%q[$&s;0Q#-4e<_.<ֻ k Y~ ֋h{G%~Ν9M\G2mڔہXu+øa(Z{cަe MvqZ0d@Ǧ۰.k2(@7ofAMlPujV!lߺ),)_, .]Q:::0X|99/BzC>--g,("ٱ1sؾ;bۖ-Q dϞ siKŋ :\t KDkR/y>m d+~,,ðjȖ5K]=Jw5kȡ@n'M8_ǏkΊM"^zk2Úd߾}p!a:TL/_5@n]*4A߻|ϟ_9S#Q\YO9[u"_gH U1,ߟ lzr'X0 P9ðn\oJ}U'xT_p".Т.߽#gjJ(.^38/r*lE~];}QBy|Q{(`m9A1iX`:Ww\6m3:|q d~4vzSk\|%-36ŜdS~=|&ӣuVb᪚9}w1o:xT=u36g8k}!DklݹuUR/J3׭]#+W,I~yCa"_hkVeKD++ԓXvIqkJܻwOQ:xqPame|m&NX!=/LYN8sGCC^pvIl>f$?xsbK=V.,7_=n]:'\6܏jScG zLO;i*ZYZv=D.]PPD<$)ؽ#1}7o`(~iİ|MV\TF5b^Byg܏bex{O׶޻ujՔ# å:əוضg*ppn+U2Ƃi-ȶl߲9J6bx>۷#Oj.$۶066vϝ9uJ>:Hںxxٳ%OD-,.Z{tw˝3;]*Jဃ1t0>kը!^?yBZ2^}:;EƍDѰ^]i|KuB?1BE߿(5WԎQz:Q#LJ[ZU̝=;u}J_ϒ]k6ry/΍*+FHܿ^\Zk"y-N8&{P>~,ъ.??=ܤ<6mϚP.F?vnZY_RBsgaa%µŜҚ+D>U+ hڤ v*4dzxx ~]A+leyKK6jqn0_|׮^mA`1nNO&͜64;ys#oб!.)hp_.kDۚ)KL#غbLDsyҜ$ٳNqr-̘:%׵KX3ڍptO?Co"øMYg5͞QREQkVFV^?U([Z?է#9?` H6+ aVӧߑLgwlۊ2JH4wBgV8;t+e-T tKBgxyyac}zA;}hNzyė/Y,?ҩ#C\o:x>z_7a:~=ѷ1jժ%rZ>1Eu{~>YmV{Y`>b/%4~uVF 3oR-Y;*ҽv3$qzwS^*:K;Y&|y)vI7_?]G,^\GՄR<-J}U*U‡W?p ,u4h'ۆqhm[pMIJ+*ي*H|$-.YX9.A%I=ζ45T)>`6XΉ Ps=Qu;`&mQ V(t-|MΟQk<+Euq/}ֻװnms/'Mit@{@넝: w8~Hcc,|<7 ۉrW/^`۳X ,1c*9}*oݢpҸ49}իcԏp5묦1r0,?M5>tX۴j>D:KGV/i۷žT󬅞X79a_/ikS!_+/u-[ _,:dg͛͘nsW:oM:K.7~>XVҹ۶!I29uD}BlE>+_rk؅9g*vO1u\j`{Hߓڷm =Ic9TGXre=vr?:WQ)WDy88B20N`9޽œǏPH :k${VKtu (mX$tI}Cr){TR5Yc E@GȶPŒ~'F }ki4gqFՋ=c4.QI:޳{(Tv9ㇷSDXD}.CE^@uw ŀ+S&K GT~YI/x_0ܾ%ߍ|v2mϹb9ŶkZRNPq<|l9<ƛ~䇵j81¬Lz{.*[>|8~׮]t98ѿtgT 1C,sd;oC>TMϪLg)g>i_#ټ+[`y7X ӶV#ڋfF:;M-r%Ÿ}%*Uil_Y-Q\Q4n'h-$9Oݫge˔uGuaM>LaWSPlXӆ|#Hm=sFJ{ޅ|LYhđf#]aak66պ&4j$@}q~m٢wѾ}d,KŜ7Xř}Kc97feXgӋׯyMtrБUtt`܉O59k2ܫOuJv)g=n\£xp7 ޿×/c܍'c*u tٓo˗ ߵ0}T}ǎ)J(.tvD AaÓA9ZgN{uV|~L5wR;[fqî"mZ1&$;*?fAmlَrΦ?Nٍ7^$ʟ}>vms ڼc?sdH6E Ql^@5$)Ye(q_pa/qGsiӊ8u?ݚ<]NsLq=zf,8:ZNyh$YfOK}nXtnﰛ1]2hOֵ2K3= ξT))~uW|hy.nőPmӧN jx~QncҘ.yc~ͫOb8c̝66:j!w/cbA9oLMKsXouW#Dap :@8 $Ϟa¸q5|X椢!5wG{̝:at޶?,k5i ~mQǃ|hlR٥#<=BueK+V(gVc]&2opS{zG9fÁY]dIܷ>\ "_gXp\p ۵/^]=uZZZ8ql2@R+/ș=5^dd+>tV(RV.["rrQx!Ho`o>&Lmؐd%{HݵFz,i@\_t}s8JO[@> 8q9J!>uvcB8l-' G/%Uq#gʡpC:!CeݻβΦ NIY"0 0hސJ}ȓ -uwnCˤtؑ#i6t0U"6y+mg?e4i?ZYf\gU.BSg&Ig'ƛ'ʇut"B=:DT>?:Fܽ<ltzTW3_ű|xs!(ٓǏUuhβΦg\̻wVc>r.թK߸n j{:]u 3gO<uڷ͐ 1Ix@,TbtaeeeR65OA՚7&~&CvuJlt44Dй)z-qcCY Y|9k2krfK,zOw5 M.<>ydFh2#Y:ůpvm̶͚/::ܽs!Gd9B?㩣{|vowMw}hTOEh҈oYYY&q۶D&Pھ2FC^/etWg;v0Dsv=~Pt MβββΦ0fۋ_x_vS61D숡C]DTw%:ػ%D2hDہu6C}X{w/kN9(3 ! L"k5Β+dtQNmy]/R0Wv`MfۗQ *ȝ9C]=|(sfkt,#Ye~aADZ\sh3kͿ@,,qtj{uu62#6'Y Igo N7<ͮy! esm::˨d\c+W{ǽP*j >~m؎ӞW.H0Ӫ7ZhUą3GNGΝ%QhT[aeeO$3f#6i7jݺ*\>;k@}(#kc>iYle Siz.(Zȝ-tuD]indd&!NEXhBn/_y":Ki _i^]SGsLp_6dCR ^<['#1@c;(w&#dиȻwQX_:?~D.1u<77Z?7Dnt^>qtv|46{ViӧO?Ni>OΞƛwb%5'1w6oo:;ܺ<Ŷr[%mڤ J:FynhIᅆb4y#Dc͟[׮ȡCiҦ!ӫ'_i0tB̑}~%݋N x>mT.խݦ"VQswh;yGgGIORzv=P``t_v=}toҼ<~XMqc <02\/h.pqr?Edlji>VVFM?MoΜPT lGߞ=`ܵ-ժ^3N.(YyŒV+`6{n:K&2X_MLĺr `>f47{pBc,^>ݍӬMׯ!j ޼eʠ~zSd$zt+K>uÆI}}ϗO$h;`j͚i'R`屾voJ1T>/a$tu-4.3¿xhצ>uVyv"$%!:ۺ̢닶jBħ|l݂sNG˗.sBgFM< :t_,U?3vZ+P"W 5ylO[bAZ\NsB̴mȕ#5۶5=(H%8/_0iL8LF:ϢGnwlJ uO==krjeϖ :MEƎmd~;wPyd3pQ.W[>ܰ~}/W qƍ*K5_;핆&ׯ[Ga]I嘖ǏELn|yq!v*h(}7M5^j¸xA5(>훗^!WS^JN. [*H4ow}HgO9ou`^wH6쳧O$قUTqg:[L|)sd&7l7ҹHx<7+ڤ7OrjĄr/_4bZ({0$$DjܠNE1k׊ؓ.ƓGsH1mɘ)Sɘ4t<^ibTWn۲~6mY516O.h`\ܯGQOҼׯ~q^On޼9+ΙΝZZNmT^Q/]VZE qÆ$QT)mZm>۶\BbE=wB+U9Kۊ-ڵjWB[.YUi4kWZc2iKUbyaN;Zz_hVr\FK`o!ʗG.Ĝ2z3I:KyK6 ?Ioc磧gOĉA5ߘ}(ٯo< *UyܷoxrRVmz=Ԓ҅ |EN {e ٳ CV wxꥈ\FqЭkUW?q n213&ݹM]_68`<2oZbmMv'1M(ڲN~iz2pFPW=M |odž 3|5x{תq1(HS5pY3x{ÁSG_k-xdk\׌ޏ1}W/ts]^/h]QWiN*׺8ƍLA, r^Jߟ}ϛ3;)ߗM9Ԃv޵K#hִ :T[ϳh\4n"T|)zHc*kK +Rׯ]@QoeEVr9fw*rV,_.NbNu0vZ:۪<^̓ d pBGp{goL0#jhkN<0C͘: ;kD-+G'4Wo'l'Z%\ kBЩm=VݲU0H% z.b^w8csw)Œmt,_uu~y_poۻN8ߥK6owy?~Dϭ>y(Β,g誕+:;۴h}C]jXۃIXԯ0GԔu2U6uS B&Hkoiㆴ9kΒoCSFoߋgF[ٓiCyo&cD%Gb;'y洩b]\^#?~D lPʟ\͚jcݚnuurPwIY(~? s33+T@z-E+okր\;5׮Hhڨd?۵S|i\Z\CL`.?ԯ]ɊҸb%A&MoT ٲx\^"SSͬE X"?%.%dRutvh3y*줱l{{C4hWQzsxyy1-tiZ7[w$'?&&hQĢ:(Ks{w:Kkz KЗ/9:KjP/5o-([_9|:K i$~c~?dv1 zC=ѵb_U,ׯq_eE[V5Wc@~XpTT{X K}Jo{mFxɝ[t Q.=QIG$-Z1lN F ]Xl 7H籙8Q7#ZD >TJ&-ĩu5˗bn9fmΔdA54U{X=Cдicnj9L=dێȱǶolOZ&٫gH}l9gׯDvӤNSL%#rck xr/9kPM]ǵ>~~꿄[II] =uua}׉/rK ]0ӧmcЦem`Цم֒nРN-ܿ{K% 凇3wc$ #e7?Lb@ה,qv=#F(ܤ3s¾fRxޥSG/|P>5ҳ&&31s0j!4Q8U~d?sJĀoJIM[ޝaufHVn,r4}m; EV(ucXg31GM/ѫk'Qd,̘znNbn=@e:5"֗{~1˰:K9g8%tXޞi=xT0t\:yfL.ӧ5Ng3 tQκ[ַ3Rn-7Ծ8ΚFղa5}r,3 :ˁꯨfpTYL#9ܼ!u&Ơ2Cf:ʛYQW`ʯWaMNk:u0ݻTNG8ffdҾYG\Dڮ4ӧLNo3&$@^9T+WIt-aXgՁC>8E ǁ{3RNSFYV-q$sw˸[k1 :^7#WOJ6eK|R\$N놴=!%sCX0_^8[+ꉔ(V1m$k.̙>۶CVgǵv>iI7n#0\vI(VE~4ӥ:ۋ9RLQ-3:F:'tMqm3$r.@{6Bga?k&vyi dXrΜ8.ꡖ(RHDNt?^}b֪^ 'Mː ' ,1vH&>[Zz):KuSǛ'tua4Og \8wF|ބ.^L L&Tc@ts'ݣzzg<}XZR׮?(S vMʽR159?9PjU*%ɔ r޽ؼKxSǎCdRc O\X&K-B %A@y$',; sgΈXɹhn!4$X5jԯ] ߿Kh,ػGwq8q۳&3 ۾ Q[lY*bOgh 6>QuH;L3Cxzn묘rE4E\ 4Br(T +{$[TѱuVVSV !yΝ; h޶Cv/C DdWRԩUS!?֌p+n2ŋ(謬MclX:o'ڴn-?/L='?.]:k>f4$ؑ׻<]cy7XkGcYgu6Xliyu6ybZBd_Λ tTbjTPA+Sr5wl,$ݷWOy[:ե{tՎ>$irlK6wVotlhGomsf Ry,/ZG-i;)ԫ[7I:FK}p9ƚoߓTkڟ32 ljc:x_i1֮/x*^˖q%̟$ȗC{LR/i7~4v#5mKΡBQkyr_;Z} gl1l>J#g8ob Z&4\`QwHG[[ԏtl=4srJkE<{QTTMzoUXz?-/%(^W,bY~I׮r=7uի>?&?(2xTRwwɊ$޳} yIǩjy|t|O&a|e||5MiNa$D{FӪvd&Q4Jh Zbk+ꍪ:i٩=K5ɿIDۑXJR:CI9}F,U(V\wd[Q ,t*]]qN(he&c|th}4Jgmv.Ls4GbXʭ|!aeMZn$Ifdt=7=t6$$z:jڵk3QsG(=m>Kfc|1 ::6cG .魳˗w;󄅆mxx|۲9WIq`'C&˟;#@ A0UΤ"mZJC>jVV>v*֚ܥ]#lۺ%sPuݟM>O[/_>a4 ʥ; K˯DXh6nȤM'_Įl:k> ʕ*ϟBya#+N;sH]Xg L_>sFQ\9wsȍ:-Ӧٓ'|i83o5 4NUZ,֬\ cL<:8vJ_t}Ο>,u;8ʅǎ*lv*6l jRMRF+?Rwӱrr7s 99~Ƥ..ol8ݱ=]tS:Bg1Wt:`J~R[`u&loS tjcY BENɾZ uֻkFׁqb #55m[|K|j6_$^FS.aZk/)˱L vEN2P>E*?e9ܽä&S *9i:B9kT&(YضU˟sp͛gzoض; S&ONpZ1+H)?ZBsďu l{}I&?~|&w5wP\վT jRnF%*_>iQI9ZIgϡpc XgʍHly]Wǿ3QǬ]Bw ca5kVPw#nĩ+ӧH&xKgǼAgUOkBڣ6'YT[)CB尧|=߬9|f窽K=]ur8mE }{o2L*̶w`8cRB?Ŋgb۬1h@/Rsʴ}ƍZ`Ю-gf8s8;ʹZ93T^pezMI/M ž~:/ Z.}+$% fMJo|9fI)befM) C5Ws_4U-]t|tV7)}vUܿ$QŗG:(Y0ݛr3Wa % gjR|zQLd$M&Ix\U]]ۜ C&hؗb(DժUгGwnD[pŋ-4+. _1l(_t^仼j%BEnWK(٧͛f-h֨dT[ {_Oh3&R&|ƻfύؼ3Wϕula/l)R]1oxADua2"_uʭLTx`iܸq:Zr{h&C;2,~q^ ]f ,o_*lp.Z3;}|}۷nZj_e~U|Y4X ?Kg\<1dqP^im-4ʽ,L3&G~|;ɱpe;I2U*WO_ϟ>E2Ѱ~=˕9ݨvoo.] ]vSk,}jFu]9C> M"/~,7$iΞ^|!uw;6;jnq_Lp\-[Cț'7ܿ9=FފOhѼ9;GoϲpnݰLfI8@٣tql{&aDKw.lƳk3ϛ!u6*7o|sLk"&7w.kӁQRakxuQmqPPQKv̧ȏeӎls0Y/UU˖wuݐ4i뺚׭2'iܬ߼n٨9✚;8$`?kz5 41ʎ!-\ t63n&݌04X޾tNMz5-Νn, Hi[UW` ].^핾{.G_pFd٘fXV꣙֐}KDq1(+Fci.:C ߷aaB(c:%&cQ~Sz)ZOO>Nc4lM7kA^WJM(:s:%y^jB*w DSf q}s;.X@+RX>_.dȚENjr۲ZDiYXgS Xh!{w֯Xgye}0);wHf]]}7&Y[uv6xlGbނB$yboߵ]QF: _~q}vnY]fIwi8i2JqU6NxZQ~`oE}{a5Boo߾-ϘS'KT)լ׻7J_9v¶=QR1$ w16fT\ֹ¶iSa="QLiXON__,]%m@ڵM/~a3%^4k4,^s͚ȓǏLG>ΛA_h(n빌& 636jn_Sp8\Ly3,'L`MA sN}$"SlGy_=u5mB*u)Ȩi)ݸk: C AFkwVǐ֪U ka FAgOu||Яw/i _|&&31ul⢮uTa$[ C?^>#R޺*޼z:KeKcGP@~y-w9a¾۷n/7ܴVmd߿_).e(Uz 䘏s'jŘ9Ɛ!){<̤Ξ>.?RJ:*ujt ,-&(l[NfS+++8Pi 77fۋϻiϗ;GL5j;y+EE^LMV-[~,M +?fdOÇ+1Au/~ W}6U+W`Q?v4fqInI#XgS1>rX;֬QC4>Tu =غE3]t:KQx5VUk-r=۹Y9tի۷BUgݹ6[Ft,TbrwP1θx[if ޼\9J:@_~sakZkI{)_D+\vu*d2o^7^cYƨ_&*W( _b;9UXQ(Z2"""q+ eJZyth5>EF[JBg1S$Hh չsgTB`ߞ]*5byne&~)ߋF5iRMK_z<- l:DO<)ɚ =ݦI>l3n5Y}}JQAL*tnN|o1˞[&^9m:clB\,5c?~aMxuVM7X6իW0ǞXgXb?:iϟ>6m|k}E}_͞=1tp4Vƍ!nUR1o`ׇrSkgO{*@O_Οfԧ94S%o,?_RD ʛIW>IGM3b̪ɞҬ47xخo9g) jmJ鬵T,j1ŧO2R'eQYb洩Zץf ͒PJe8Sm7p<ڴl|r|Rw%jo+ήoIZJ|צI[H0' DCY k'%[wiR{aRb`CZR:;r0y>,vm {v-wKQu]&K(L0Ɲ; QӪOn"_ Xp!<~'O\#:GGQG$9)*M$=w'4Qу۰1&'K1~ls.O]=;N/;LUe^/_];uTGNBMis#zv?p\{;BԼ-Uʕ,zn8[jYݫz-%EuV8tY33ƌ&" ıcA_v V.]RQ%9LQv [Ty3GI>/sNc᯼fTQK(*gO krΘ6 vXN~ϕ=L7oPz58y+;4 2NR  5eKame)VCg&M& m4xc'Vs3x{,Q_fGߍ&󦙪|&>cF md wCv0w u2ꀦZE`j?{D&^Z?u-&dzM>t`dGYC4⶯,~떸|b쩰2 o.IY^]VL^H+gۚq6/5v"B9%h>wv'$ UKc )èwIE۷Jصc+<׼N:ۮ];~K5 eFu6iuɎU{wп_$?w4:K akm>={(OLPgX6}yEoG#msߧ3жn do(?! u6_b;<\ןYļrN/_LT`@^*_7L;SLn"?bE>?n߆mڠ^s1WJs6 ĔɓqE1f#ը{BckMSLcɮKU \я_,kټ9_KkV!_ٻ{&ZY %Y!fX84٨QZsfˏW Z{L6* u,*>f6g93K&e leA=R|ʔ4mGPCC>)?6LD~:xm ҸI'221| JɃ:c8cX ӏ[GG)ir ;C%a>fWJ?Evf)c0j )wLn7jk5?ЙXha,Q#j=3ݍ"v "a `""݅ݭ0〴}rk{欳{dkke)IǏq0,_|xM7=m_T4+g~ WFMclƐA8?Ԭ?9k8kɳ:5<}+ݻj} )[.@甇kp L;~tW{~l35#زn^[Dc^ eg|q]۶1N߼{6ոyztxhבxoG@<(W(,/; CPh/me cزyեwڱ!|}7߷OY:l=SrBs6aܽ+Sk,-~ݚ$sqׯ_1,hB'##X7xXAjUQFuueS}hh)?/{%L2[$ϟT5~ uoDFF$IvonߊDژ6y'XQփ{ucqjqx.˹w.!:q"JƳիT|>A &OXkDÜ۩LxBB"ytCgFO!2͛6QN %^ad D,p8x+%~kȡCg %3o-3\6k:U4 ޿}D 쁰0T\{oYi;٦(Ͼ>תVq6Xwvg| 8I%*6Dlՙץ}۷} 5'~Vwd\[gΛ7/FY3r֥3Xh)a_K֭u\LN%sl3s 'm\/u>,×/߼,^ݡ }D2x o?c}2 ۷EHPPm&ݻ{Z<~ uj!Щ+/ʩ|㍴0{d>AU{;q YEqYYKV`4N=gˆgϪzs9tZ:wTO/^;76N8Ě5_Z6, 9ǝ#47W4 t7`ٯJH$gnF ƩQz5ԮU8Ҫ#}͛i*Po^FBJ۩^NN˧O dyqE/b˦MY/յ,^ ѭ[X18sSg&#lVx^~(_YrX(Gn1A46K9sb=˗+Itaϒ&vq}6,L>ygmSe*!p6?Bsn#9wN@g?|g+Dߙ3a劕*YC<ۡCxk= 悈YBP.1V;Yhf[^X)y -F7&j.ܩfl춍K-'>Ȟ.Oe*!Bdol߆1S1rW.ٓ'2Nj⸱X,];+VpLUp,_ ӧMP!\6(*8sF~UB"lm\[m9܅{wn{3gа^5vZokE\|bʩwnsc~g]גYǵth}=yJ?r/d7S]i֤! Xpez_Wdp,m/1͕cROjʕ8{dXUHRX߂gٴr܇v~~|~ 닻e!!!$|6 T>7ESS^j_:ھ~3WBBBWWط{3[Yb._<{?vLplj,7+Xiӣ~g+/JHH$;wIO=i^0 !{5oVXQ%J1&J#/鑦xCذn=磹.s…ͳ}oI򬄄4rdφ_lus4=}ʄLBpq7t":~~UN:g,ymA5DY;kgw1#kʸɼiyk:ɳsgz6n޼E"xo_Wt^xN; `ْ%mԘn݊Q5]Ip#F܎T&__8 l;g6-#}i =3NyOoܙ5xAQ/4FW J|\py|Gd",Y1k >GsXy]cb<~9oKt%,%L,k6'Pl"l{X73|ڴj'rmb$gɕ3',!>ƸG4t(lb=|7)7m۴a7:`رYO?!֮] χ c\}z¯C60>[6aػ'V5e,?jذn(V0"xAYˮcNX幊 ^>bYX qEcZ[a꤉S0m$_*Xyެ(T ?T,VH߸k׮)_zucb5x#yVɵ_|r-WxI?mr_{YZyv{;$JH$q*T`1ir"sәӧcYQթ:Ixv-t Ϝfa)%wl<~z+#Dkl(Y8kj+URA'^ނ:'=_u,*[ DvϞ8rmક+j (.l~}Lg'YZ'݃͛#woGYhɃU+VHH'=j21eKU<;iD^_rk^<>~>|xjd6l+#mO0.Z@Ng7n~s2v22=ϟ>5mw<;NQooǷl---UaX8[Xy1dV(_gW,[N8ݻڳWd8hp1<5n={b<3 R[Lyp%?7XKC{fjb1uk/CҾܟ}IN|Θ~Ic;#+yv0Ё)yrD=i@ŋ5ZU$XZUH PWk@bLe  BX2k#'D\쏯]:zv:ʅ]jݹsƛ n}kGCѿwwܹxeIz ֫FLI{%'?{P(O.Xثvm۲Mϖ-^ڳ{,]P%$$~}I=!X<%X(?{`D޼ eVГG : WO xz=ljc1ݺLm[h}/čFbٿjgcΑCѨ# ,N;qslzZ5v~@1sG~}o\BBƵشf&~nc;_5pn8sqvk&FX_\=yu9b䐪9cN6&|QwtT,SǔǕ(s{hgn)&A:XvmиP+-bo]BBgțWu|svgbixüٳ0Ԧ^>+l;~p,۲KaԶ|30~(MQGa¤cԻ#]M8G4dtE?iN2Zv*_FCVu볽O:l7/!!cbĿo^;h, 땨zʜyS`xY6Ϛ2V>炗]l=.ÔΘ:q*ƙtDn5Vbyg=2q{9u^=Nubf0l-ǩM8{ ?ww#8{N߼/M_4x@5^3cY7OXT ?SUinz&˜^Ur+[`lIO85!(/EY0IHwblΛ>{݀۳Sؽ Ftf܂8^JL?w})wpG{Ods'qQhըę}5áА4~>* @Zħ/H.3Nsh̍ {C8l#oܹu-8ԅFONM!6V0[c]l:̟6bE7l /N=`mF@O)zunq#-q&3 E)ʑ?bێsGaO:O>&;?[Bȑ%ҥ 7KgP&,Mo.X4w*.T*7BSFbh[tcN]?V=`7;lwRq,{p]߱^mdͯ'gic9q_D,I?rh~D9O|@52?|G\4޾<9xʹn ψ׈g5dѸ~fɚ/H}lT9#fX䰽u2ؤ~y6~@Gϱd'Q1=؞ ܊G/2w^c]mo@+ Qq퀾ƿo 65SgwnEբmZ".]8Xn 9}_x"000@QlYh(Scԩ'SaS:TòFJhִin;*/F BG\lvBEUуqeww9~>OH\;u6{+c["-O<m& ̳4w@mRrq ;1ŲKY[,Y8~Zϔ} A 8x]p팱VX4ݙs}_|{n\zVAw9Wvh]D~s֯exYG}ػc3[xp+XpKU?:"`\LgǶl 㝖͚&眒Lu$*)5~ʜ|ʖ6s'߉WE&aϞG`5{ ]qrr-qF?T!+re W/)mGB","nF|&&2N:Jr!x2;l lvG%7l':orW&ihsrxvnE{k6xH8Vg+L:y W*-Ϟ>e'y5g_xT7당sfø{wX[qlqPn<}8Nld///V3agS JחHH ݙfۿO{oGFL&Sx6ƻӄb!WjC{º_#Us&;g8-atl:{FD5U:k|yÇkSn#o'j=ԮU9Τ{7Y2gE U~ʖ) Sce|_l<>K`ګl3g'|{kK|}1yHܸt ukVm`FLGgn֘fy@B6`$Gthސc+VNX̩1yp~ W:ϞEGXp*~+| A>beR#{'6oؠYg?Oer,@Dvn/M&&=}>!iTS[BⷈX)k=~yz8}v38 mtxNr֪'|G FWy/e|%Ρnm-ߖhN;{6.+[YT'oH*W,/y&aѼI"Ѷlڄfzz)Kޮu+O첍HHH7c5?s"OBwouV/ 9سm16M٣~k3\>DVPbYccӻ#cZz-6!!!yw=;͋Ǭ Z[?c>} 1m8AqHGe- ɳHҼ"µmʶ ?}LaEXj5&V X3t(.4"A&cSoCŊੴFFg%$$|v6ְ`NT7\ gr Sǎ~#qSO ɳIۏ{@_zcG"!!!!yV򬄄f 5~'<|pB[vFnxΤt<8w)ѣGf8ۥ_ ITDtPNHHHahRٿ^0Cl ]}k1uDDZ5$JH`,<"DE%&6VM HN,!!!9YBY,$$$J<+yVBBBYɳg%$V?+ 9YBBrd <+!yV򬄄쾽AdiĂy3޷gNlZѣ[7qsE qK.gU:uĸOۮ] 󃽍5>WyDwq5dD^˗,%JH<;gLԮ]K/ƂЭKg-\/_ǣ`Ú՘?{ϛ7n\r׺ ܅R%K#d~:G5?!dnԫSV@*U0 GlWg%Jh\t=G/RqTTAa}8y(WXg ym gסcLﳕ9u ;oGvy[7oF0s4ٮ$'KNH6Ңx~->}?_ѪH[4GО@ o)&FYsp5 wvds9_sreJlcg%J$ Ł8ɳŶQ#GbI<{ԬVUuV8t PF5{wn%FR%ѯo_3Gϛ[wgCxpk:r#~!ΙE ES=|&ƲIxIz޽}^={,_tɒkz,Vh٬)߽iFS\\ cio/w+y6Nڵkb+b?|D.P>v7o<:NGTydƝooD:_>ߍ[k+6-[MJNN@-^8׽~0DŽBsU#98X8qg}*WϖͨW[ E ݻ'aaȒ936_֖()'.:bӆu?ڹ\Q\ѦUK4nX_͛s\ʍk!߭@6i&MTv5ܰn 8s$M{.qw[IK/ǎ-x5t_0/Z;vuNnٌ$Rϖ-|ǎVAp|dɒ%''=;c(Z ?~8c׹P)!ԉc.)rt'F {|6okۏc`%>u ||s>w ގ7W\v/@Lsfw;s͚NΝ>%yV"6gS m(yV|7gʄG!h׶-Ǐy\^^^8v4w[zt;'Ǐىs>޿{]p,`bqtmZ(?k~:u.5b8k]W?=+(ܿwWJkܾx5F%JHMe3kG ,gOʯ\ϣQ>7쎀mo %<2~&yK>6l֮EfT۪W ΰ^ٮΚQ򬄄YɳigO|aϮm۴C`okõy֭[8&=}?|%9sg!?XyvTz@sfǕggϜ!yV"7%'K9N^>>V 6 { G8eҤh/x/vk+lS:uh+/-ZqlF*+X{qmD>7t=֮P{;8:rLϮ]`ҽ 9;}6%$$JH>fZϜP_YeL;5>vqX-.TNeV?7K,лoTԞ}xA)[ѮAϞ:PgN?Ch;}ܦϦ>>ϑOʥ xIGyG}}+'9/f4FK  oL~] ɳg!=[ap|+] ǏXK֯o}38nJèXlTN&"iN •˗QhޞQ7Һ`ۑ#{v(*G6|T:uiYdh7cy=K L .q:ʔ*%zdΔQU+s?7Fάy uC"HZHyv_'wnսWp2rY=/[Zheۑ<+,Mpe֐WqKcw_"M{"ɳi'WqL玊]va!CiYb%zd?WX7Jq񂹷v=i<}r1Oun\ _3Ee1WQ]n'uZH˂xk떍^ر#VFݻ![ xV\llgcHjrUo԰>xCx{P` vmUmX ]ٺdIZ ֫wp0o73ƍt؞V,[slCKK E/|L޽fY0:|KSrP}:x%\0Cbnn&ېY ɳg%⅃sq45e.z녍NSkN @ڞ:dsns>1<_JnǨ,L?nm~*@u d 7o(k/][7oƢ8(jR=Ga'S &}?W?w.S+xلsE?N2W'!yVD LS#G m5_iȾ}QyVgwB~>زEs>]|Տѣ&%Ç cߓr)998gc'!m_ɳJu=F6,>/U?rc)5<+ˢgE^ R6ҩ#s?Z5k $hཻw0ϙ }U]v(W ~NxG3ACs%Jt'#3ܾOرs wcz2J e^ O=~cHݻΡBɳ~۷oT<<| Գ{xPl*,P?M߯F{hܣh{08;ث|R&.ѾbP5ۑلAK"ѡC~gꓨ{Rϣ8J:ómaYZ"y\˖~wNՊ|y;xT,WҠi?#Tp!γ|J,J-i'xLb7ܹrIm?wsNIp=:n^GUlT6Tzuad/R܀i^ѶG&N=1ݱl'#C'EfG6гGUN**[5,{ w#RŊD=Cnݘ)bceџyz5vKN<\Ĝo?j5,4BWM QN>u\g w̶zXV+Ɇ!m5iDI'?9UԦES_8aJW|UȞ-VkT 媩tz1Mj箲k-/On;sc.X5F[U4V8~,U:q9?6GswDe3ZhhFb<1Q-k;v±9W:r8}J(ꝷlT5_\BYIdZ:C8t܏Α%T;89%̙13D?WD1λscnxó߮-m8)r˗O~^j}){G ohI`7l:¬7gãvp]g'ݹ4]V1y|.N(U8xE=4yx$B%*1}NDA}K\V(>ȯ+gIK \cY3f N<9>w'cUv4q/t"[_YeCnM %&g &^i|_xQU|jپhoh6VW&Δ&Rr\Z4ogBH<uPT /Rk|SOMYYo5sw\8{B\:@[˗x!&Rٔar1*1ϒF1Zo1 y6}z)t (4|6z%o7qۧ}*s(M{ƒŋށzc4]O[ kV4_Zbyn״Ĝ5b/]d3| 6xIk޽T̗̓WUxvzZ\PwqfbEMTl]YYBsygkacf)khXQܯjըmrM"[dƍγgAߍlGukx6&"n9]UTIOxbRUy6q//L dg]`mqE.smԨZcܸ Rj,W4F sfء\ӄEI'+ߢiS>y۪&Wxqkd]<i϶ooӶggw(CyN; Ksl2׍zEŽQ#:&`UqTsS#??+P2i@d_r6iD=QlanαC"9O NQ-xΖח,y dO: QqzJBx8hqwcBB׎F_B6tr1 w\`o''a_9Y%'o3st?Ϟ>C̙Tde"O1u$aSGW|;Y2gaB 9~ԺǧOˍ%gGGնzMۨc˗ J0MsfΘ|ozQ<|MǹnޔʳsNX5MK.DbpfzzO<Ϝkv聆)6@aJ+x6w\B|Z ~I ֵ6tYpRi|/A<%l1ųWLժrTċ__BsYMPHLR 2ʥ~q=P~AgԒ<7(&}ɳ ] q ׮Z@gSg͞6-[DD>t*Wy| Qb\[]+k?X3qs^V-|Rk0Hgpwwg=3de޽zk'#|?&ygJJ5ed4nWWW4פ٣̝TiAv#FA͛g,HɳmO{N31h%9 n(_~;9W0t] (' +kv]ZՓXiEilFFF\'7:ժQkv{Apv,f/>Tr/_!9nU4͈}dg4-$ZyӦK,f=Ѣ aH4$'.'E?lݲs*UȞ-׬"uF51 *+ s4m~[pŋu{d?\#+ݸBsnDizS/-ubn # -7ڌig>U:Qtv5u(u\~WXgIBɃux`΅ k֘UYe *Vaa,I7#}{$sTgsrtg=S# ,>$l+șh 7zʶ/?\+Lɳ-7jOhkUW5|締#>3}Y&ޤ:zdO*yj1Q38yx4-X֮]] ~[];wp."?#ݻg *N|#m+wo&=6O< O_uJ*n޸z5ɳD->ϕ+9BٲiЀuvU rW?Wɳm$J$bF{]̡}rXo>ahwlb}<SJ}ϟ6Mv쳧Op<%]hL(|jB^bSg)F4Gc;zx8G=ilXgiG5fwW_YeL> c/kUs?Ť8>nMq\\Ҍ9Qe7V =p2٧TW5F\kO\|(_נ8fZH+\)fϓoO'fPg1ax'5hNHˋƩ0Nl:ƃ羶I1-.[,:ZtM6}}U卭[6#hvC@l ΣIxϜkϞ9~-sZpvn}\ՇX4?}Caq;~2ω YryӮA1Օz!iĿ @ys~,Uy68hJ+Mj Sp<uڦYZ?| ׂZ~VXwr֬a[ꟑ]`X(ht;ly?>f}ХKmӆ몖(EdA9Qd~TP +@jѤ^֭ 5aJ FmSzھzGNaѽ!úwؘ6MXy}:k5YWFePjq*=+E GZ5Ѯm[t߉ToAg>|!w|2X<߽M^?wBCZY<+u$$a%)s ͷLyi(ߛ4㺆:~7G3y; _>>? 777֡f ۠n]ԩTڵJq hް2 [րa꤃=uag.0Pnca5ttNά,uaQ= àEu3ЮYuC&d;cųХs'ޗRr%J @_?Eu˥<.FAHc*A6RÞ];f) KKA¹QbqiAZ06`fOrMϊɶ6gIvsUa/KQTrT+_)P'%yVD "uٳR?&5(_P Y/?'ʕ*KC)xwHV*;OjB[jN(S"cޝ{zJN>&&!9YrD ǥ+ ?z뷤~Fx =oӰuwpj/mX mӻqNo=4oXAYz <==yܔP|aEކY E]cǎ4ϳǎA͠'Js,KR]*\Tl~߾= ɎS4^FyQHwbՁ)xU[X䱣A X$JH>)eVyl 979?_ԫS!_qX”ѺU+vNJEypY ɩZjHh׶ ՏӦJ<+!KDJ$-,sM۷kԳ" ߭[8HY:!['W+p4YqZ|`b,9YBBE_Aڝ_+9z5ix[۰>ϿysѺE _fG`CWڶI]nѰviI7~ɝϐ<+yV"غ;=W \;=M 0ORNůY-qgbdw؎ZZUY a& ]AZѢI} F]qI<+c8 ť٥SM =rzu["-ɤS_[URlG s?PPdΘcG>/V{lhٲr_-DbEפ <_|Wh¨U:t[׮|-J֪\gk[g#4o 2uo׺5թ͛Ah$EɉH1pqt`ۂ}6k#QhT"#na=Q}eˈhbE o&.VM+`d:TϜ4ʖ)+/3U MPH!{Ugbƍȕ=7G8#*{6_D\7n;OСwvFX8NW&a~[vâ]ۺeKx{{s>wfa *lӦ Qe\qu89mpF9Mao–TS{ἹўW7)4o3;g޿'ρQ9k<=+#ghwE'P )nm-GB_oy%f'QWg]@޽T]>z0 .^Ll[[ꉳU+U۷oТY3DFDȾ<):v ´hիT6 ̙9CMQW8O~B噩&׺L|16fj{ٷK}Y!﹐y۹vJ[ѵ+["9ɳ;{׮1o^v}q&*n_di3]@*KI-<6^uzdOh~Jܵ&G;pUsvJ~W+.i_LP.Kcdҁ{NGF 4pj٤L![dy,QWSԯk'Ν>c&&wWL ޿'GP4sp ._Nq6w/[Gtm յ>*)T(sVz<~ĜB9tK,)퉒F'X 1gTbEO|G*+plp2fztt0H1gS-#o=?E = ޲}:3g˗$Ξz=Ɉc-N?&|!'Z9Fw|lx {:9ۦ1pmROԟ_S^x*}ɔN(U42ӇGh{>i?QL4u ndh#2AhI&|Z>0`3;򥋩I'&WcɰZ7iT,_T*\s~:֩#cR/%2%dΪ^ +}7-m e wY+|կj`fnZ~9/vʯ79beoߢ]Vi^eyu jԋStoRWWWw ~^i1)bHjTZJ:PowHjW*y ]3/c0mk'c1g3g-A~Y&T._L)W|Wv@3_̋QZIAM>lKg9b&O=Bp 9,  b6fwGfU/?}WΟ};e6=54Js?WYsV}ΦG~YY4jPW#zw#}m2Sd~hwoe+p 8wFФQC\d]|E]yLN3&+[lh&+իm0P1VjTM;Gj7%۫S}LݙG р =d->}aSvlЎmhѬ)39fU䷰Uޝ;>t(sR%̤п{#TziTTC?rᷟL4 ˅)Bwٟ9:S[T?1j|39ʊ67kM}֬¾0C8۴q#9mD\tI.Gyp>3cF cxV,[ҦMS9r)=y"ݳFcf^RPzWcQ?ڴsg}Gaܹ};"XĊ o1RΞEhV<&qT񗘙D糨Y 9;{ L׏7mDL:gMr_~3vj8/-ZZ&`|#٦es9yȓw|o7o\7,iy(Qܾ ۸M4a?n,F`z smdjov9 3SS졃QR% \ C0g3qɢdR[tؿo/Ǝf [Zf}Le[y;F-+rr/0Z$_qxҹjYӧhD9{Q*Q\کhؠސ:PH1yȯS N{y,=rVa _;$8nق p6yz褐?***8u[47s|=~:C8~(vMH̚!C'3hx9}16 gs9Kx:5 ٴ^^^2~y( k VJwk54Px!#cYAY9h*WeK)9:qr#%gwmdxU}gVLLY7ڶjCgsΪ+`Hcx &:4CqzF-p-N۳fLG*QbqPur +B QZeCϯ26$)+3Աc{kԩ |бCt"}r`}/8s1xгGxzdsm Ksի] ǎ7z(tR1؇ʕ*1f:z GDc#[[ۚ.ZX!h#^-oŜ QzC_霥+L5 Ccǻwo#e\:__8{7lڨQUŻSj467;٪T?`fctl^E\B^=c{ X2֤-O65d~ e^6[8oƹӧ$oչ֮Lf&!32[繹t?/p l=}Z< U*GZ7f1+&afm|UدtѹҺ:Ԑx_Qr%Ԕrr N;W]5Y9˜e1gj꒸Jjcck6mܘaqNk7420_r2(g.i7WXAVѷkC uۨjM#m7\*~Nm/IsjhVGĹX%xZN>T˗ƽw{ի2,s}8K>>2`NЂys}[/?6__L0Mԗ}Qߔj\p; 33n@-t ͛6ER(ϲ1:UJ`sd>]oF'%4wc„me)#;bƘ>*LJ6%K۠mMFn{؇V>iTY] HJ\7T*[-7Cn1domi wwȚ_.ڑp=2oڈu&&Y,+p, Du6(xvϞ>ɲNm˔3ԉ^x1Gd-5{4 Жӧ455edR>;mZ߫W:kﴬr=F>}1PKKna(dYn&x{[S86D !ܲI#D_߰~=}99+J9)dea!ɴڞS25jR{aV?ўp˶3Ŝe&%벴0OSΒѮ,^}}0t@7>!zjd{9b2gR6-2|+/ٲe ݓ NۣqhZ&o#$oۖ-]??4WWX Eʹp7oټ9ٝal~Yl3|r}:lMh菓cO=F6yʗ6rRZ#BFXXNQ_9˜M/ΟcΪ+۾e2^i |t\-{1Yڱ{v#&c${pPm MqgPm/&:1yv?wӉ?#;i+֋wҳOU|H'w-( eavA[Oy>IHd&gOۗyq+j4wS4QxFAZ !F5m㈳ݼ W>e&ը^]</afj-BƮP=w\2%.^8_ N7V_Slϼ9s[SSn(˛[^ <6dт9bD]WW8lْ`5uu D䉈x||_,lzsZ ^>+>GmF 3gjx|_}hO?//ڙ.*??N^f6,Żb׭=&Y3Lm2Oժ!ڵwHcvwE|L:˔<&֭U6'4JڣkܰtIJ%KPX1ygpv_8f+{.$#ZŊJ]ޖh׶#Oc lcCu+c$9Wtqޠ%Sp0ɍkQװ_tH4.Iybecݫ&LZgD|fCLnҨ!w}ngm~>8N<>|rbsбsCm7L֮onVsrVJ)ʤIܡWs< ڮԟsigc&OЗhNkиmwb\\5Ǟ]8Kl=\ʺNؔTK &`lݺtuЈv.N#ΪQoܸ~Crs U˒Oz.]U%[l[:>q3d0s6r^Stb5R;wn޴QL,m=R`^L\楼]@o_:~$;SGei=!*(WM,+>srn,ti[(~5JRzTr\w+h+Pl.Fjpwse>1g;gs9=!(R0=xTli'[7o nGʶrr9]ShaFbrVKKKQ򥒳~aaOprrm_T,Y\c9#g<7eIR>i+l\4fŜ>S̈́HmQw]8~gkMxg8 ӅZByp8i߶-`wH*W$w/Y^={`{9S\|YA>8v+H4uDCyU{!]}Js^frʙ`r?x T+[{ď>䅳 Pƕ+1Xu)ˮMFyk+ƃkTc!O%KQYc2WU) {H&+WN}YhZhPkog'mɦ1nnkVTA&Mك  %Uejw,7Ry hkV*>lQFu<&)FjTCMK0P g@ ;dd6G8y,' V8~Y;Y.♦ąQec.O<&w~n]]Zvvm3V>暈Ǥ?> -ߥc>q羽{e XnѢEXh7a?-RTPvrc_%Wx/P7b6qk XIս4E[ VzUh ;6o܀7Ul)Yԇ7T'_~,֬ZIrN99-dIN_=w\=D@zčaYWs()-ʕ-9sd ×^|"OHPL~GOM!oZVY=߿'òLE>Aqvܗ>ʼqV E=OoFv&ח^'O'bG]%xqLnӧTӧ25=tbY;c0NFmm2s`,_.lR駗x>8&`w ?___.}bcxZm*X`4'ǭ7L.Cơ<Z1nHZ5&ei"_pp tܲʾ$l}Kz83'O^q8s W_g|c޾ːv4S;lbo-`Nys&lȯ e54ꥢ8ZCm,e!lP$屢~Fs`P aGOq֧8inq= gNVmZɓ#4S0TWS.`&3YLdϦUo;b(91&w/ROa7#Ix2S 2YY,9KkNjjwō+lN~6dQ.3;Ӧa0շ\8K5i'{1F̩S1wL,9˜e2=gLʜ=_~>ޞ !P;b5W. F a.7ON~z|Bhq-> ڷEFْŋax}TT!A HՑAˊmP sŜeβXYa,ZTd%to/4mT4~_VoQ~2usrT>~iuF1+wܑw)׈*2>QPNʃ"7/sŜ~RWF 03VGHS&WN?oi,8KbEWސAow,7#Գk\zb&J1m_rdW޽[cI OOODvu%?)OyU6͛7e>ӌ:~AYs9J-վ:2-_0gYYlV6e O'w2$)ξ| H` Օۣ\5y}=|a8{ڷkId)d7D>cFG*Ο7G暣4r󍌤- 5|0<ǎae>=ѱCxf2gYYwMЦUK /W9vvǬp\{H'l*Ud W.p %ԭ#s;z:Ư8YljYrRv[8Kq(oݔo\RW L+:u|v3gLfOMDR\؋,w/ԫ]+^<3Lf&33JQtw,V&[0˗='Ο'sSnu&ک" 5 +sv??Yo\pl0}>W\l),-d9)WU_z<G&@RY,9˜.!_v/_`X)S1OYg'g46F~P>",ɦK.wM6r>}Ga*+}LVrj_vr; jאk4#l]m:x5s9b2gh̳\[ok+v_]GY%Kir^Ǐ\ 4J-55H*r}?Bw gRMߴQ0S1:;4fLѳgO9mA3{Nc;vG^D_'I̦4;y_k,sŜe~7QqzmovժD=%= &+xfme QhaXiTg]V(Q֮˗.|ݻtA"кySܺyS.[lwRY YF*<3=YDႨZ(9g|XdXˬ]3sUWk0'%)/ r,WiǦھ,f2۾,,s6;gս+z&5@ӥ\IOmM~V|Ys9bg6_AY,ŜQVMӆR*DyRyРFl{.a b%ғj ,zdR_V0G-͛!|eβXYp4ᄞji8z s9b1gYYs;$8q,\U9˜eXYlu-*&:v<>>Ob~,Gy`-\0V̳y(ً{|n^W;x%s9P+b&3vLfXYlz7lc1en^vt ӿjm7`3G4՚1mcǵ8v,b2g+g͝`9My~nܚhAּ;\٧Oz56M)ٜ|YC-O|D('wY9bu\~Fn fca[picDkDZKr{htc:c8K?ΜeXيj b_duVQ m;`81agػ.8aZŸqj}d#gdfdŶ/s6c9ka±~`P7OuϱiB@8czy(&MSRŜeXYl9/Yl`7 elJ8K}뗯gβX,,s68;Yl[?EO` a+og8cSY!!}9b |dqa\ҹs`"}c(H)OZk;3b1䍳ܓ8u6Wo8N]XZۗ~GglgǍ+Y,VT:96S\fk; |wƦ`g%[b{{1r"g'eO Qo3[u/S065 b1g3gw.F&]sFe$g8=J}^O?s^!LSF-xmcqjlčAb~7/<9kLpƣl{bY1j#֏ϴ6lj9iN|X,s6C9:0eQ춹gq)Y,V9ɶS`>+t챨¿SbX/GY,9!8)MM C;ٚ63ybYDٖ'΅?bΦ;g-[x:̆g[κeX,fr2_~$Yt%fi .fo 7bXtFDZ* ^kfΆ<ő}cX,lrvy",{clY񮈉{b۷89ykmYl>q/Wb}&{mqGdo]8qeI;u;bΦ+g=R3bA[,g }bXtFC3m୲Nl -cX,lr9 .)f󰕵ggcX+}VL*n )-&obQk˾g9'x3uÔ=jslϲ[^VWbe&{ڹXBKoeڡdiszQn|P_ĘLrb&ʉVHA>}Rk?ZJ|X,VCӅoS]mvHKm_pccֱr_gdˏ_u^zb/T߽}?﷢o<śׯXOǏqmպ̸P߸K 4뭭_YgKgȮvJ<>?y%v_kW/AӔ.M~ ݍw^=ocҶ;swrl/NQ^{yczam|5sqXb[pVؙ&C狼9,/gFbc-9f:EՐ'wnlupN8Rŋ&UINT맅vv B?v///9-ʖѐ6i6Yף@ eV?t6 m-IP5F%nGF cw`޳[\<Nί[z!}U*c@-tj??aǴSPPAq(g^ܿ{Gne=u^Рn͝}z"iΞVfϞX<}'chҤ (ڲG#yХsgms(׭Q ʗ ]0o.fMϟ߹S'ԪY# U;uE (?;YY]8jk8%kMva;/=E},bx5c/9ڼqjV*Y5ϸp<7kҧ"O,rA,7mݻuVE:S=Q?00^a{?<}Xڍ++Ipvg^Ɣɓ0cdZ[i{wF<; ]}1~̚9C&4^_%"ҩB,?W"ODTW@L1Ӧew S[ű|sEU*WFhP T1(ZEߝ+P}۷agL^?vJ:+lIU]@V/qҖvۘ)ns~XÙӧ?`ԔIS&%`rhP`Qq#&H=~EܿO/M>oOq-`l)lbr-A6KPby䶭[YӦs0p6bbb$E fyC_w@X[YB2^݌仉3 Z+Oqa׭%1xߟ,V&,=OÓW~X9>}g5 { 9w`<8)Qjnl.xC8;Vۯ_D95ޥ~+/td?%IS++'CySNJ~i +9KA lߦ_g"9l"hk$g/_Z}M#EHS|d7kn `>,G EwЁ(Y5Mw 2GT@n]bŊ0q9gcڵ(]޼y*Rß6~ ۷۸ gI^/^͋/BR%œy~͕Koۆ^=%ܳawSmZ ΋qoqv"#5Y\ VP?s]~%1#G]떒g'4 rO9޾}dӧrLLWK5?48Hr ;s2BCrsgDh/[lM$wn{0C3ُõ(ԮU ::~䬇 fc8vj3NIƙ]7_ŋaqx"8kea8/xE 4MGw&RKd9}V4QYe?ќXj%>y"6Xy݃hcHF'8uܧI1 ̰cхT5͘<˸~7bG|/Vb Յ`NuMخL_-㎷~O ǭyUR˦Mw3$}{ WA'fL=d;ߛ,V}is;aF DHl)M[wP1?_q.=MFZ^8:Wd b vk"Aj-Gqql)N/_<1}xO;P?z}٫W/UΗ.\Ow! 9dM%/F56oڮ\a6#8;sc޷+k]u=23gY,}9aFs`srZn7XF"7|x{a<_^ ="ۛ@Ӫ߆Syeӓ76j߹ԨIkuSX){h^r6&`Uy`2%W)Sr 6==0kL~/X e2یIFX=dZ.^1\ M΋\6:ʼ iOŹX`WYejZ eĦSxu=yLy/V[rr[LSNslܼͪmxn?&bۧ+ܷ5 qj:~P{V cvP/ 0YYݙfpL ?x@P^ [ -7”{)^ )8^peJ@fPXQl_d^JXUoo>7@"'&Rpi[ʗ2K%cOhplri\8wF'y4?z)]ѪE Y7P[.rA/[V^^p!X,權)b2nXuŒj1: d1Kޯnc]J9K͉{,5eGB1*Vvp,cJ &`z:4}ARs?#K+3on<_Ro߾r#u2F~7v_$9ۧW/EN,gL8wZ;b"aXٮ7 {!}]Ƃp9D9Yu ɁLS{9>|w|>)7^:dK(%9KTxmܨΚYgӲƐr|Y?_9LVK.ZH|[RYkuלY3T/XߩAO\loo8aW"z"Fk0];YZd|&E)fLSj~xC`v&ݦ>%۷Q.:].?.(r(w,o>xyzer(R%KcU+WWSrА%zdIR%Hw40>ޒɔCK&׬ZERY3w/M/RZ549K+e_d޻ kfcϊ۲pwfMֲdc;Lޓ":WK<-ren7uRm 8K㘹]niJ^zU2rUi*- 1VZU26(0eKP4-sE6j60h@#3o.l-Ŋud׭-JN:z La=d,qr3K³O0j[ahfMFay'bZbΪ)lV 7)8`ڜ"us9.cxZmKx7Y[[Y gL9Dt}MNǍ( -[7enQQ3'#zEXVG?*}('8q[&8.])QZ6`N?zTqCؾO4j=ǻ[kn4'Ʈw܁!A)bo\CX;^+`%XLrغt6a6VAK6vLYbw&=9I!_嵋} k:hՂQ)⬆߽StI Jgar6-Q8ΞLrPi;UW^+ݽCg T^?rfoLNoQN%iwym_8O6Lum>I_vcgMݥlbc1Yzzcf-OZV*Rk&FlnYWW/Or۷oPlxRMYŜ`Β6.rP8 N5gmӶi>X϶NO_9pp_W;oOYw:jsft0+վC{sy3$6ݙj&ǭppcqۑݙ\F Pi's6лWo͙&tzvPɽ5{q=vŜM#|6|Q?['|~q,za8il*ia3+=j㌋gf;Ζ,^LE&Iܴq#4kZckc4[6guhbiwnjkmRʹL5mW(rS|prLG8O= y/EƮf;֪Y=2=ysҦOO/8mT,SX,l*tD7qfpw,QzbX, {=-ex<]Y7&憭C1:6}b؍IJQ5gS4&[rE*9Pׯb1gS=a6I;[yӪ 3MƋY|J]^S'7T7Y9F9gX8IBua6 {w[Npt2wIzg!S I:+W,?ŜMIȥصܷ&{޽{x]p!=f =;iޜ饙`lbjxvޏP,94WpREU8qds:2sgy~,fr&f4cr•f;Fw˗Km99:29빻{ٙ!b~G8LJ3NdhW@_In<ݒތ)p2/D֬͜ѥ#_9ֱs¡O҄;^Ć=ƺ֪)en֭s>_WiSlNFb|~Y,P8$7)r /8MFX-$+e~s|ۇ>:f(g[.OU.#`4oʷ`ʿpQx>IU}ݻui `.7lr#4j[cfh+ 4iP>4|P܊0vԮQ͟?wlw=uWCh԰h?'8mmдqcn>x2v6r l5zԯ[G%k[`ߥc;rXsp]-g+4_W 3x~LN:^(h5X.]UtPtt44S0a$sؼi]?ZӦL vOAΝU>ڴߏ GJ}UFukɿ޾SР@ܻs[rKqECj:ʴˁ<=ѹS'v˔*!ӧaԩFsfhW\?;wȼ&dBpO;mGٓ'Xbڷk'SٍmߝeKfH>~fc&%QpޢZwnm py?XÇʕ~=ϟj(6VNjR 808[f |cswiӧNmtvDWK˖ vmN?olaoe~–ءjSׯE_-+U[f&EX:= ξWp%vmKN;} cFAg W3`㺑7_a PbЧ0'n?-{$dceOy(Fq҄hܨ!.Y=iR0-J+*J۴n=_s>)kW\Vqbr5 a8,Emݲj%5Wx˗`()Y"QmU?wOίNK.P?BرkWgΎUsWնhAȗ7\j ರ֮gQ5kH۱-/?8+g,xX(<_/(Tj06PjAv;s<[S&M; 14$,U+ӧI8K1st.T6V"l4qG׭Cܿcҥc8hHp l6_:g~}1LGbCy7f͚Xr,},^,*ǒnٌݺG'; r|i8K˖;98pX5p-7rhW;ݻP8^Wqv/J* w,?U+Wv??9VN39fҎ癕S8{F<&9jj.uuu&\.5Xyn3䙳|¾ժV5ܝ[[ęl?T+RX'W'Gܾ}[#*,z{ n`}\ӍzMŽ;w I?z$.?ٓŋ_z`= ƍcx1#I[+/$ɦ?vTun=B>8'>]0o.߻+x;v+.=.qS'cY!~M#q];q3@6mb8%iكa?w ?^֭Vat$׌^ׯ_%[7$Uo6ZCc'~ao_p[,~IF GPTogs6k'2-O|7XqI> ۈ6B\βXDc2v8{9mhbGnaX6}NoȲYbL2׭[ӳ{lCfR0ȗ/]Ödiߕ>Ϗ>W r|1(r,|X$d,sGZ}@Xc> }upw7-vPش.[a2{Wދ׬DqˑQ|^Y,s61X""}AcsFɳxcY /'Ξfjۦ U~+ s +;0bmHG,?#}q78?Yqc]19)cO._&ٽ ֓a6QS3N~i-jUT+bΦ^|Mc6:-Eu<֮_ ;J] CBd[#Jq9\Rɸ}qHwxQ>$$eKkQ8{*RUZ/S_u߾y#ciԕK8Tu>y,1ٮUN@o]35>~+(G+d)%奺}>}8begΞ9q@<%9N+9k f峖\kӄ8g4PdCUbWΜ׼o+C~ΐ{~7B:ѣkWԮYCQQQ(YEJ-شq\Dԯ{Uwʗ@2N&Iq5VQbElX^\2rM['*++ڢ|ٲЯ4J­71uGyѷO_4jP_~YU*Wƾ={d5!HujD^(A2r6oUnI9]Yf+.sQN#h;\NM~i-AMS'oRGƳ;YΙ#h͝[<ʩ{7K kkϜ<ՓWgbϗWekk#Amڤu*kl޸ڶT7k\r?ŻΜ2 %/]XUY]|SN ( !e!R* btwK(""vuQfzǍ QחV{ 5)okkx=Rӿyv5֘k)W_ƭk^l?I.vՉF%d#Z4铥8à.\WyvZl/4Tn7CSl0yd.-g`tƁ3} ;Qޜl>5tˌ+ΤE]:Jge'MW%,ף9Xdx8P$g u޴﻾_/j>gˣ+0K?smxKP7 DŽqE<vg)O[f[k\Kxk\zoߞs)Og۶nmֲs= nn?n7MykƉ'lpuvwy߄a\{&~sut0ed~СCrCs;xij2N^kc ouRMn^n ,σ끚zsh2xr34 2Оu6ku/ 䅳gpbm/?>`:iwsOpu{jlLW) 6Q<u>oʵ1P[0(>̽(Glb6`R%Mh_vaCXA6BKm>'49v:CȍD-IP<8aAlHWkۖ ³?={MފcE1_)BŅsg!1VUq@8NIơ ?γaRQϛk&,34b#MhkHc@{=f@iPnqC`xX*a9 غvGږ} s$|,׀M>jlK5%Ey=|MP%*+Yj =196bAz˼Zn†+D ~ Քxw:)\af/ZY n\ɸ5LqS=zwib~cێhz&Ic@MBa(L; 1g+r a)]xӢk-3>H Ǹ~rt͵`l6V.@Fs1[e'ԗ~ݺw+p (LÑA8sغ Ca%?ϐA٣x~g̎Ӷ9C f[r_}؏^TC&\x #kpe:[+#l\k-"9S0r@Wϩjjy+8PWdW+ݩc+5hMS>fc>9H \->iaf0e q)l]jdEy"ߴVޘpغ.wn/@gߐg߻OJ ZOŏO|1=5zqlN{a%yi6'@=^f}qܧ{yh+ꄦL;wbuM4xy6zy9ѻg7<}۱.۠/@۽&qZ2P$c wcĠ>m VNUI1"#j}&&~z/^Ggvl4f:@=X,2ZXIcXkPvn^:ذ Ң.ٽ;ckI⯿T"Ӝ%#=su5զd\ :zU= _/>ð0exhNDF| Ε=YN ÷u5Gtک de$9m2=AVbtu}ODXg+P^7WW\ΐjqtd$ۧx{ {MwdP>^ʗ%%}35'OpNͮ#>9Wdyr":*ׇJs-]ufq*pAt۷ {vZ\ҒtwEvVN!91n.;wȈ%ƍCHpcQm?@DXv}:Y?T^Å8g6nܝؘTFa^<~p^i{Gw.)9QRć %bqjHGv8c =Z|uY3=G]<_ݫ(. WA}:ʄ`ΝQ{ZnhCsX"3!;5s8Jv aq8} wnABv1t`O5kgswT)ڶ izm_---ı֩h9Q,(~}+tK@QA<=! .N?n,Y )"Boс#q5]^=SoQ;1ARgtFZpsuڶUK D:ˎН=&qgۺC8{ g."$(l8ln0ed6g4LM|ij5yv &A}zp--Ąxȁ4fkO:Sv\ og{{a8"*xΕvmHέ$>;?ŭ+|j`E>#tt0vHLbё8߻Ɵ) Ο;gϠgx5oU1Sgssry(B\C:aUYnaeeTE8nSS!)1A u(M~ݻ<8Y^_iI:cI Wv&˾̓ 񘧧vv|YRbۯ'Z| ٠eR >f4^z&NпQpwQsi>tjN NFR?-6,7+Lu+Xj{ݶ VK ᄬlY-P"Uc<)dz'w3ʹC|Vk̚و/E>NC0]S;xN.F]0r0 <ed0ٓz/A+|{}6ǣm۶i5dlyWJO OKn8}weG(9vAN:?&JKUVC dW.[V皈ߵ} =zp̜>!ѳ[7(M={3ѹC{{׮(:r۰c3=r$fiie Bz?=Ɖ>x]|s2Avߤg7a+**xG~<[x(lM(|Gg/f6cDf%U"x$ rzBO um?٘鐟$m7g& ffݟtGx/ƍk׸qs8X|GaޢJg"&J{OK@ZHW+f&:pwƥS^ڳ9Kqwgk7L4׮\nr~ޕK a9d'NaН3>Q^v}MY5CEċTEv0/O&3Ąz4;Ǫp?:vğncϞeƹo̳o85I㻗N|ùpf'&Dev$ cNb|\1j5]/ 񣱀/J\ ,rxwN \zPz|fBѻyՕ~1Yf{7ϳN3tO| Pz5=׉(/{ 5V [7l*jϚJl GA,Wa\Є_*/> <\Pk˕ɾ죇hf™S`|)٬dy9+@:xڳga ܭ̕wg<|I#=% q͚1sg`^`O_6#$;wNn1hJąbπ?O:{_Xum*<8I{cr]iMːc#/5H wb_` =n8zv5e,4NO.uzLSRhmcsy~VejG6[BZb4׌rQ~oR[oH؃ ̎-A.Gvل0ߝ8{ν^WBINN[,1]MiTْϽ)c<[.:RX`6pZXږ:Kzbuw+WIPm@9=MK|,mϒ:$0ƽ6d0n^] <$qh׶ C#ݫ'.~n:<Q=#%>  P>vߞ=[or}Jb"v2RpD RѶuk.@ٿ tv񰑼& }/ >mՂ ̛=cԈ>TıNBwƎ ZWOkVAMU1a{鼕kZPo8畝,dY^S*o)姱t_.'5(o| SW]u,n_9+2in?cG.˧sGDpwނ&z8Ư@J5yNn0 dK l;ŔGk׳ x?8|];wY9a y[7Gs2宭fSL=7+QN˰z:7Xq1V1AB_5O8*_k0y˦pbv+k~1,!58?EauZEyaTeQPV{[Q_.6iJН=k5O =d$snnj1>׬nu5K޶\Tc[\H_f;@zT9_x~ G"j>$?v?| lm3.*_ͳE 6rDDDDD07g γkW[w:| ِ,9.Rķ|  ٜ,4[/^koDUV_-.:dq$퍞F`(_Sai6NԒ$mYXH 84~>1K+7@w5E[l8!8w K|'g{Ka6*aН^ų%4.>mI0D岅ǣfRRϒŦ>!n#]jRbSSnkgQWEtK$ ;sZ4oybNKƭ};yxlՂ0źkE<[z:o%5nߺyB >f 4%E^ <י]֑ۣo55rXh&Jٟ٬nV.nrZ˓e2rOUWܙSqTȦN"c=olShNUaRoz\ώulnAhhLGBREzW[mR$ΝGVךa: Нu_ѮЧ$Ǝ}o~rRS+~ax.ϻ93qVM}JEy:;3ǏS_)H5䳮&˪Z0Y'nJrr#Ow=~nԓxQZU:#ϒj}꼃۔d\}*ݴ~E*JJ mm["g7@|[\(@Q}1鬆1fϜ{ U3\ <.9q%?{5Rc\?)g۴[ѩpnܪ#90 % 9eG1ە:( h>L =jɾݗScеBU٭Y# n/-Yn=ME%ݯߘrV@FR R񍸔!y|,2FN& <]:w8Ztw}QTX>P?ߟkmSǭ]HfN5<'?7`B8hhۃМ&s!9&/iGҳ_`^.L pkH+BgbH=0zxح^ oܾ|  t<jB)OP87Wq|CcEƎM@bûCAfz1d\vX@VN~حR _Ci<&c.jJɟOiIU,٬ڴAxh(u4c"a|):әxe@\ƅr?V_3*E<\/(#z񊏖g_bn>^ ~ O ?aK zg ZF7ʏa0{T:EnƸjV"7{vHrp_ܷúpݼ[d;6,<S#:<[`(Nc 3֟eXX~%Ѓ٭|{kWf!̌g`XP2Nk@א/QrT&I $E:!5z'6!xZ,2V$MOǥHsCv}.9-J𬍍 硪|fcPG-y 8g+1֯Wp#}䮕ζɮO545׵c{FG󱉬̕%j-פ?:G9pضU9du{B*~ |鏖g& >ĬZXp>CIg)#=kcY|7.f٧Mbho>GTC9QaԧuEվGp8' .&X :~qxf6ClIY8;lBɑxx*N=Cl/\+ ڼk]rPe%9QjXR\Nqh6ԯ f˖LuJhkG63F!=~V,dlQ/ƜϊYa_g9f샑6mgٴ$^SR$n{+[7o#0ϯ"^J9O]n]xm-#~@?ƻpwyt^6бm+lϻa8V|ǣwo`RZDoSӳo\d?=$N&xT{Fu^Xi`Vs9Zsnk>`]8w<[ Y0WP4^T3T;͋p} G6,`a=1YMER>b_) &J;33`nW'Ƭ6|\,eU-?wǸ) L>6qSS&3ceܒ Ypf.VεIz1Y A/[c d(ʔPiCS]a͵kqnCm[͸^q]{j7F 6lP F 7ˬ^lm5n^:_y}m^!LA[pP|zPxdnܰF=>n]@a{Iqzn`]P^Gۯ/p\fiLd<'^giC1wظAqrfmf|V/66ŀ_˳djMTc±ax?>Ֆވgn\j v^'$B^F ){k\w0ڕY&d&8_\k|络Z @gu ߅\bVi {t*[>"5f<Ƕ6Ss x8eɢ|Zl{{mg ukokG]YC'9%F<{yܼ|ǏAY^۱Da. E v"#5^YulΣ"?s ӥ%܇Lԏ}fנGۗU uuբ tVAAz(:;bQعՂUhI̯eӏ};s Z!{TcZ#,2P f6j ];v9 oV̉#nH wmg) P_W'W!>d+lW`뺅П) ʰ] #첁Cw[ "<jj옥'JЮMk_߾:ڬF=|{ϾK%ɼ~u /VWgf8Q[#7 wI<{z^Ζ܆'S0i ٳT[׺n_lg t5D:땰Zfo8[RmҦ*#_<],XW-Ӻ9pHۙsUG;*T5d CF;rܤ0J-[4ʓ֫)>?.pN:($&ר!^AE_]T^.'y=w,OuE =O{<+Wp9Wq]\HÇ#7',DGFEEuHم_\Oӧx!IsȹyN@Vf'Obؘz TK$7o䉗aWr8 5۷lF^~o.Pusb@cJ>1'<[Y۫gPQ#ܻ^m$oJmS9ןQv2׫zZ׻Q\b r8okGtmm͛=/$Й]n;gO#i }muk?|iɼQU]5pn]?SKk;Shꅕ˖}64q"%-:W!Ŏ)gѿ[e]3iƒ>CUlG߻ȍ!Cz_t_ͫe|CTwoz2x*.P{eM)'((/{[NMzX-}6SLzt]I:Ao+8Q٧췗]TJGGl޴|1Tr2]e*9v9d7/Z\cEe(y9YPw*9yRY _lj^C/ϷaŲeloqY+!)i< `r9_Jsrlv'١qL>lYz`|ddӢ?#q2_hli?g''qA"?Z^ prMjπ轁\ 4o9Ξ:ɗQOR~oB:wˍi&](ه+sMhHb267o_Wk[EcP9߉t_=:f9{6k+tnROg3Ҽ|v^mV!57XԸpGoޫ\ќ^Ucr8;~9/LMJx~'ۯ2WNNFXX\ |;+yֺ^Sų/iϮ1oot`iCVB\dedj ,;SA^v+&%6ȳA{u5ul޸ +}XOѯwѽw/D=x ,ٳ=tF|+xfˎ5e\^5 l]P/Nol ߻gIx =~nLfX׎?7_`ح ɣ;}">BA8r-m ] OZ?Eyh߈@9ϴltЩusf/6#]Xb46d0?~#Y92_wugVϖW6ԝ~XOx.(ع}[\>lXg8mUpL^g?KOz'!?3@Է8'g-cɲ8ӳbeJspIQ^ڒ]Kz 2b{ k5Jbe!/-x/L5Gg+sCBzwm^Ͻzw Rm"0x@/s[rz-G~d l1_ &Sjp*}G SC:TlMxz g7Ƶ;=Zɵ@֟_ Eilo*q5iBKEa\ ?"x4S}(+ek_ TTv(= J*7, qæcg?<.8ޢ^zwnXoܾ> ;s/3tuޣWx x28/y.$G@In8鱻'G ;iW#YMY[X+CF7\ƎnZT?:v+OSdh@E~<VՈ5G^Cf=:`:~AwF"E*M2 RmR@yEyGi)5q^>*;P/?~ G;S7ʧ/۵,9L@SU A74u Yv>cQ5qBƙ6Yn:S`Rl\e Vعs"qƯ+EM5e{ֻ{7pڴ.NsB O9M _۴ZM%r /PRT KsQ03%SE5CAԏRڥ~G‘ȸgĆ*r|]^oi/gkL@F;'{cBE^+iv"|27C1ߺor?//9Gxp.-z_/+ 6=ψs";7/`U>v\)?s%M…R1OWϝqvWNجEّ1~۱Pu%?T c~\!lLRiXn)(ɏav:#SY ~%]z|!=⅒+jë\f- JcmH<?x զpuv~{/Ν3qBTF,26{9'ֱ(nJ8w" D^04LJmHO=~$7Eb.dGBou&Vɡzk6,hpP pݾ= vyb3$yo}?>ğl~v$7#u @Ǐ۱fK~]r6] zvmt<{TcixNnu킹3&aJ ׭K$"lngC4?gԠtoV6@P]_Fj .=Sc#\woݨ =42Sy̙JM1~VGԙS5uΟT'~_V'.iBJb ͇ 3>4Uv)Β9yGY0vxwe1ƍqnDs$6oZ䥆"NUC/N٥߳s5&~@8o^1l,ntU>]Kg xyJ"ݮ-> HKMc| ~1tfhj`XmeɗSN;`:莕+Vpm?zsqX1uMJJ VÐ9}NZg5{.(#;wЧGg8罁Œ9od֍]f.ջP=o TxJ]NmZpN\?~1Gf<ظ2}69 -flr9w=d%z!1 ;6-p7ˉ7Vۯ1Fߞ9dz6Vn6;¬~vP?|dغyWiH|[ރMxp_]Vw3[fjs4=-+GNJ1^l֮4>`-?Ө۾C[K`!iJ|G=﷭ӯS[|`4G9e'y4w,hכwm)Akxb+55n^ a &Fڪ5 %-1 HI ǃ]ǯKutƃHj.PS&NKt];Чu? qc@EY{f?0#Gzۑ݂?,Qur֓qly89so6AEB\NճІ:pڶ1Z#JJcǿvv`xVy D3|;z#4-<#)g5w3I;}_}u ( Kp{9@UAX[ӬD" 9{HGNt"g Fw s,hcmM3bb͇{tFkYOwsѾ(3ZV0s\`aAp1XGMƼ;lL ø{V`>򵇲`={p+ Fn`42e2ҁ:7-Y)_f=_r8^Gz_xoЮhNZ[`Cz;77ZGZ]KYY~\lgP>P#8~osz[ 8h<|ndmƏlqQx3:}3HxX[Y)qATFx$lBcr T<=,>'%<1:[ǏK `d!BH9rͪ23ҁX`>C,jD _b OY\UPS 4|[[-^ c4·y,(^4I'țaxzvZϞjݽc5CNֳmd'/lmߞ`$p0Yr  =kRoP; ІTg}#.|S| (.l9vYo@m[P/}?d4_fG{{y##Q`V97~g ;@oMS!B}Zxc;psuo5Ǐ9 q#$} .cڀ,*CVQ#*&Nl\K P_&ԡ8$ޜ] -\66T;e yfQU=#_QX@21ܿEzṼԿ__p!0Alۺذ=da/= 1:9={~ (({E C}{A,7փQ]KcFcY=3^+O[oDE\ gaMX"?5ˠAt%0byh>)G̙3x.5.BB[n]O> nǣ1g=g}W\:;;'&}Rq]~^cH0=?O{㋢%/pG}x.41[NF[tiu7#ԇ:g8'y׌=cBQ ||^-m1 3`ĊNxwOzOcH'=\Ut2=]0ĄڷܶykܣE+ͱXNdEPdT?ȯtнlڎr0 ]x>{v`$<?~}zg#i̙x2ߔɠYԿ/HMI8 Ȁϫq[+ % ׮8@;g&0z6J07>:ܺ 6;lG(ݩ3_ ;r:g} Joޠ?zވ!BlxӦaӯo_0i%y8X\H^SV rMv6]'+ uPN䳎͍r16FݣGn;o9=+׆E!>t0AwE~_# 8Q~>0/T6Sx䗛c=˰o^|e#~7ҳ&Mvll^1=[Y~u/6]br1@2G=zvoOq-Sy"D bC>8~<ω]>.Ix h4pAgQUqA8{]I/PL+́ŚUXL0܇~-Cyi kz}Ǭg#oEuPnP/DEcJJA۷lD~$jdYO-=kod@cY>__ ?064h>^b" ޾lgtEfXHώɅf]č0%%K{>U畚 89P3nǑ͢pa͛6-^?v Ǖ=cnAqM#ވXQ"5A,~GӽA9sf~ZԮrQ4C':b|rF_(H ۻdGC$x_l׮"DL&hp;&zg?1(/_p{,*>h0c1:>gGtY(ږ6^ W._6ֳIkboJb* KFS) DPB+7X$4/c]?4FX{Иu.շ<í;xcTb,? עAcQ-y?#г8.ԫ8zVyEנ-c|7opf$lWcnݼۗeCϢ`x?& ǧFcotLrR"ѳBf8kFF*3 Qa !"3~`eY+ ;K߉}B ꬘w-ppϮvna!7B"D!B"_3V  B"D!B"D!B"D!B"DX72V"D!B.6iiZ|(6WEd9P^;QaawU`cjƍ`uM_.[FF/[ =;p7* k8(Qӧ```o݊Yr%8yT ϣ űMMk8TE8GyD!BGG|[7o::8ގ312zn87]zj2ԯ]ϧ@I(6 k2}:[;8^ #Тz i| o q';⸾(!\܁ax?JY~^~(<{L<{"D!,A|0SNɕ-r%M8o ʭrM6|r uի8_ʁlȥt(*-z@[~>uB߹Otw[Hώ;EБߍb}(fr]mg((4h CK="D:eF2VHdy\{+Lp_AsϚ3t2ғq`_o{dO}3 OF:Y]U rĢ~NpJJ50X>ey9^G:y8;;smmxz׈rˡ|>Ϟ:WOh*?(-)9~P@?_p123Olnl= :PVTlmmc6\ߴL?BgJKA cp~V8jpFzkk`6*_g"HDݎM(W][`@༟I'B"D~t= 22Ât6i@NZ $N8ù|cE}Hg$&<(G/{`` u_'d1{"DQzv%8WCp~ۄFeiGnwHϢܳ|_ CϒF"D~AQ)?z=ct[+fgeZ:ײv9έ\H|yD!B"D!B"D!B"D!BH'"q!B"D!B"D!B"D!B.5V B"D!B"D!B"D!B"D GXX4N2V"D!B"D!B"D!B"D_oZl!Xw.e%/вG:񙀀c >& |L@@@@@1c >& |L@@@@@1c >& |L@@@@@1cQ[[{?.ZOLHʢz;w 騫 ?Ϲ׮>xey91-5^t4oGiq |RFJ͜;H"=bxI,V0n̛ׯ?~8g ǯ67SUV,W=qt) >&l>_d@~'N;a<Bg4c^^^NVFhDF>&||-A~>r!0pcndgf48MLϯ |'>FsJIJTUV"|L0~ܘADJkkk穪ؿXQRf>ؾe>}Da555p/$}ܥ%%ղh;|#l3nQz+pynpذɑ1A‡o*.",#%5u$kK n?&!&"#%?yݗL6eϸpEVJT WNO0/?~z= VVB1A۹Cƒ;zC7c!Fݡ3_C coûwEu%;#m(p%%9^ssɻ?y{U1A~QqS߷gl,Bsf26ԷZ+,kVh/&+-ypokkky'Mt9k?}0I `2}Ν  #iilCXRSȻx3KN҅ :G@W f߻GSMv~w/R;⬬6/0*]UⲵYc۷DPs2%: N)|/P Aq1QKXߏ44#ڄ|#w[&&FUDݾ|9v7^gNCbϜ>7-dI6 .P_opkiII.ΤڃZJ"ؠqLo=CcwWRQmb~YicLprt%05;G{[Y3pswIGbB5>&hǎ mmez+wggc\pAME|@G{JM>&|L@HJL5u`Y)8qI eEy[ku_F߹}U02KN'DŽ wz),_<--yS"oE(b4ԾS[|KDŽ <")>|`j `flD |lonܘѯ_yVx`|s3r[o;)&" k|Φo6߼~E1?d&]9u'uwzTv~|ZѫgOԖwUU2Rh-YMm>xQ\\]2GͰq/;ӀԨCO8>&|L;4w'#L1kmr:9ΏK_Lf:ԖElټ)/7gߞݐ' +~ژ\Ժ2M).*< >%IF-M=c޿Bcȵ.očX9Xp=11lllز23>xvl~tJ1Frr@zرuKWSx(+yƎy]36K ++WED`jITwi"Ban$!|LqGvN J6;C]n5CN3J'+-{*$=choY ǐ#g͜ =V_f*j4_ھ yzc |&fKN<ə!I-ʤ]2pdc뭭V3ǛD]*((j91112l-`~*c*+*#|LU| ˜^[[>h̛G͕Xaj~LQwoϞU{{1p=!';GS]3n?= 3mMMbmmHM![4_}cJRbdEهffL-\z>Eś7R>n N3ktpPbnm1pu~PYQa@Sar>ujؐ8yzx{v_cFq e}d1ٜp0W1\5N{kjV,7^^Cmd}EE&OyHrڴ+!Nb =-c% M0cXXKCSoԔf;e120\o,+S| Ҡ*+UQNx劕g<ኬFCNu||xqyY5kn>54=\-8lD]ƦBBTlTS]Mfgv$ wU>>7g$'N;d/o,HjggCYԷ&%9Q|||( $S'O@>;,7^T CYYҒ!j~~~֮YPIA:wʱ";|ysuutm4]֠624x^%>:sFm**>,'I񱴄Z|||22}`5@Fhgܿ/㭣8r萌܆L/>ЬtB-*+m-MZ prj?wҴ+Ծ?__jkƌnnΧm,7}zh C.HnÑdk=癙3fϙs+VTEG~8zG<,_aP傿/c_G,[V[[yFVZJql^mXr2 [+;>qr0q]mՄ{׮ܣ-jݚʊE&FN:9JKI~Qb];EG;!>%>qА]3328KM>|Lc׎mU{oJK-Z0ЁG/+۷nў-Mce/_b>'_AGvލ8U412ZnUya4fN7[ZTTtFdeo6 o+_WVz4InzyiQ;GUUiS?1׷?|0{VXu#99rQg>CoC|nm71ov:X,@C\r%;~Ǐo߾mjjjf; ۽/?q>Hؕ3| gN651.nb;F|@ߠ)6Ad,7Ѵ40cehmmV:(hFʃmuRB;8E kF>+ܵ}e9|Xj3o5C%|L ꎍmu!)"=ܜ㸘&ƿ}<}*5H+[)Y*ؘGVkX3}bY݅[)vǶG]g*--4~;t{EnۺyT1ׯJݎ۶#t7fH/3|Cc}U^R,ZL7V߽0$LfZ|ѳ^eޏt|6 7^XР1'|`r xTH47orwXm\D'cj*W+vӒk_>8UUxl~|qNrg4!+ Nm:_~)Ys)w{W߼*osܡų+iѬum}W%EŌCO2Ӄ{+/˄GW\~_ɭ{| M-||[PwUnl\y9}2B vjuʼaY>j-U)S檎U]] {GBcKANOK#|ܹ]ɋ;1w.EG(,n߽ўE(Ś"i.{}ywRZf [9^µ[kW[Aon;QCDŽۍ5VR% .,({MO|S~xQ~:Fq7"MIٸVkϦeY(.hvܜ6defyGH'|ֽ[k~&?奥kך:&yZ9?~~R+/=rR;wU;X) 1qlS||<'f&Oߊɥ>댭e+ GjǍˍv6bN$ E3n=q#$'% Ls;C| +ϭJZhg^ewIrR{ ۂƖ {w|Pol+ԾۻW=%,,Іfޟ6$)Hx% {$|P.+);1Zo7xw-N#>6SJIx]ƏدODu6VCgݷQ n\r^%,w4b)'=ᢳ`>>FG&|P=Ҟ?񟄚eee7Wv1DDxu~0gffOqqϐz[6Cmw##7:YL 'MW6m:ގFԴɝ&N"|ܩHINnd9? uuuJ"K<"|7MLbZC}=Wضu*u93T>J}I~^cs^{7ǝ S'SY;";]x!0)[sU7C]%Ǝ]SS ٱ^E?}d IsfLMIz𾸐@v ݜVo'ukִ9xql 8~p/[BXu3=v()?kETVGF;g[[qfK{kǎqLTT+ >xLJ[kKqQQUj@n%OlB~YVlehBwck8EoI 1aUEŬgE-kQ9@Ú&a |L1&^ n5?ȶ͛?OLLrKm0ǹukW(zN1c:Xo/mk&ޣbMD^||72R`D[>&|Lqi}(>.z^:CqruPٮ^|\7XW[+-!.7M1c]?l| No>^nb(qsU>2tuǎ$|Lq;wSUٻ{Wč6?m]D=|lf9Ia7Vy4h>hI)QBCrR/$#C'cDŽxVS ĴMSSӧ${q3f޽N|06Bp*ם3V,? S!41cM`<|b@~"4;w9cV& e%?[5g[uuXrExXhy WF1&HOOc]?vR|li$7˧fi{-?4HS۳Ý1cؘ"dgk[^Vfd9O{>@ݮXNJq;CΞ Fw4mi|o^Ϛ9ݼNn=s:ǦYvb>}hsQSSnn.p=59yr)q1މxƌ;[&^rOٕx}'^쫗/'8~ۇ0g&up}VzD\ x?{;d =uVOص}&:e%3K ME@]devz22?zypr"o1ěׯ̞OnglS"1R;y$]JRo;P71nqwqf6z=$#>iw7:M8&:)S[hc^+bbCouT煅'1a2_rڴSNNg=A9ٻǫz>~ D޺ՉP49xo>j~zH<7/*( (0UZRB>{îU|lc8Wެ歈_Kia백xQ(!&fboj,z&|Upwu߽{`MVkVM߈͗ss{A\Ϲ\.,^_=88\ 8cxdD8{R0n_s;|d!5ߴ޳|15Vz  ::ń~b_YYcF|UMuMM[k{1&FP{+fayErlac+Sŗe/L7vvzekj|󍫝Ӯ~G6g102R g<ܥݏ{ٳ诘3a|4Q&FvQj|ENP2o^k1wn>&|"TKJRRYYy;[c /]RV*B>ޱuKlԝfRTkИ‚|~9XLT>g[p҂|N}>0ǷoOLm߳sR ;^YQ!$0L IYXݹ}+==8֭Zfk%~(7/M )捰-Z V^λjrXM|yyy >xHMY>n^1vhqQQa={Bn436ܽC %@nYvSMpϝ۶A>VSSqn޽ 5;{͛^v}L67c>^^hFwnLOcGn*+_6Ow76S̙!>>TΖ8&.QGG|u ?_fZ]]c_o^зϣqzKN6f$Wbp:>bDUUX)\~L1|Q#%Ź;}WY }ia|| ,4|)'@p=usk@KC Ȅqc)lzOA_BQ~N;O7ywr\=-5q1"SFi)]<Jd>KxW߯+ ׈?lTNǏ7:zymGǧfgdj<#de5եGuC֩a(%E%w4z rC~A~_G 4{inh+}[ӥOlM>VޞSDeBR6[v^{7'P_wx&(եM +[tIS^Ej9_~]pR}.ߏj|tz@RbӼǷ#"SG\g `c{n'F0iHF͈ݶyV i7p v9bfZ*|=ÍZNxwWh7DEIbVx,5"2F!.Zۆ8N| Xjܹ s񋲒2mq~#Z/ˡ=$+95fzutFKn˗[YϡD&s͛#qn>6O}?n2KdZOObU{yfwd&k+| -iznUUU5_kvjE c|Qi,Szx06jqG׮A-fXN Gh=--׬ZI(#)rg~eJR)S`[de36K/>0]f {>܍lEE[sA]qL@T@Rk{%ֶ5FccG|p#>6i+++Ѻj.^6mb55YbPaCX\Zg"-!N)ԱcF%)*$+B&Z]-z?<|,y0vE !ϐGq y۷jlX##¡f`2s,o^ǫWXB[v(]qLa{ՐG$s\;X߀,be%E :Ȁ}[or/EE[âąHi)C]ӏ潝kXt t,}Bfgҧҝ}i|Mfϫ0{VzZ*0ACН=N8t<-кqKkP \vB%H7kWl,-~q>;~>ʜ쬯{x릍+Luu;\BD},9X3F2ۛTlmRMda'iWcf¢ $>bsL{.$5\Wq7n1Ffgf\3R#p1+=<.-)n}P^;qLo!KÍb}Gf>nɉcSTXHs 4z,׬zV\6o(@`y1m莭[8l[Dfɝ~Sw>&իVA&61ZF}b̞%|7xyVՅ n\IAneޙуh׸ѣM͋]U WW7.d91upne |rҒkhh)>pu^fm}gjjԱ)<\ʿ C79٭1|f&F';#'Dk'3|룤DCߟ㈰SB|)>tpԜ;wnn{ m{Qal]b:5ǟ&5UUGr2:q)>UWW[$EDD(1/7w"[+| M"|Lgz.GkW~|g47m1Qw&շwﺺEEJ c%uDB>=avk.I^^SS:r5] Nx΢7΃𐕖D$ >| :|(1ܣG|baIR=/?[i~{CJ^"ԉOą\lffF搤Mm6z]}EGE+{S>.yBG{#$=c??3ϔ|ygI0[>~wmee&#aIr3| q> ݻՐW>-[Y~#>^c0SZBl=ح5s4HqsHl?>Pc^Iq۶lXdn9Y!T~Xu5c줻EԔ۷:||`=v~ۘh) ^ D]mݟmhNGݏ|{)p<}떎u +b" W͚=T?y(+73ZІ|UGEXS]=Q@)A K10OE)j32y#G>kNds| yㆎ!EǗ5GɋBqѓF]?=>nEWaC }87;u`o)Y޽F޾=#$Y>XfhPS]ݡS\|!| ׻G޼<\>n8 KkV,pj -q赫7Bfjld|y!&Dwt/Zhnfzs( ,׮)z~ħݵVYYYpfd۵dvfz(3=|{?.Ý,Zhgm }wo ܽL$%-Y@8ukjn%jwxd>w@6PS9zp| c9 \>9#%9 .vfGm>&|*|}Z>vȱ#GIWEᖖr z ara6m);=)1o>Aܾ5ijnΧ]߱uT>Hbbb7L .}t?n@1w4{lE/Zjhh2 V!wlz%0Y#88NwRd FM ݉up&?c!Mzs͗fgw)L,>>nMy>-+% 5cDŽ;@K^Fr k?}4QJXY@jP医[ɋ۷lq>u*-5%+++QźQ#8?+HOM6Z sf|үgpeXSSzH_qQ;w3LB>1[69xg}vS=M>s1Uޒ8ǕB|oVLi-/z}법"cDŽ; >}Ζ\`ښ^=zRq7m p ]|5***>d=҃|5v衬,K/NKMx7e'J21V'R_z0e~vv6|nټ)7'h(vۧx!_|iYT kW!kt!644ѣkV hw;x۸FD >&|8~Hs|[[1۾Mڲ{w|5sm7ƍ[]ʴŅ,^M6Gyxxh"#[' ?;s:(п>f7tΜhrLD}͵.ΐh_OW5}}-֭BA>pc~>uu%/s,,з/yB rrE;Ԏ(|O6$DŽ w 0iр,Dg+OAq[6{qcIC  gg(.gYq$u~ ~HIr ؿw vbcGdȾz0'騫 Y6Nd^nV>^) 955pQe{W1l"8CCY>=$&,O1xe(8؇N8odz\| amey98@i㔔SZRU0U?{gVUqv]uw͵k];,EE@NnTBDRZ@@UP/{~w$ss̉{wޙ3--È\Ǎ9@MuUgG;DԔ1!h|w#^LtOlDǃ1HjRl]myP/|?3F**KᲒb!o5X<[n0( @/aH{o-h(e)Ѝ`}-WM>&P? Y)3#LE5cĆ|1a^%ڵ41!<wf%BJDpG4 e@G;R{9:7 Bgk*1 B W5M%(77g_ޡ gjyy5x4VSya:9A`@K_tRf7/-ʁu-cd\(^#]`qh"}{"<^W8??ذPQ!ܬ ?x bT%LZ }¼ƘS<>AqWWV ruuB575bS3^Z#U$Yz; ?6Ow7o4emeoIH]M /Q!Yޞ.=;cܖ@h()A8n *554gd\wKCM=88svk4"=6.]lOS2xQh!\d\t1n jZ[g N*K0Ysǎv.^(::z_*t}}))M ]%n`𸶪2~`H_ /QQb@q"?6V%<<)p5|Fc`Y ߝd={ [ 3P'"pk+D_oWV4ʥKyyΜ UOwqR! 4ǘn!9#=`ꀉ#NƺAxiÆHzU= 5Ύ69A+uk횙nEݸ΁Lc}u-S6$OYڹ/ ?Lj-5t$`(uc.}f=m䰱0',*,<o{ 0]hm*zQ|\=ࡡ/;y9`5S-7c.#T9">^dLj rst|eh x|v$uuv]:OIP`wM48 \U䤤HcኊFLXYUKSXHlm6]hӆDDD[7oB ^,[#t"!@)%9v XHخ5emZfbbplww2;{ƃ̘G lB^@<ᢜ@> %yHa&̔8xcbxy"J=h-̸8oc8MWk\:G{q#(vVܾ {gN9LjG<&&&vtp@,KBAN;2N;;`CĄy֌ xWb;=yL/&"jjlչy#<4Ԥpݪ_)rbxxL70Q5UnEJL z> wn."pIzZǏhmUAA\7s0!PH xnr>fop`~?րj~`{26)au8BA2.d6WP9; qW?ޱm+MNY$I =pwslU^y Օ%bxj۶]-Lbyxv;z 1QWg畋T"==v6Vc_V,{qڏ;Z}za;՞⩹c񸲼+p&!>z}˗qSSClCCCt9uJJ%;Z:jIIh^$& 9>= 91w c'ǎ߳{˦ 79A߻<KٱfcfgS}.<IfJb :FJB|DYiUoghTcSGG#+ 1!ᣓjox\1Mє< -MM#8KCxr_?Rj^򸡾F]tRBvmmͨega}9>Ap764lmY辽T{EiQ2h^7CO5#ǹ**),㱨7c.O]Yq|ж.AjmmL~xxp:JYiԐӐ !~2Eoy8ϮdNv_0M˂wyKĄxEy9Bx+[/ܾNsY٩ciouF&W;/P %1L4%ra DREGW _CHY~>" .*"x𸹱.*BO\5v4N%q-0Y 1Sf$SJg_ɷId$FW i׼\IMYxQcN`#O AY3*- JEG.ȼ/-û UW[؈==B 2x3F Z<v0Dy`gKyXA,W1kJ+<ԗy: j >*yVdcD/#ԔG?!#)??IW16[hEQ6&rSh)iy<<ŏ󸳣c~Dzgfbg))L )1Y2z|xj'FSc5)?Ǯ8r 惄(ǨHOzo<67rgg$M 5$mbh0NA"#9&+#uﻌ.]|gqvέs2jV?cZ))^^SM~y#x 0Z[mKn1+J,6. ^4eo4AAO|]Eqp])NvlPBcȬ\q|LȖayi1jEsRևoll&1 . 5<gf(5Puw4{j^O_g "taSt4WGnvt <}x~8"ɑ"KWȬ\qfZ=~|*p"~yyq޾ytgJ۱x 40`#}^?Oi(ב# ˆ?EC֭,/v 3Sǿ/]tn6ǎQk׮<5J$<I1Hj:N}^oC 9c+Aϩ^LE *qu5C޶8PLZ\ɓ`""$g@r` ؗ>S\FHP#--YTWsY?ZZJ2ijj2724 O}fN󸦪 1 q]D`yG{ޞY~"^(*(PWgfb+.&}`Ħ摝ʋդٕAJNd/;O wG& y7oܘĺ1,0A-X5&riIq2ήB b2 I?ӧF]bin<YLD‚jjhxB ;}⬜TLt PWY0=K; nj{dG112iVWW8iXlH 繧;0๘hil ~-LRe4`c'IQyyc9N2֢V!)ihh'9zzܖ8;pxgik$O]ʼnC}<,SXh(Qxhk44}cHq* q^*]]sjoXf=1a^"AAcr︹n}8Nʊ y)PEw8œ988hmi~Yg%A;G"=zvBsRǃhܿ A}yS```@@RbZtt'%)//>q9w&+Ϟ:alh;;|#:%jWQ`xb=48yݽsN,<08nzc֕ʊ)hҧW.Quv~^]M:/_.} /Q~`>fAħCR y 0f8((0)FnOx5<=lmldeH|`7^'-94{VBy7Uj+pM#Al<>y{{&Ih4*'U ؜8W\lPqAVIN ;PS{u y`x {8)~xA'{Iy8 <(VdofawHJcIۙ#2ńMi~;jʊލIO\xy<44dqo0Z9?ǟ?Nxj```n?c`mS^8A ǃ*w/O7!E*ЍEYLԥ Ӎdޞ/P?I%:;,,,v6Pt:ի,1ВſINڏ WUIQWDB9jRkpBdB+J>&>&;u=#-9y"/7ػi99{o_2c475=H[kKUE9H3Ɏt{֬3cD ~Dqn|ٲիVfk@y¨իϟk)&ыߗz{6:ΟWF>(I44Fm '#MJHYG>J^mU #@`qLdٓ丏t3RK矫/TրZrs֭?F7S֬~Uʙ1HegNTU)o^[zx>_tyׯ B{D 8GtuvYc ql~㱥${z:WfHM1W$GgY?`fd8z "!>bfb"z_cVb_㬵c0} ƍ֖1:^PU 8oPdNp57Aϟ\R>NO~q8&^Z~}[K7ϵ q=>P= 0G y<|i#GHRK~zEbmYߗ~?ЏD4$0koZ[9c9!zBV ` x>848$g'z{{j uчO]8uI'H1\MJ|53Ay=BKs[===?_|p!E0pz =b#SʲBUzz'bJx\YQfme58}Μ8^@_@% 1=qscFkB; Nyϝ@AOrsru'pN4\R֦#.NN238??Ir_ou*ˉ&۶!3鰑[&z5П:e`Uy%1}xb5~ċx[79~J`䤄 W"Y xBrӼM|\kJy 5D^LJhs!0/%:Z?0y ֕_P?W]Y9g/<8hBgGy 5~ov0m- ;;;~:}}_'~[Fz 5kx S]qό4p ӵ67|jkxԏ1 GhypƽN 71Pdx-ܷs?}}[/gr}=c Mud,ZYIOq7^6/7;ܷ! 1*Y|Yh`@p?ɱuMM.];<4dMii3ϟ?d;R_)?層@cwny1ciieyv*eLQ7mQa3_Gϝhkm |<8/7WI^VY^}IIJ"$俌Dƴl%5T*J;;:L@fP`৏h/c^cx*)(|aokkogyTQTPWQ.)Bw z`_WQ'(T^aX:ǨA˗/ؘo߼~;L}岡t{'ƫV>,,,HyXK j=^ 1+38ݻ.%nyns?#!!A-0X?\byW<@q8U@X{xxy`7EQ,BՁ]E]Yp?SUި\,*,LKIFAuz`o_\X7z8~>ޱx6!IWqPǵ[7o럝Gys3{w8o;{&CFzl tme#""Ӧ @޵¹siiQQQ<ܷEE)L n\c@q#ؠ};o14]0T<<9w11_'$_G6{_ooP@JEYb =~$Ƅc\OBKJTWyRIq XA~T૲<xU+g玥I^VEpS&?>ֺZ.tf<'19ؘ虼b xr]j/c^_i%\aemק&PgcM2~`p~3^BCIFY^d`lab"tZOz̟07Q'cyLBLEDǃ.Np_"%!kUԗ/Z:?!dcV$}8{c;&zz0DFB sNZϜ:0U(Hz%35$qsL|SqLn J>ٛ+ˏ1AANm }LHOw|gK-1H%AJ}|jas?vf c}z%n0-~h4 ڲM͵鉾)o^`@MYo綏Xefd|c"""A,k%y̲qFVFP$XXuu>Ϣ (x>)PӦl?7KukJb/ü}*uDz+ ?/UEل=('3%_'Č3)6Ey`h߿;:ۑ7-)*_ , nPȰS<Dt8)|^ A//{ip ?/.qscDwݶڢڲ8 u`9adV[S=(TLTO?(/4O8/kt]m+/8z$񡟒N;Ɔz@CM;;?eĆj(EҵWۚ'GMڨꂖ"{" gusFHβ7W'{-L?}1Quc_̒ fcf3dpG[˻xWsCtNI*mPWgwO]޿$̌ ڛk5 "ex?L:@}1~!k ±aO?$~H ف۬?~̖  'ښ$qa~Y; j"Y[k0_y9i4_x35+d$UUU}`?4щw31#R+Փ!kxOH2ѕ玊Srqz,)*ʲ^gL)$G| ښj* ogO 1--,ZcYM;@lBw|+ F|зTW/ 4@ńo=Tvw46NOxllF{NJ/'3 7)o]QLKFY+IKOץ+o'zcchtTKf`@_M pŸ~RY^8<B564456twu!Khi t :Z1_9 K>5D%)xX6}I.i^X/q|cQu}UXp[ %Dq3m߾NT< 2iNVblI{

/ˊsQ6P\Xx<3DOGD֤D1,n08!y}'۷nFO&F: W^WΑF؉ܽn) ܮ;}Gxar>]320xzx531+u ##S'\7}H&FF~%jijz:iۖW= Ƶܾ={Ξ>}ɶ7I[6m?r`}m->BCUU g2ƚ͕<#RDg57 ~3k~=zr<ywA}{?e} x?~nojMI,X_=Cy9^ּ==ѽ, 5ߧĽ {v0Q"]C?)HV%XGsW]nŤy  U}qb YM%yskjjΝ95~H} Eg#Cu=uDx/+Y 3'OΟ9=1CH6UDhPG;+@rk3IccEyT7<4i9) ;7 qC"#xu :~8<<WO;;֔f77޹ƞ>6-ΛLr{>CZ-$1\7Ǭ$a!$ݻ}0q8٫|z-#+!j1lX׆5ϏBui^ pCACyY0,S`;S%jJR{ICUwlWWVd&cSzۮΜ,\'Uxz10/o<V/|&ִ5y y<%\-{wX$y3]HK. d(ʯQ̕( ד]wwWKSD1M6ֆֺbq20]_]J'Ȑ AACϸgd uA ;\u)!^E3#cGc(c㟡֖lY MUPR-M^12zk޶&Il̐ǐǐ@}b"bxEo+H*Ȉy=]7`fj 7ِKK !zo{{[jr2|2 ! Lu5I/gTNrAw`N$~۽ jXSSSL螬HKRs))|RsSt`Oify_u3/[7mmlDHǏ<<}(Y;7CCCCAACACCAACCCAACACCAACCCAACCCCAACCCAAOq/cD@|ak : dtD3oO0"4Miiͣ3psqelA~>Mΐ )1$Pu7/p"Guc(( ܌Cv .9QB|</X+//wú1Q;wlOINfad,**%{*(GG:=9|𠶆zrRř3ӐǐPPǣ׳7lI?/ \k 47RUQ!th<33_z:F111x%%)+/#^u550$/dꕉl,}ǐPh- #汅IQ7Ić!W\yL~0 nue(}vÓ1{׮wᆺ:+K[6ܿIq.NNcGgxᣇ>0@3ŋ~w'vU4ԋ~e˦ !@ևdLj6uRJr2xssnݼ j`oGoO۶ e*ʚZJgGlL( ̤[\Ѭk׆S7lؐ 0p:;Z,E&z{{iF®6+." Ke%ŐǐR4JNJ@O LJI47 ScEy0mR˗-#tdMT%Eߗ,ܱusc}=;(yykl roe'?_x̙)???xfE{5 ¼<<&/ke(L8cB0|Gx(w_8٢E^,-FS}l )Μ^f ; Hľ=uug¼ܺj v [x xxlia2 mښ$DpֆXMIq/Du}(?$؎S{G9ٶm\UYIL@vfF؋7op\TWncccuk7[r@[[X;$8L022n޸QZ\4e8N~by?޽b2Wl 0/?|ٟćnIJD$/ @CCC/H{xxptpLOomn~8*2,毧j&r>}ivvM {r<E` ( IOMErlc1 ǐǐ8:ǾAC=GPUF:nO>f}F3Yuրg`t8؛= hkm𾪢\K] l1a!}-ZP}23}hn!3.x Ǔǧ!!! ПKҴ44ҼDy[_[_v ~կ_Ż=}Đ XjKs늊:Μ V1Җ.dzY5&nin *-)gxlZ{̈M7675}tV-Y`~^_oou%^m[:;brsڿYq&:ZwTT쑃>fTS575VACACCpݺuaH 5}i)q1 Q,ʒns-ݻ{7f6VkZUW[3/BB`Fw^t$%&>zwq/ypx7568>25sv^S'^ž(+;$X r_JRAV5vt4ԐPǐǐm]ccE2m| //FI ʘ&|}u!ۇ<&\uuvc*vdrկ,/î?d#MO~=#6\ҒRΎޑ]A '/#r ==F*`9ڬwm-pZ 1;z`-@C/$k_ lYggZjʈ9}D?W}l5% Ѿݻ0kג{+$Drs޺W9iIP&2Ŋˉ0275D "ׯ[^fON_GLx`3xs|{?#*.*wŋ-YnsZ ]8WLʞ>uLxzx._ ljѯX`Fz5r0JQ'Օ˗ f?e}@cy%r2Rcc喕 M`L3RFZ36t{|DDNNO]@ ]_W3 :~^~!z .]cG;['O|%3<4 p|}YXX@E(.&(Fx|:Dz% `/A.߸~ӧjkKNp^y;"<>NJy y + Ѓ/R󴫳e=֭.}bkWBFȁ`BO[ y Hv>|`.<~6{{&gcV&@P22`m[Qc8u"(HEwbvqrB;ǰ9Eyȁ_ACCCܾؑa!AήOc^?0Dxl͚ 4X7U3wqy\UQ"4&2X}q{=#&%2798~!"듒<%uut'hk8:_A&408#1z:`s`{11,V۷hiiZE9|`Qtdd؋P0!s~&F*#/DL^},}s;{e/111l$U^G%kkm-**P BE+˚=@\GÇ VGK ?, ~1xL^F@Wxw'0\d[J/_6){ބNRlLm[kh߼[[Z /ۏx6]zj}m 2 5Sw-M?ODWpܻ/BYY9>HD.xTU ݝ$;܇ݽߪrcP+FUHN\L4#=cErlinn]TY^5KK:;:py\SU-Չ̂>U; :cX"pzgBq޸ۋ&ލxo̚co/Ɔ‚ձmd۷lvA6f-۷n>IN~y=),"_l!2"}f-6_{ivf&0+-.to56ݻv1yagk{kAÈ/)HnoV;eS^JB<''I83 =48:;4orڿg72lnqsu)),\b2{+ϯ=@ ٸΎNcG;4a8X͌r?eoZRRu@_`_+Q_D פ'<.._|!.&LYXxp  %>Zfu6P.NOKI`xj)dX9m洔d]vfgW/QYѣGUd1[`aaM}z]$G~tr钯oֻTHSύO1p&MhBO}-Y!n>#mĖqguy)c&y@KNchHkLx?r2RcHW{|}:o11Ѓ ooA;H 8s:jjlR%Dž׮oݸ.]kue%xkv\{Uq=OOO{jdd=T##$+)2#${F6 QV~~22u^׹ws`c/cBl( U61vonn-&VSSH&;;ݽCIN&?DDPY8g6@aGG̰l^o+:G9dabsc]9²{93~ d1hgGZdPɉ s**Y#91hX,9)QUDr\+Zllvw:s[ ĿpάOy99f`ab807󟿋qdf;lֈ(i)Ixhi؟>{LJ($Px}&WݹU~rϞ1CVFp$KEGVRT zz=aά@YqU\&y\[ݼ *,PIOMNOM! (- `^S`oP^xQp-wiT}dHt /yyށx)j֕ 8<ƤN'))ix}˖qkJ7~Y39& sȗ-)+\S]MCEYӧM@?g,(C?M2⢿'--Mq1ѕ+))6:yiƴ?C^b"_XY^s>{{{U/{R[﶐ߠ <=s-BkqV 0(*},^ѱRHHdKo} m[4ԍ c-]yzx;dܾ V=}yY) x\iCC]#'%q+",lgcL)-5G-T^R\rҮakTʨ(?@AnNNfz?~-?^7>S߮ }qe1J00GǟRBBBg+v$DEZ <XTXE.+-Npp0(Q .T|_:I 1M9=CټqDŭ[ɉj\Ψ  .+ gmk'$41(%1ANZ@ӈ.$f<Y2{ v. 9Hy{:~[cc1|@U7oʆpqf#.{"Gy#1$']c$$!󸽽005D3޾USk@-D!I!OVWg'1ocC}mc,r۷X{w_!ର05<9&A&;虏x4, VH6y~U^Fy!0p;:gfbܴAOCM[e5E]EIMYsb ;Θ:g_8`ikgܹe tuWkW01޹U~څ)591By99Xσhq<~x=޿w/1JAFilbj7p9g*-iz*Jei EиslOy`ogՏ:_Lti3Vw|/3fgc~ٲe۷PQ^SZ\LEAV[ ڢTcC TUUy8ΛI7in.YX$O<(8veӤHݓx=6&z̾T_gcar7Hx;D4u Q٥ <8ˋ8?7Nc}vc=IןǽsfϪw"d_*/'g?|-7*g==Ǡ6_tpnOPQQ{R;<~xj완pnl}ˁ}{ @pAqac)~V9?6@:%91 64x ԉQCʋol` AA07A%3cFZvv6_1sB;kf͛/]DH[K/8EYRSHItRf,YBl^k+-uu rr\l]}`L$r Ǐ ՟P6⎎JZZaAAm[ &d)Bd .jSE@~}pwg:yؖz˰Nwܙ7{mxY24wƴP7FY7EyX1ښwn*][6Bf7y]ueʻwF{ᕌ%d]%3~cmǝD~ USSVf %MK klcӮF৪0ھAƈs}m?N?0lmlZŘ1`\A~>4tt  :*:jH g|[D Gx?늪{wbc]NC~2X44051d_N?g֫MC//mnEo˩op3w;s4nGY=-o<~Ԥ1/=rlw46Hش^giC4llv!H  p!2"blLfZr"tZGbf ׎[N8vȀ̦[C''A ;;GwwWAՒB}XU~gWUagk 4G{R3BC|m(qVeJr2\ayTT$x NEEC~޽@`斗yP:uxLT OfFGixpZZZ \K-Nt.-br6&J>V 1r*j\<|6i l_#HOdDbnawH!Y9f1|+(p,dphsKMCQAaMPӾw*]X_;FGFx& oE|B.[KGR{R3Q~Z+>&z>nz񜛓ӧgޭ/8\g]JXuddSȖ-6 P;++*5չf4_9?/֖)DD--HH8ąW_Q~.v(fND]*%)IN,y (pKKIi*s!A Ջ̭} )؄KJڒTRB扣n@hk3. '%t16##[ ߟd9YY4UpE\┤Ν+.Ό_kJrl,,pJ=,/\t1r_/|T3cΚч1Dn( x=Cd]  KP,`o7Ʊc=j*JJ <QQfϺQxB8X76N%"_1!P"<t8_zyþ;ibl$%n߶ 3dd"## Gq NyIe<ƛ~[nծf11+9:;qo|\~{/w75jkk>5ѣsg'%&76,;9;zpyQaӮ.plz!#!5vy\-o`ӆϽ\]KKx~֖ͣMzXc5a~>!e9{w2 Zd~nVMy.T`5x L8C__\zwΕL1R|_x\ =YF>ޞ2{:pHtt$ǸHA~>Rl**ޞ^Θ۰~<&1ALPuvtkJӋXIqSc}1 %6  D23SUQx;sTj~)Ill67588YCiӒp1ha!"`Ŀ(^55m۸xB^N6<4< Eypqͣjd?~Xipʄe.!85)dr@kIJKWNz ҹsO:h(ͣ^J"͡&`C}Ľ $Mċxt{{{==ilߴa n .3 5K,{^[^8ԿQUVfgc[)̶0)x03 ,^U(6RSRxvOkJANvVxiP)˳:<$RWYCKMk/\Gdd?ya?#&=] 2 $tu!Y=c&zw+Jnlmif_(/+#-۷RH~{,yy._㱛LJRpzTK{ Lp(HA=&c!GoNUvCc16}A~/ڡ81o^p֨xɢ9֊N6!ۜLxx<*<~$Uy0wk $YN|.,!4ߩ#J fiqNi+$% xx<<⸏Q1|<ܢS]|ᰓl$HY^20fN;:Ny>u8=:΃ڽ]^]>-= RP.7Ilb5ʼ=\OL~eyϞimi9zΝ}5y ;[/< wn)11q_H'",A-v/]de#!wmm쒢BZjJ(#FOK{aA.WVΙ=[]U%*7wC ?>ozx VӑCB[6y*+5vuua_yPANNXPnﱶS*QZfMKs$W/y2ǐU8X ߻L mme xY("FՊ<+(INgfjb@G{ h qʥu6O??ޱh1< ѕrE4UڴAo@ ^E9S'RW[Y_TrdZ[^HDEHObRwWdc%aefc^54x|\VFab׮(~ϟHK˂ٲiӓ'N{u}]ݏw핓E<n1QX?޽]v6-% - ~0HV;ש3R/[Lm7rxx^V :`@#HƧ8@5xyVPHh*@+#$!^ncܫWGFd{L8.xY? QZ%Hͥ^³RQm2I>0nAR +Y(h)Ϙ:E\LLۖs˾xOixSdedOuhvjofeޥDd FZ>6J*%-ZB fӸ^S5򛵄bXxY)IN_@&(( 7mkm#XLLjLjǕwnprʻӓrw!!!l]''+@Ct40YH9DY4xuTı5 x$ ։VӖed#Zt4FZy9t ll`$& }xx-E$L7KoWحE v7C"Brp 8'%;#9pJT+cm^_y=?` 8xx<x-&,dm9q~9>ԔHONe&]O9:췱0ܾUw6P\CCCUUUIQI< hhhhiA"ΧΝHN(/ ':A &%Z}3%֪ 17o5kS-wyxh߹s!C a}Ǐ2/_~Unnnc=.(쬬fLi.Χ3};+~uqҥ3]ob p [}ل7F=s[1//iv- qΧ 4Ωym9 Va~N[7rg,ef <{dwkiܿ/5%e K..b+=V 47?khH|a; UݽwuUUH9^z%#)yQ~[ ??Ix|3Z⛄͸ RD@<.Kx!bbz7c޲q=]gn6cjNGZ '3)DGZmm33S99,M}DE,ͰBC8X'$K9{׮T@k1' %ETD_~^u:-[dӓ/!!! K;tOliͣG ~挤/7/~B< &tw: !)< ?6y|=?YŽ+22!/߻;fc?kl'c ` |G$.xo~ih}>]q>u8'|x<<=t>^xݳa߾<^agmz)r ܩhk{+%!x>3#G(_8 ,$*=ol[[--vm۲ ɾljgWIQLܜ涶!*-XOOΚCo]]wn?,E 1B$p.?rZR|:/bhz]:6o:vHzZ*9jx&zI<^h伂Y3 o3.㽶6X;}/:*xajR7?/L҂ii ?>XHP( "Áتf;d]h0eJ22N%ڏKnΞ/xҒW 23aނ|ccmDO+.&zLv(޹}[RBa9mfYFB< 3fʊ bBm3dի̜~FQ"n߼QDP@^FTW3sƽw3S.]ͥ(/tҎs4TT7P' 1pn9͚URRr1qNc8V֭Y-ˣ / {0iki-W- u%i)ɾ^yy*2>n7g.έ6,]rw$l pxm>_u=絛0xib<˾qr2Ad ̐ I/7^"##4{lܯz8J$+^55]˽Jh}-/"`6<(*(Z'Ɔ獍yW }+_<w5v`A@Лoa%j`wPUY^ZچcYi;G]|!**ĸ~.lٴV(˽kk]rΎ[ՔUc"v/6oL(˛7n :*9PX!/+FgǏ!os`³ZvfS'iq%鲎a<y9VL|x4Xܯ3kFYI7PSRmUK+Xk彖u2b+NٺA7<4?\ox /^?߳V/<(!.65)AUQ`+OxxMܿkn=|az~~I<Ͼ=K]),,(uA%DE0a i<R *+,Ac9Y܄Weedt;Çf+ mqD$nDO{mKJڵ  iԲeO?ֱGORP`޽"%!JM!G*ʠa! ݶyndN#CFz..t--(!#!#Mb'V?|H>xBbc:拸zz`ww  "3=bl,f[%&$@8㫾:)1!$8{iDXhNVrOwŘ7'Mb3&ŀC[ؗ9Lv03mZ~eeD&T=xx<)e6)~D_ ĺjkjz{z}T]u>>iɘ5ɓ=띝 x-$Nixxx<>{ sf;wA]fQёÇckHKG2xx~E 3RS=@ם>uBw΋g#)&x'BFFDpppܫee[UE:kDEEbZhQldD}];ۀuF'6}¯jl11O޶{7\\ll;WgY钢ғ߼^8oN5/Izy7'_sč>z[XXnJ+qx guV͍ xjNcu0͛9 --; 88$8䘓ӂys/['9#bdd {ֿk`544BM}s>qc.Yt<+R&Y}-/Ac$㉫Ғb 2;z{8z0c蕑&YauTo^xⅆql[okmm󕑔+Bv͚ܜ\n҃7ddΩyTKǏzzzv2xxvfi ?4'-l?|xD<:fy̻ԫI;3]i% :RtcwIc$caqș`1.Cv_ 0`TvzZc?ʻ7K猓C!1ǶZy|\lp'0]up/wysZ?PP̅N,<5} rl:czى7 '(\pmQQm?g}NS^&X)` ك^8ξVׇ?1-e^Ex:t$`l<ښh䐛0RL4YЀOow}BBB]!!'4wkX ;=̓P@BB<<._~phWy qÝ=8Ս2e='/x{`krm-mږV2x\yn17Q$q^[9)5%rxx]#Z{Jqh~<>#$$ (\ǡijs|A3Joa`ԳG%VѺ:BB<<.~f<n%K+/EZ}^&mmoCl~Aս~s6>l{gkK ښo^kkzeCS,2 &y\yc#kuzz&a#b5w8uwuU?O MOj)~PgXxX YYcpC818 ؅6h;{a U^xA±[ Q !^C~ާµmS`t -? \χkSuN氱0Ϟ5B` ,SSUefd̻|6s_J/#=mܹn MME &(3ݣΙ@kVBLM/ A;3;Φ ixjv#ÚZR5Hh| ts5Î"+SYdy89pgNMIYr_Z+nfadTUQ[}wClř ̝-/''!*2k¹~9M˛7kgma̾YNVu ػEQNϝ0x<>y s☎34ڹ) wqvh|cx{1 O;BpqQp<&-LM`c%EŠ FWge%<316™OKVΛ@GxԟǏ>=6ffޞ` 𨫫ƨ?S.]42з^8F \z% 㱼tj2@qv%7IIpJ,&FԤY+ so/ #40ى[f%2ROkkLEg~ 5ikίY55nm;' 03g󗊒6^;y|9-d J_VҜ3k*1&*RLdC^?93cd[<.Agvww787+c|5=$$DUUp7ܶQ||7 䱭mdd^1QQ*J봵θq<ki~Hx<>y p+pm!!g6|F'[)w:DZiU9gwX4ov͢Pws>q-']XPxNjժ<7nsy Axݓ't7Qk&c8 s%_Uee*T=Lj <~zݓ;J}qս;OMV`C 1/7Wy;Ϥ~^^̯ '4H>t贋 4쨻~ΝܜyWsmt>xN&οc-W~lG-ߞukPggx|T`` j)ի|}|.Xp=ns3%{Ԕ>, j۷caXhhӋ3]MTXئ-+%OMIZ1T%7oVomm/a}]bg rŁzũ(){Ԅʊ ˖-΄nͩS(H߽kPmKJD6ːﹽ$Ki~/Ӧ%ǫ(!R"[\rՉ޺ݷŞ7M P[$D\p{v_Wgg\_cci{wssve] XeƼ=xW2YY`>X!;jqdX]Eׯc1o,O|dWMMnnnd$R^Nv||ëMu^#}wYDJ'#v_<)s7S;x {<޳ٽ\|A|hYh7ms9uCQ^~0{y;ڴqcЅ |{r% `1̷TUB Dq__ߏ{\m~Z!ׇw蜛=ܨG v1&93#4?ݻ_,֖ܽfDwu Tf!O|]y.ܴr8籿|7?fg_'~gH鍑c+žvl{Gxxx3XjHȩM!?v[==zp81",\UEF,0?MMEԌ1 M rmh9>pz `<^]}P]d#!?h?Q~(1uq(CGkˁ=;?7Y]f/VV@nO6]fs Hy Z2i@\b iM m.䩻h;~F<ȳ6PHnj @ ݶ07{u+ħN/+)Ӊxa7<x?]89g{=]`r{O478vÇ2^!]55ԁ %EŸ vȟ/9>l$| [_Wcoy˒S[k+ ! 6/_`gmu(y8ؖa>XOO:q_z{ߕ@KwPCU 㯞>>>+L\{:* SBX"*ve+oYN6'ylݺ~0_^bٌ7qTdCNx/`xrh,ED֦{...5,.niqǐ /l4րD=]J2RcI Wǿ4q&j*TtT$౼ &/=Ͱdbd TUVbfbEɕK 1cTq5N% 7ށjefeҗeg/fi0eM mO.k0TF51n7/kx_Q!*J?z=۹gSSRN[- 9XQ?v{p>ڻw|)+ҒX'WUT۳[EQ:1)l!^cǎNN r22-e%Dx7 p=]cc8'x$%ai~ j`8<1$baՀݥi]|zKn$ϑ@675^?77{ :;1,0aE<67Yٌ9+`ݬu] TuVI^\\x^G~<~ӳ DbU.2i.Af!.Au2:83WSYNtIߨΜߣNwWq{>;LX`<s ي+ p5ANXZZr pQ RȯYgXcT4)ŋc#x S?؏$WcG*i[B$6:I* $j$j91}<؏IwMI^>|^I 㯃E%!f=5)Jiq{:h),'uK+R T9]#1[ 򸪢\R\l}~gG}1)057o֊ ,0tG٥l Ȼ$d d€:xdsM\d?q1y\^V{11>UMO?cywS09;9:$ԀM-VIR0jtKU!1hDsy 5QSRr SGkt@X`yE8x!lX^A +4Yl%X,{I [|< z_1 㯆EYsUimx&zgVm|Dgc_k*X]uc-$^/F\|qL[ZeXKcK,La1,0"O? O K̨.-$.NG[^HȿqZas+_!Fm,-˗/ `kJv䱣DpKSWyj*4`%"xR$LZOExiiVJ 1ʲRXր󾓣SrRҗxyFnluEٗt qqW.[ v{0a?|=Ϸ mL a<~__@g_LmfKLK#Zf mU+\-57;&޻Cmnl~<|/!& vb#HoTTyu:9.:1&2)6( C1QԷoCk:;m S 3Sh`hҌ AH/ y 8&()c"Љwr9٤Dy12*OdzglׯUעqI^.%j+_)"P[sYIQa3ci1Gqrb) cZY@,_XDoC'3Rw+(s365]ky ^ӡyafϦ&]6 3ecSI|Qt|znjSd++ȿ)@S01 NbHOѱ27J@M<0356VQVڷwp 1o;~124PW>qWWQD_{%/o4uŋffǠ>_~ifzכ&*"hvvUlY[U x۳鵉Ё6[Lp䤤( ?qlLG‚u0${ 1ʡx^no?{?l{zڏ^ƣx_431{ ._Z\ ⲸpWVJrxh|CA#a<<^^^rR=4_@%[daa?-/+TV\o8\pǏ|^`wn!~ATTzڟEn6$)1aSM`<E`ymCiinpsxpSQ^N]I!>6ɫ,/;srfb@X7.2AVRL6 7Ν>L#?oiIgWq1q deAξ x~֎+N6ӧUD':':z3YiIw5dX4<98Ue9"7iI0'`y+Vy敧}mr83ν$.IFH %yq@dG?z.`[K3UiM6\dDYd{_L4D*2B/j? 6.O 7Wˈ'~V_ c01,ֺlH!Fw[Q݄(B /W84=tsC<'GeI. #c0/Avp_ ƙ!ZN:@]PpV3J TeWfR`㤢[],0bz8aqv>e$"jo:ʲnuָ2>6 m=ٓi.//U^gQNv)NT4Vl,xl[N}|}LWI_M.90SLCMYJME'+= c}}}"̬!H?jBZ[Yl #˲cTx#Wɮ@&-ĺ'q^e$Z[8RY;%ղ2wu| h:r`l;Dy?}Ͷm΅~8&&y9Td7d(3c߉j2ARdFvѕ2OD((n\ 7׺v6Ɗ$k}UeGw˭tӢ, X`wC\+5915Ywh¬D[#ɣ= 㯌aa:; ?} ph+t_cLN< k6RPN讗2&&zZ**rwnS9 */.@KNp̘!EYN(uuWcYnZ_NC UNCSSOGM3c u} v]K++"#""SUE+"yNYhrrV_FGE|`||*44g}hpyPm@}<||nusq~#JNLpvꟀ$ġ!ϞB9TK,.. ]^!%./+y jv)cY5 Ӽ9٘FL =iEFDNSd>~ ] *̚ b~^mʩѧeyY:ք)+>DDrݿkʋd%?z^!?9PbiOxPya\s}?~9tp kkjx{Go?F'%srrTa=|#nV{)-!NGK:ZoGۯRv6 ej9HOokm@$|qqT}l{`Pe<vv<\S__sqrrqv:|@kkK\l̩%hP0GDDܓ56pcUgFZ+ Μr;׵$RAɂԑ`W[M.C8))."ENG] 7 ?5ō#w320$&~omj;o!'~n@2xQtW*KS><2ZNp-9θ'c>u4sg :j^}M5ǀPžZ \c=?MDcJ r<%ELt3''VΟCi݃y #8>PrjbQ =]iiz4dD/p0Pp1#/'91p).\=~, :Tb!}򐅖ѽJ2ýHP]UKfmb \d$ f[Cm- p_HO7LKX ;\wtϯS] iL GFXJf7V (A58J28YR>uTV''[A:|ĩG tSSQA.XW1a']$7I]ёlzRAV0UCM& ܓعrsuG.u0xB-7#~# ӏIP xύqXho;~g+Kb"Ę(uUf{cFz*!Lx /s1߸.b30?C<$޷g!5|<3cDV]Qզ 2l@NjJ2 z&L ^^tB5P`8xn"v# )эGBB`7)1m篿viHK!NxZ|O[P$4}קꑾޙgc s@z>5 v;3חoK Gq^O: 3)ͭ=~'!̄ 3QQƆ'==ssk M],/ʖG.87 +Z<t[ RI qXphoF*0(*-*,Sl뢡(N 0~HLCQVv,4o0L^Z\Wsdgjǯ]rҥ[TT7q.COIFzcĻp-*Xd䀸nNMM'edd<{f=/_8wr޽`4x JJB<38'*,LAFFx@=Sح--bcc;yDeE9KDH@x7'ؽtC<\]|Oacс{}]†]dbhP\Iy{ܻGGG~y9J EOx8hKc5`wgm52: pG]miQA鱾^.M(L{eH^N.?7mmts}(3׷0`ci<6ҐẄ )NK 2ʳb6 ` 6Jb " eTA,]l4{:4Oc u;=2?;6;' UQuA>>/Ύ[66 跗/_E!P!}rb*91> x  ij]bcbMe9<)4p G̹/_6<{zv&hvmU h0gab( 5t%i-6qME=kj*+dmz2yqqr\r dC 71/ _7/`011ۿ]D-Kyi{䄤+{V45(h߻{ii.)*VRTEҸ8"9԰R go*_/O0ny?籹{mᾼ XHԦwUoEͅRcy\Qz@mqTnrz[MQdqfvbmIVzGaF0%S2J 4bnj@ )ϟDlm)IvxܽyuMֺ܄@w/p_̯ֆj wHlIqNUa=:77^b)Rf&⏄Μ`аw1<8m۶Ĩ* AJsYa^3'+@}4Kc*mmUQVfp7{ lYq;QwvtMT0n9w(H (=vccEʗXS1V v\ r@Y\w[E^8h'xGuelea~!;#Y@q/$hcEdiPu ^]y F#'Iq FFF /ొE y v{:MIo>xpvvxXS]z9rM^_0?7CPC;]ؚ*o@MsVdMq( ) TL7b(vFj c=(Zi^}A`JhpP\d08%640@Er65?5p&10-Iw2yb-9|0R#}ݭ) ε&u5!mW/*@ۉ.0W޽ >xY?kEΝ62^JR"""=qs>ք^@N;R^Rx v<<a`rq^v&/+b0?s.k?ؤиHV-a#wXr; ZT^] Þ;]fR$dۂ>NIz)!?:2a',-PAm7VoztIxiG ب.e--`BHw(g+ sEYa:Bڭ'+- gSSZ^ZB9rIǵ5)/)9 x |a!A}]] 5Gl :zdxh𸺢,,$v}m:_"A?- ut68A6̃7:PPJsv;СmiQ]O1-JHEIRRP0$@eIB*O$tw;uS5Ӑ0Q6V.Jn*fzZB#zA;dmAGʙ+ct(͛ӛ|>CBfg.WmF׋\V&'+)==<8y2@q! Cc[kkP %9!e (D^ g''(V'ꪪsgp TU0  }{r2Db,-,}xyb}7zz.NΪPc@?yFm~LMQPYi96]NV  `s S/ZFz 7+OSUIQbsĄjeښzk?Y" ]uԄgN59q*$A&[D/@5xLp.u\N*ǖ"0^^^{$(jnl-fX !U0 G߷h]oWgǞG>''#]\\ĿrYVZJANI@zpS@;$'%RWs_~ ;oʡ'~ j0t39Y'c /]<~{/!^UY )hgc5 0?/>ؗ(K޶Sk( v1N-Ú٬ .cg'y4ǁi}@u*rB1h$45T]I[cË EG: ls1yYWs6sUb=4)H 1RPbe!qP0-` K3fq$- HsӨ.Dą7<6SCjr}?m{wz{ёa^Çx 4݃G-,,|7+TبH %eE\mI_ n.f~9֡<\BBPގjt#$+t1W֗r2SrP kUaqN&wPOD졀$PMY.4:;&'^,^kfGkȉq]9wVV48#hCDT >NIюQ!^2bd,ls=~ 庒hhbZch?@w͌о=jo< ^_{dg^@MO}v>8r(6:T$ʗޝ=}j䳶uqgG'#=%&"jmiyUi7OjoDg'r7tic"'%nFp唛ʆPkcfwCF-=ֵ"AW_]TGZ-+-#޹ % #̷Q\K@yfnz|LDytDPR֚6LTw vuvN&YpѤz5zU懁W:8 7?;7+51ψѽw؈3sRj%Do1:dj7=1 B++@'aadx[I SPP!ŋǎ" $aeee``>KA^i38 uu "@hjl8wy{S!fI2R3Bmo3pqkax"N44dky@??{όmbNQ{TL83pKS^NWN]<{\iNjp_v Hx2Nu%1PP[]JFc$33Dy0詖怎o1~t񭩱ڵC{w޼148Ε>o#^_Pxh02D +';Yl rs\w_>yd#;}ꪋgpAD7FII!!1c4hfat ȕbfz#uuz:͌oc%S`35-[:[ShV։D'PyۤW 1&= /}k3JV&Zj cB^[NrC\42$ݵ|ؾJ\1!栝e9҆|Խ0L"iJKR9౟X_˗~ _A3m>^WdLmƜ8kOb4'86<%ʞ伓lg"^1Q 1ˈs^cK?_00^zlylcaaa'+)+6V$ޥn^u!N^WMp mi߮lhTGPA*',<yយ?a苚P̜{:;=^.˱珟L1Q^&j-V 9Q--d꽞"lh1f>gRmEQXRly<}IkmE]2c^,^Kom,ltŹ+/'rRczÕdX]=_"OO-//''s&  =zZիNv>}?-Pmkl4H#&DxTq_N]`<7ukc(KX<ɑ)QvyL:І7)Ɉ{; g'9Zd$EmƯ#]_Wլ̏|lB+!.脡'}1!2U)fMe{ yesCǰK,..T|#CCSO_fgEħ H<" h)/9c{8Z(4sRQP<|>™cy)^ 'K/[?'C7۶ʈ=1Dڏ~{L~L# E<z7 RK}vf/W<. Hk6/j(ŇZ [K=|@-&« DKBIvmMak#e'/ qvV[mC}Ϟ9a1t`c3338vS<yݻPWCY 2NuUna RSEJ<2l~P^{*όwOj()B(<`wsi"sy訨ĄxCً/RR''ё:;{Op[kk159Y\z6DDxMUh*)x^[dfgGGFvwu564 "ctViinuKs>2g+5)Is;ۯ?0IEAruuGAv3qWOa^++0dRRTw.Nv6K02(DֱcG./-556xLfz2zܜq:<8Z.+-EFBsf:?vf%{{yA܀'N<?M{yz)+:[MM !y CXGK{ 2f1 <ݽ;*k6RNV#MhKs&rJ$ۼu+ "@oDcsU2]S{А 2sp?E#[ZZ*ɌrvttvrRrBq0}69y*;ԡ"|(+)̘(bYU]U.)EE@N BB E%T[).Ql){ǽu{yxf3gfν39sXhzYOww[@wWXǗfq#QcvG!6||]caȲ23 ofxs( . n <N=~А qKSSjR"<$/ZDxxu<6PQ8Y^KZ֦FXoe_w׷ ۣ6W4͚s]y,UUnl YqGE_p(N2YSH#%ʜK._ϾXؔEgulN'l+˹^2Z5e2R̯?_U\3EZZdd ذv5>}cx<A==6Pmff$''c9Whkj5>y<FrZnNe?/S&K`ksx\ZTJJZj.a9w*bߺ9~㱪*ؿ~X0.06 &^VHrgVe qrljZ;$Ex]_"b]IȤ s FKCy$m\Ft"ٙ8v(++S`fZnŏPLtqƐœ{>Mݗ7aIǭ~lI+C?5kcS}%9F)) 1c]- XCE?w?3U^أ%?.&'&C8PUe֬jo f-|kJngO^0~j{pt⟰px \?V^'%%rsrvwiccv~_)Ɍ߶[HWsZkfc5-ևb͊e?6tT2PI v`;IVm~eQtr{mIgay;<٪dv ~eX3r-\㡹8f%fT$y - »Xj TJg*uj*H5auzj ̈́vIKENEA.+-)Y@MYdF#ʪJ$Wuwv\kE^rdx;\_o/@W[NFp(/-jimX<>>neݤBv'cctԔZ|\,L7vp2+/xLf5;8s1`8( <Ƈp66rYcoi* &}>7=E47q''&2R[?vLMJV]Q^gx̱G(,Csc=VpJP/]A Or\,֠xxy !ė%ŋ2c4T y͕) o -4OlT幋gƳ ~vҵWRreFRuK[)~]PD X ں #< I RD]4+)ZRM9 [nM8Ք?blQBt'Ooo``%yI747UaaAyWW>EEF<~ IMN691;J051LB ocPfzZQWcW/Q!Y5+Jcq$fVX)HpyVCr#5loņ) \vr7VuI1%u,b!_!ê"~R~>5yѲȧ&^޾q.P[i-F:kz.+ezgf(O8CSC9KSŹ M,X^軍x'jh__WRl rȶFW]A֤ &^핱2U:R aj(SF0@HF:R~G pRTh(OJ3ɻo* x9A ϖqۏwns.5gnYрEד}e|twZ*G$Nq"nj]87,sS,+F{]WWŪ$u:ʂXyRz;3elZyoC_ $c?]Ӷ6GtT=b =PSYH9+2Ѭw\ 8MU&ǂ oXPb>d,ob z$pҾcBUv*d_"'_wbj yfhu W"CT_@l:+Kayőx:[͛7--5yw&Gp[s2^OOG<‡{iJB|Kӧyq;&&߿XW&CӐ`!~nwW3K  Zhh+ܔt9W}ϛd\W ݺq:!!9S\h[5Wl >fU/ˍ$Y/9JpTs``c$倓2<~Zfn"gO|^CYBYN*3#}#YwlcPUaݼw WWVf}թ"+AmbmU+ln_`Aɽ"z8:DOu,?p{ر)\s7>ni & >Ԑ+* l\zPnYnO>k0V DTE1^8paV޾qV!e6XS&s:*[:{R#}wL ^RXia_U 6\K>wCP t't8s|?FY|@+'tẅ́vo޼n>g.%.>nz1ب(t= BSUlWue%Tl"PkwSgG xLGM8/{7z6606q|O7~P$ÃןruPM͝O%KZt+,츃=FUeeqB|<9%E9YYu$޽;?sccs7+~YmtO|P_{门ry3#q믍 c#i~Ɨuqn| .QR| ?'Gy:Yk͝60@N"&kϾr^w&ڢ mg_R:{(*!8bb̵}k{[d5<_Ovqnʟxbt)-x~:+яVUXG􈙪a}U9~5ɑ^eYS|b! t==q$Wh'SSK-FBޮ6ZRUvkNmozԱ"Zj4"nߞ@?w$_NϞ>inWw*o߾mij ,׫WY῭ME|\ x΃'XW';胑)lγccݝ8߾Fh759mlomY_S}9`d`p&؜p}ݯ_x_I!`s6v`]Sg 8_OW4== e{s VOԓǏzZ0v43޷WK -.scVvEY EYAmϟ?:('-~HǟI^VF"Ԕd xyXJQ9QB\m.6xD-(ܶU\LݝpV*rRYYY*r7`˕˗׬Y><,˗$'JAF%0m840d ed`ZrC&vCw lba?j faf4с-XJ !gpP ,lݼP_휙!E 2RyyyBL9YrrфCDEDPSQmnok-p/Z`A-~B:=p u *LAN*!!AMAu 5Ƿm%ۥKkx_v7T5,:FVF377wO?ptdea3nNQ*J~Ga׀VSU*XylcXcmIoztia[soB"!Anㅅ*zj*] ~n{tޮN-;aq_E qsȉwucab|;C7akɢह8v$DïqFq]u% k8 'NU/#۰, x+:2RMY~pĺ5n\ݺu MvOg\غxk'\4g?-Z:Ƕփ@q㎰`ogGOCax93+WZhT\;"""!,U`aK\LLxXk~,Lq0wEWڪJ;ۣ|Vf:yw2iҹӮ>^&pB]Ap{syǦxMMN03TS3^r\TWkkjضUZJu+ETWV w"(6knwuvVQRPcffx |cK%I?oొ'77tVF ;S;+ƚ:3qtb͢/>zNh{>hfq֠E`@ zGETخͱ};fCkǡ!{vc`kVvuⱢt0( xr2p]ユaߥ<8-Ka/ iI*~9S_~ '?;¿`a&aw*)xFtJK ]7<4&rrb~i81 'q06Gs]O-0M- #E Z63muKv,fed`o$%&664TW}odx($8pJU2r3@qQᡡ5UUCBB:pÞ߾}+,$ErFGF޼ {33s;<~nn.!OEy9!vϟ=w{]lL˗/Ąй-FKKJUUݨyސꪪgOqTib3VW`9}:>6i<~ł d$))%ħ${d%,iqgOaeiu3:}G([w\p;gog {tHׯ;fg+-); np耙i_ϧ*W F:))p>pDA]zZZ׭s>~%)2ߥ1#!#."r @%oZjبH6w,˅w`N5%WZ[ZPRRz;}V,fff3713 rmaű}fffn!j#V 4HBbii0xTsr$'63ݟdllʕfMĄ]w7 '?C-55QQ9Y[6ilffvbl"!!yL0jBOLKIپ |z[k+7'GfZ|`5]-Mq5_㊋ ٷl r-aC22N<TWd%887ޫ(/WW[']/g~zbٽWwwp-K,WVR;Z࠶G,?ࣹqss =}U;5e?/-޶u˛R>;$Fkk+ǺkvdoĂm顡ztVjRjB,9vg@6?;˾8ꨫ~eT`nN|ghK>w][v 0[|9&f\baN[bYWǧx<-Y1&fG@*uٶض #Xaƍ@>u55 }.z|phB#|}(`M,x,IodDDZRr2ULLL\l TW͌ ؝'P֐VN8CA u7B)I<~|mm>bE1'Foƶ`QQ0`Ά~7HH 3)s6OOIK --~^WjyxHϻݸ8b~8yӦ֖泧O5)+Iqa>n>j@jiq1d{hO?NMMqubSylia!+%igmEJJLEA[YY22 #^=CY6gv@`nv659[|qB6hIWXOR⢄a HkTmbb031RSVõc;z#št4jȪeϐt@_7髗WZ̙WiiZn'cc[6`1פqu(BE !h r%p>xqbL/<GP/y]p[### puZ*ʬ4AB.x KH`3ܜTHb/;Z[ɉ338,)10#Fn]P[8<8u5W&'%$cy\_Su~5vuŽ*.*--M8W`x [u {ab◮ }=]q18? KLL ׏=6&K3ہ_A!te%ź;;rss?#]619Rs=^y9)o~ vҢl!-?';6:S;?pVů^l up,CG[+<  ?C y9vX&+/Q. Yd .͓(˵4 't".#ښF.'NX&.@O+xhp,.$.rOp EYue;>]m-]]uU֖3NA6Ksa7jkT JaA337䤥-O CBBB.xx۷o߼ysꤋNHP 76ܩ/45Y kq9ғang3E+bi^."$tDEYCM-=5u %996}]M$nS..,_<b7CW qP` **,lb/gosKIc?_733»:xPOS-=-Mx=wtv3rJKKa<zUS#o:vزŋ`''&L<<,X`ocf !ܧOY}e;KZ[0eafJNL:h.8 㱁k|(j]qL <8h倗%%%%x~a140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N Z ` 33PP` 13` 3333` Q_{` 333fpKNāvI` j@v۩ῑ΂H>?" dd@,?n<d@ `7 `2@`7``2 n?" dd@   @@``PR    @ ` ` p>> | t  0 (  0 0 <" H"0C  0 TMd" H"0C  0 <M"U_ H"0C  0 TMd">& H"0C  0 NM"P H"0C  0 < M"p H"0C  0 C x*M?d?"bUv H"0C   0 <2M #" `  M LUSQdkYkHrh7h_     0 05M "  M 8USQdkYkHre,g7h_ ,{N~ ,{ N~ ,{V~ ,{N~    0 6:M "]} M `*0  0 6FM "] }  M b*0  0 6PM "]T} M b*0B 0 s *޽h ? 333380___PPT10.(г%  Blends   * " 4 (  4T + 4 "+bb P@ 4# "Dwoh 4 s *"PP 4 Bd" P@bb P 0  4# "Nyh 4 s *"P   4 Bd"P 0 z  4 <" a*h  4 s *"  4  f?d?"+)  4 Bl`M ?#" ` p M LUSQdkYkHrh7h_    4 0cM " `   M NUSQdkYkHroRh7h_  4 6fM "`p  M d* 0 4 6`rM "`p  M f*"0 4 6}M "` M f*"0B 4 s *޽h ? 333380___PPT10.(г%*  *(  x  c $ 4 p  r  S p 4 `    H  0޽h ? 3380___PPT10.0(0  0 0(   x  c $;p 0   p x  c $&p 0  p H  0޽h ? 3380___PPT10.y $(  $X $ 0A?wvP $ s *޽h ?"` 3380___PPT10.mg0  @0(  x  c $7p 0   p x  c $Cp 0  p H  0޽h ? 3380___PPT10.0{M0  P0(  x  c $Ip 0   p x  c $lJp 0  p H  0޽h ? 3380___PPT10. G0  `0(  x  c $hPp 0   p x  c $,Sp 0  p H  0޽h ? 3380___PPT10.  (   X  0A?,',P  s *޽h ?"` 3380___PPT10.380  p0(  x  c $ 0    x  c $ 0   H  0޽h ? 3380___PPT10.pS ,(  ,X , 0A?9P , s *޽h ?"` 3380___PPT10.r87'i)A-y/15+3 u7? a9  ( Oh+'0B hp   Anti hypertensive Drugs iweiBlendspwei24Microsoft PowerPointgs @𔧛@#@Ɨ}GAg     -- @ !--'33-- @ !40--'-55-- @ !4I--::-- @ !4J--@@-- @ !4K--GG-- @ !4L--MM-- @ !4M--UU-- @ !4N--\\-- @ !4O--dd-- @ !4P--ll-- @ !4Q--tt-- @ !4R--}}-- @ !4S---- @ !4T---- @ !4U---- @ !4V---- @ !4W---- @ !4X---- @ !4Y---- @ !4Z---- @ !4[---- @ !4\---- @ !4]---- @ !4^---- @ !4_---- @ !4`---- @ !4a---- @ !4b---- @ !4c---- @ !4d---- @ !4e---- @ !4f---- @ !4g---- @ !4h---- @ !4i---- @ !4j---- @ !4k---'-- @ !4.D---'--- @ !4DU---- @ !4DV--%-- @ !4DW--0-- @ !4DX--8-- @ !4DY--A-- @ !4DZ--I-- @ !4D[--Q-- @ !4D\--Z-- @ !4D]--b-- @ !4D^--j-- @ !4D_--s-- @ !4D`--|-- @ !4Da--ۄ-- @ !4Db--݌-- @ !4Dc--ߔ-- @ !4Dd---- @ !4De---- @ !4Df---- @ !4Dg---- @ !4Dh---- @ !4Di---- @ !4Dj---- @ !4Dk---- @ !4Dl---- @ !4Dm---- @ !4Dn---- @ !4Do---- @ !4Dp---- @ !4Dq---- @ !4Dr---- @ !4Ds---- @ !4Dt---- @ !4Du---- @ !4Dv---- @ !4Dw---- @ !4Dx---- @ !4Dy---- @ !4Dz---- @ !4D{---- @ !4D|---'A .=<( {{ppddYYNNCC88,,~~ssgg\\QQFF:://vvjj__TTHH==xxmmaaVVKK_\`abMNOPQ/01230\W]X^HIJKL !"#$WRXYZCDE[GRSTUV>?@AB@MNOPQ/012345678HIJKL !"#$%&'()CDEFG>?@AB /0123456789:;<= !"#$%&'()*+,-.? ?'-- @ !s E--'--- @ !d"---- @ !d%-- -- @ !d+--"""-- @ !d0--$$$-- @ !d6--&&&-- @ !d=--(((-- @ !dB--***-- @ !dH--,,,-- @ !dM--...-- @ !dT--000-- @ !d\--222-- @ !d`--444-- @ !dh--666-- @ !dn--888-- @ !ds--:::-- @ !dz--<<<-- @ !d-->>>-- @ !d--@@@-- @ !d--BBB-- @ !d--DDD-- @ !d--FFF-- @ !d--HHH-- @ !d--JJJ-- @ !d--LLL-- @ !d--NNN-- @ !d--PPP-- @ !d--RRR-- @ !d--TTT-- @ !d--VVV-- @ !d--XXX-- @ !d--ZZZ-- @ !d--\\\-- @ !d--^^^-- @ !d--```-- @ !d--bbb-- @ !d--ddd-- @ !d--fff-- @ !d--hhh-- @ !d--jjj-- @ !d --lll-- @ !d--nnn-- @ !d--ppp-- @ !d--rrr-- @ !d!--ttt-- @ !d(--vvv-- @ !d---xxx-- @ !d3--zzz-- @ !d:--|||-- @ !d>--~~~-- @ !dE---- @ !dI---- @ !dP---- @ !dT---- @ !d\---- @ !d`---- @ !dg---- @ !dl---- @ !dr---- @ !dw---- @ !d}---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d$---- @ !d,---- @ !d3---- @ !d;---- @ !dB---- @ !dJ---- @ ! dQ---- @ !d\---- @ !dd---- @ ! dk---- @ !dv---- @ ! d~---- @ ! d---- @ ! d---- @ !d---- @ !d---- @ ! d---- @ ! d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d---- @ !d0---- @ !dF---- @ !!d`---- @ !)d---- @ !.d---'@Tahoma-. 33+2 EvAnti hypertensive Drugs %"""  " )""."System- DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` D>  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions#Thiazide diuretics, such as hydrochlorothiazide [hye droe klor oh THYE a zide], lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellu- lar volume, resulting in a decrease in cardiac output and renal blood flow (Figure 19.6). With long-term treatment, plasma vol- ume approaches a normal value, but peripheral resistance decreases. Spironolactone [spye row no LAK tone], a potassium- sparing diuretic, is often used with thiazides. (A complete discus- sion of diuretics is found on p. 223.) $Z$) g xAE #$   <$(  <r < S  0    r < S X  0   H < 0޽h ? 333380___PPT10.$  0@$(  @r @ S F 0   F r @ S H 0   H @ 0޽h ? 333380___PPT10.p $  @D$(  Dr D S E 0    r D S H 0   H D 0޽h ? 333380___PPT10.Yr G0oZ\^ ? F`( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` D>  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppX Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).    !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<>?@ABCDEFGHIJKLMNOPQRSTUVWXY[\]^_`abcdefghijklmnopqrstuvwxyz{}~|^RRoot EntrydO)˗PicturesZCurrent User )SummaryInformation(ZCPowerPoint Document(=PuDocumentSummaryInformation8d/ 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` xp85   ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N r9? 9F [( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 ՜.+,04     Ļʾ31jdPuH A %ArialTahoma WingdingsBlendsAnti hypertensive Drugs OVERVIEW õƬ 3 õƬ 4ETIOLOGY OF HYPERTENSION +MECHANISMS FOR CONTROLLING BLOOD PRESSURE õƬ 7TREATMENT STRATEGIES õƬ 9 DIURETICS Thiazide diuretics õƬ 12ActionsTherapeutic usesPharmacokineticsAdverse effects_,uweiwei#beta-ADRENOCEPTOR BLOCKING AGENTS Actions õƬ 19Therapeutic uses Therapeutic usesAdverse effectsACE INHIBITORS Actions:Therapeutic uses CALCIUM CHANNEL BLOCKERS Actions Therapeutic uses#CENT jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 886x kA$  @D$(  Dr D S E 0    r D S H 0   H D 0޽h ? 333380___PPT10.Yr7ar ? au( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` HA  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppiAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88$x  Therapeutic usesGin both the supine and standing positions; postural hypotension is rarely observed, except in elderly, volume-depleted patients. These agents counteract the sodium and water retention observed with other agents used in the treatment of hypertension useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. Thiazide diuretics are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionHPHHQ {H$  PH$(  Hr H S 0 0    r H S x 0   H H 0޽h ? 333380___PPT10.+rTu" ? 0uN( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` HA  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppDAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88$x  Therapeutic uses4in both the supine and standing positions; postural hypotension is rarely observed, except in elderly, volume-depleted patients. These agents counteract the sodium and water retention observed with other agents used in the treatment of hypertension useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney function5P56tmH$  PH$(  Hr H S 0 0    r H S x 0   H H 0޽h ? 333380___PPT10.+r3 ? f_( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` HA  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppDAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88$x  Therapeutic uses4in both the supine and standing positions; postural hypotension is rarely observed, except in elderly, volume-depleted patients. These agents counteract the sodium and water retention observed with other agents used in the treatment of hypertension useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney function5P56tmHr ? wD( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` HA  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88$x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ6JH$  PH$(  Hr H S 0 0    r H S x 0   H H 0޽h ? 333380___PPT10.+rx| ? T( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` XM  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppHAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88$x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ$?H PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44H  "beta-ADRENOCEPTOR BLOCKING AGENTS "beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. H4  $  `L$(  Lr L S 4ȵ 0    r L S L 0   H L 0޽h ? 333380___PPT10.K$  pP$(  Pr P S  0    r P S L 0   H P 0޽h ? 333380___PPT10.5`$  T$(  Tr T S M 0   M r T S M 0  M H T 0޽h ? 333380___PPT10.i$  X$(  Xr X S * 0    r X S - 0   H X 0޽h ? 333380___PPT10.r@ 5? a( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` XM  ?b$;枚"pD0 2$$i,cn 2$*[,<3@*?U 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppHAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS  Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. 0P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88$x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ$?H PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44H  "beta-ADRENOCEPTOR BLOCKING AGENTS "beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. H4  r? v ( / 0      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQaSTUVWXYZ[\]^_bcdefghijklmnopqrstuvwxyz{|}~JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (EPEPEPEPh((AgHTn6ݕGv>mB=u$)б;^ea\ϊ";UuSAk9!տLֿ$Q Bft4P= Bf&k_+9Huo5eV3Z_] CЙ/H[kEt4P= Bf"Huo5e@$: ?!տLֿ$WCEs&k_(V3Z_] CЙ/H[kh{[ks_ k+mXIu XDVZ(J/ SWQcѳ⽒O:)qQ_4ѼObkGYċ ^_,1~N}cY`*`s\wŋɧ ck,>f ְk_:ow wjvaެH!&>_lS6{{Mm o 6XN-Q{>nχ xž˽`Rm`OEc7xum2dw3\:ohOM+7^ tnymw])-8Ѐ{Oh㹬坜5܄U˰l,c8/?u~K S=ݤfhn.'$˃Fsd(()- jEK%KBھ((((((((((JZ((((((((()h((((EQEQEJ腮\yq/P~_O?+)5gtiQiںmNS;}0Ƭxoö4 A#o~>|?|6Z,ֿ/5'[ŷk_cBcHFζ4K*m2/2xLGF99_$ƿK%Z'sO͵R~eI"KW]B'M|~1b*o| Gy^[i^Q ];7@9|84ku׍xTbIvb->PR4-c3sry_&Ծ"ۚ.DO9+a~xB=n-f m*cya `aQ#<&m=>hk{-&]3sp} ''X}m/OlAas}y Y'C<|  W 9q*[_B42,8`r 㨠1ԿS!U/4o'EHF0GW|=u%֗j,s J0vۚ/ h>+H56+F܄G_) =3/K`ԕ(*qvl〚}OmkOg%²D_`}ϝI'nq^ӧ!FYʄYfr0?8s[4? isiEO#I$-#9I(@-R_Qjםs4e*QUoox^,\;4X$ qtY IF,Dw3"}\=E|?ǧ6QZZ82pIǁrOzEPEPȟ h_[WuO*ZuQEQEQEQE!(h((( (QEQEQEQEQEQEQEQER(I@((((QEQEQEp>,_!kşW>KD-wVO|KSM]C[ \>\@A=ڹ_4ŧ:ЬZƧf2+ʼFǾ OҮ{6;>FRT#7L|y{>ꨚl`SwuAFF$W2aNXGt+â.=ť,vH}[Mmx^tCPdYt'(U6;Km_MP,E2@9'<çjuaPI򯝼 k49 F[:erXeQaGzh>tӫx*Z%eVC}cc{u4W=+gK˻D ś{יupz߄:,ls 'qP4W|Qдx/6v'9Smlq?#xof2yrs`N8 { ־<ȒfvFuQEO*zu|J]_E}{@Q@Q@Q@Q@1E.)(((((1KEQEQEQEQEQEQFi3@ EQ@RPQE:((((EQEQEJ腮\yq/PGGK6KXB)Q€>{㭭 oehh^8HedJ=}/?Ai7$ ]rC` sŽ_7ž4 gRA2/-$7I2MW%ce mFNHl#J2c+w.I89BqO +DŽ|C5t*2rr]G͹1ހ9X"E20 >X?wIQh^,<42:H eAyav瑾, +6؞Xu$ K}Cwh[ϨXG*>pc?Q^C#͌P3ƥ*S MW^1PKd`c/< Sj؋[i"C1b eaU⏆l Śm䍦G˘bU9/? b(P28АJ(?{, y'#>kr32=:V#^֞;ı\׈{fWXwaۏWį~J@wf'o־ /_(pg#0ٓn+<{aK%vͤa`̤rd7dxqG CE~/HXyQfh^0 8<_xZܼ֓y!#$`aӾ-GB1iI_eaBϯ>"u_xjѥ[/mq27n10+W7JFkm& K t@s g$+ 4Vm7R7٢?S+x ''\OovEnZy(;T.O-Sڀ (>Mi|hӡ(ĻWVn@=*S^򒾪4RQ@ EPEPEb(3I(4f 1KI\Rb3Fhњ(&h.(.hJ1KE%fQKF(QE((QEQEQEQE( ( (8nR`Y`f]y)w6@(2>;^@Q@Q@t6FUE1w&?,WOik mϔG#zQX^ ׏Lb2]@Q 'OJݠ(*[Eul;TdߊE|ݫњ KrA4@yOJch+fkA9 ,)?u|A$}uE|  'o(뚊 ;YnneH` #TrI=|  'oV^&[]S[U_=wwN>5_uOEq}+@?8}+OZkojSLLkSS=NHo`3g(-PEPFk&>ϨkeϗqwmP*|stOEPCJ9 :' "Շ=VfLtٕwvI#9mT7N6B0p mTjoOF\jۗ0?oN-mUzw OW7I {hU?"ʏ[I/G[KKI?&=qGM*6/E/c_ KRh < i6QGʓB"q[hUai--%(((QEQEQEQE6(((K⅑gĠ8TD+wB7Rns3\mTQՆA`+A3'd$GY[:]#x諸(4bSspJ!e#5^FximB}FYa_ëp23X2ڲ `t?G+ i<;-zd'p.=I <){4ͧ\r0B8g__rkkDeemUч* m~WWFDS1m&b)9_UnNGJ袊*+xo-eI cFR0GR@=jr/.'oD2O\ f>z|ONh [:epF{3]s:t۹56im]{` 9j}Fz##4okPơ8 pIC<.XҢխwVDۓ38_E6i3:^<8ez@^D??GOTP~D??GI|(J)h(|o}sx[sE `ޮc/ׄ eIyس'Ii#> ig=D.Bq}Ԍu=qje{s^Eyg;q D8*G נKekHdMBkۻ$YXHPڼ^l(}24;B* VJi>&B!:r}+ݧ1]KCԬl;Rnt2ys@>zTqJIJF2B ;u.G;pr+m!o /H ;0H^PoSRRYsdg`veOj8 2n_AQn4.hLҏfbO8r 0H6yJJ vA ܞi& 8D)B*iP`/_M\nLWxv\ NvWj66y,>܌2#޼ E c.:ȋ襠 JZ(EQE:((((EQEQEWxh&sz?.:@r2y>53aFnЖY4mʴ1u pbO824QEQE|S(~$jie"\H#E5@P=|%׾,mMne^ llT7vsY“[Ά9#qe#_|5>%È`c=ž>猡ݤ߫N>$=G/' wW?'|.ci '훙pYpO0k!At6קg~V(]V)h_:.ɩi4IcȸeЊ֢8Ѽ]tmu\62q[S _Yݥ/4! LۗHY(GW9g utD6EWFYXdz(!+# RXdP"0e`zGQOfhf=ދwߧI6'X=>*\EV^!7&-^y1(cN1ހ:+J񞉫\5{=@&$gw=Eo&`I;cRfiZzmY&^} AE;R]q *J&b~uy#P,dTh[6%vN8du<@s?%MtEo?A4q~摠,} WW?4ۧ֠ ??]Vyi?|@D@xE,3]#Y"=Xeicl]2&\/ 8 Y O|ק5x֞7Vm5\AmA2IUW:|1VǍdF' [P_ 隅֗29D6#cD[~R8υ3mu GEN[[Q]!~PJ@Ċ|C ˝+R&iEަ4N02IpA{si[xV]gR/"?uH ?/Lp[9@·<|MxTMLN< }. A?i5;/Xf)"ex- :{Uofcͥ6P$d 09<`v|)/!5t͙c0Kğ u/SP.m lr95.ei> G}FWiV5id 69ݓ>6}huf^AM!\8)yMKᮛ+_c$7B_in8|ukP4I!$k6~<-dej0|`RR}[bǜvz[KG"+2=A&x~[ wi\${Hq[jON+V~,mt>+{[(3HbD WaO[s2Nr3}oˆ,<YgBU6*P۸瑜Ԟ-'E @BkW ) nx9󜀽nMݦ47 g~ {fBkvaxzEaspato|QQxm;Sby`$ronӐ$6$)-J/%w;GoN._ZkO @-0鸕+V_j>n̉tRܯ8Rm^x8@2~y\V?U_`=ފiwb6߱B8:fPS{ӇJoz@4Ɇaソw8j_eZ_@S4`r|>ssGҀ:zJZJ-%- )qE-Q@Q@Q@Q@ ((('Οq{Q@ZyKPsv ݬwSL x7a-+QW,+|7p qjp .gH*o4KtYz7~R8m <(rׯ 908E}}_%hN#k$n9daWִQEQE WxσF˺|#`6^(돇7o$*˸ O&T18-|zk񏅥}f4N2#F>zvwV#l-nB^r:'#M]m&=#Cp>{kKYI"p؎ y[%p~&g+1\_]vs}E|7od֬AlGLA'$koIǓk&Qy!q+~E2]X1.m#ܔ1Uxڷ,|C$*$8~BC=(CTѴn캥 T0[n\8'5k_@Eٯ(xAQM)ERPw=b^Y@/4n 'R&Nx(GNO87 *E-tP)藺~%joĝƣd(6tMnjXJn)$n6 FX֍r#d]VW1&f"E` 'n":>"7xKoXxƜ[ɔa7yOUNK𦗤kZzf˧ #c"HH:|r0q2G >^= Vo<:ҾL>I:ՊgXR_Idb^1T(I۟  6HH]1F3E|]J޿&SjZ+ઌ5# CҮvjiǍ8fG_JgzE Tt#^Pbր9gǞutGSX/"h7$9=*3ZVa\\cA$0fR<F}kl-u. xZ"\y7Ƴ,:I%q g ޭ@7mO^xdƍ$|g {y>/ϭKii{id$bn%I}8iP6TGC^PwSmwh7RaC VSB<ʏwzϷAYz͵Ew#ZŵF!#0ka|X mTM!`@\cko$&Th~u-沖x {O&NQueECܢe@K_tm{1Cku[x涎ta)$d`LeGJC}k?<"6i/.m\:4c+ׁ@<lK6yRH8~nÚѵ3z7iuln< x>Se} |3zfppZ2~=+9K@&mgLῴ~h ?<>x$1ڼҽ҄u\}39(M((((((QEQEQEQEyet/oYǩ?rl,xU'ľ 3yqS1 )Щ,HуsJ"+N{M|>$2λK XyspςN}H >{hi&' ;rOּ 5t%]T+Ϩ\o!*̅cw7cėed.5(,@CE kv'o#z׋>hH{oEvHH=_L> 1Nz҅f1@lpGʫ k{ MkmʱxϏCx0GI<+:!G(:&gZE4{*JGK4 ڥFFŔp1/pG|?  !1" y]~X`n..tQT{³+x#Ń~uq[Ui!p:yR">Soz Zqo`S?!EŠ:5(s^/4(.@ăpqN0Nsx.?"l;q@қ\ٲL&s?*Y5]:DIȹ+=Fp?!^84nݖ[>^3Ji#3.x,rsЌFGLPi:.cXAmj䗍a{qY ݟ>͢D/#hTL+9+gӥyZs4l@Nz|UgWJsn1n~;`,>x[MԖBK!GB$=@jZkHg-"P,;8!^U.+sԴ`}:Objh-ZP D;;8dҮt.l"OUU;Q>>[ZI ssqi[Mts3r$ϩ5kO,tkTL9s^E-i>E6wϦ퇛46㈭a<;V1hCk;݇R;Ȯܰ- Tc{Yȧv׉VD_:,!sҗ jgI.!ZmcDW>|vH³=9(ߕ{7^~x{C&,&gp%(;L c:x~U!''P%: ZJ\E-f4( ( ( (EPEPEPEP3 I}oa֭$HΠR\ ~nkTi:&0N20zWԶu_ 4{ϙ# d'3@Q@=~|Q%,lqV=w?rg3yY=s^Cx3O] !Uԍ >+|-K ,.P}ҧA@EPEPEPEPEPEPEPTM#N֭VSd]Xt$Wh ZMs+`A0Nr1\׃ xc+:0QwHQEPQKINIFh))(jyؿ_ʟ4L~.(#/vh*E 4b\| \覭C.SP͟/osaxo~"J:F RPGFhأ4i0(4JLIE%-QEQE( ( ( (EPEPEPEP^{I4WFC> Pd<gvS^\?{9_F[M_ig –=t(w ȲF8 |0ס@K$|sMpA|̈ncf:oR3/dXH扣teX9>K|D%EY$F6Ȏ=@qZ(((((((((((4RъLQZZLQZ((J -!!Oȉ\覭!ejuu/\-dh={ נV/tDM! ͻ*63*q ֟_&JIs&Dz+ʾ?iq|? -8 ,B3JgԅU::t։im\Ɗ &ErN^; iG/5{G89AǢ]xG9[\wu?#w((((((((((Z((⒀ 3ERREQ@9o-vWWzCE 1KK@ IN%.h1EQEQEQEQEQE:((((EQEQEQEQEW+< ,BdMZRpR`F3H^\ ~=晴{[i"nc=:+)''h(_>3om5e 7="20rx}1_7p>&i^"_/͎)Qy y}Gp;WѐLH@QEQEQEQEQEQEQEQEQEQERPI]PsN}ƌ}%7qϽ-f\ot -%Y}"FZkgkOHG(߁2;*^૿,pc2\oL>n5mkw"dp_<|Wc}ېtGN:\䁟v{WɠRQ(mQMɤhܚM)3Z((((uQ@Q@Q@Q@ (((((c&]RܺݤhxβCWk1+<+kPuw~с{VyY3/&40|p@ ù54俴 c Muq|"Xg7$3i (cT մǛsjIS8p⼋sՑS\ХvY8Gsw((((((ZJ\QE%U{m6Qm,NQxO\Ɵ$z%ѺMǗwWI4@<bAqgJԥ^ E{4JQU῏ֵi .Bܽ瘡>! dl$1Jz<:P>qrhUM9@u*Qqt>4y'y3\R4qҀ*Z%;{k>V_.0dXdjЖ~Tg=i3@>Gxϰ4@&c12uh*q)Ϲ?AI@;qi–A5p}E8O:ʸ.ԡ4j)|c֦WWxSNu_9,LRfIA @ @5fY0+7p$+`  tR Z(ZJuQ@Q@Q@Q@ ((((((Cÿ8_H. k"JD6'w7U='QWѬ(( gZ@Q@Q@Q@Q@Q@-%-QEWIl?|u':φ^!tދfҁ>déє€>5v#m!ִ/;ߐ0ɘv{J?qK?@ǏHqɌ)ǫc'oO>9#4ޟ+ͧZ,m3#JA<{՜ C&$**h٢4fFi)kڗ| ui7?gXdدX:{W|)-PN">ߍg-bOIԮbͩi[؉pp2@[zYVKW'(@?w!뎽^x.|z[ƥqA{&.L刧ٶ!P[s]֯-F5[ɴk)q#yACOp{6zo<}[mD5Gy}xkό BY8y4 pZ5|(Re]n`RYZ7V Ih8&sx.M,V2IKs vaӭzߊ+ 5Vt+x\d9מxx0xSXI,o|б.YLR7x'yfow6iwrܩB<>0#!ƞ.SBm0oNN1X@zvi晚3@&i3E! 7|)yX'm<;TvQ_=~k|"/m7))h (IE( ( ( (EPEPEPEPEPEPH x >`h%h{o0.FO s^^{5_|WLa-uHGc'|9I,`q@^{EYi|Шil]or䑌#1;סUmB-OM>M/ v =>I|5Y-w1$sz+ҫ_woψ:߅$F,, t}@Q@Q@Q@QҀ QRnScJ z@ E%f(c/ׄ N/}!8ȭxAx^kZ=NUS4c?~2Æ|o|;G3xatGmFpAQ7r8< s*)݆9?x5K?#knYͧ<[Kyȏ6q||fk}Y/Ei[z/ hͥ[Oohm)` (6i:[j0ďVUd~f|J^j(hws*E-ْld;Fz/NVIo1-WLu%97oB`IrGNE`$k1w>1@N.6AHdB_LGo/ YK r*̮_åpO]W-f$˒@qξ9.GG4KH, 7˜}(73~/jw&"[s8rq_ k%j\X=A њni€E5NN)O4:?dg Od:WPeO{aP]ʑ+f):c=Ks_G+PAd޼$𝆯{ sc==yoX:í˴C#;fhBĞ@UQ@Q@Q@Q@z0AE ( ( ( >#8xKzmίkNP7rTf>#i 7 ˓fJyْxV9}xե͍^[o:I-~'C{! x:Ii^IG%=I>cM/tYn8H\rxf"^=6Ҭd*^6+А~Ugu>(SbzSZ.hm[YͬnG`[7mEhVdQuM䑐 u.a^Tc3x|C|7g]NK/-EQ84]J?EoƟztM緗<xֽ&x[~ ׼</nV68*wHFݠ|Sc\x_^_E>u\!q21_Khw [^8n|![1aN?kuGt_"?ҿN4_33r:x:W/_JSgOgJ(tGt_"hg_gJ(uGt_"K>kvGt_"Y~:Ox-\|.0zuϵ} i<#MC)mo`kDy$RJ`rr^xAajxᱻgxn:'Cqmo?/{h@ ?fK m9g#}mnG3t7m_ٽgi8; ^Gm{1@ gG3s8'mo|&uƹ x6o:;^)hJ( ( (EPEPEPEPh((((Z( JZ(+|O״dT|p}ӿ W\'?|f\ {g&Lt|IPy^C'˒'##+LIn+.A$ƲF)cv5Z͠$H>  W>hgZ~!֝Sp,+c_~^==m̚|?w˓$u$װEPE.(PQEQEQEQERI@ E%R@ RPFhfhfbJ)h_WC^?Q}W?n: nKmfQ@&J(sFi1F(sKM(((uQ@Q@Q@Q@ (((((h(+ym@ʅFR0GRQ@]7g: +nu*8=o=3Ʃ(jgt.v?,dp}FG">w~?xu+mtdw"KwOLW++ǚQ`\09q;OzόK(4XSoxUHdK+iQp$M@+oK)z- JlfGDRIwFWPA uQ@Q@%-%QEQEQE- %Q@ E%Rfb1EPF(b4O+ [(> ^zDu=-b(1IZ(1E-QEQEQEQEQE:((((EQEQEQIK@RPihi( (p2fk jDHŔ$Q sS4McKoYnc1ȍ}L֤ι0 09s@=OBylU\Wenj|A#oಎ\|8=ARr9;ku..ZRs pP<-lgkfY_ ߆4 iQM!̘vAk@2xniDӤ[<$R5h?G93BM3fP7V A?|wt[]ЛϒIY_GZPRQ@ E%QEQE3FhQ@ %%-%QE-PEf (%-P_xn|u5|WJ?G_CPIE-PFh3EQEQEQEQEQEQE:((((EQE-%Q@)h'D`m{Cci^˵'r}So|͛oc8|~5U|R|Tyg* lt{;֘NK1@ KK1@ LPQK\PRi(h4Q@ EPIKE6bv(6\QJ)qKmWY퍢1 CdF &< Ÿ }zs߀G||hZ7mKĶR]&%`SW#\< 5O.uk+fmnn|Nm@$cע1@ bPhbRPQK1@.(ZJ(((uQ@Q@Q@Q@ (J(4Rz>\YlO#<8$~JByt P | -7 3_涴c&dヴgҀ=@5gg 2[NH/ d4]՘%4/w=hG4s2>HeeL@;e/%47Vi{||@ iYW- )5Qi!qԒ'GuSF~@Y~ui{hSuP}Ve?4Q\Pi|GhOu7κUθ"2}+7ͺ=&un__4V`c(į S!B+S4[$Hwv dO@II^ ~̗%H@bD9y's h_;@MQW̫Exz4ReW/T::j4fچgY n^K &I 5'V5/whSp5&R=L@9ugy?1鶓̺"7 n?n;T[Xb XeRG"WR0ATۓeAZrp?O ʼnΡ4I!;&J;)9l-Bݦfhg=LGs=SEO<˓dAZ%Hv̸=*3Th&Tw4>d_ʀ$"cm^ȥ)}oϱ~հHa7$z }*4QEQEQE( ( ( (KIE-%PcHٕ\ep?:b>c|z704MI$P} zZJO㿇/ͱҴ>WS[; n9#m}iq' I'\r?`{]rkG8,2i$W62:ʠy8$ >tWS4Z+H졹Q S9R8/qc{1FOJ#Un-o!Դy4_ܘ[w8 s觭zb(u^gYTҴPԵIŽ #u_z_mhRCռ3,S2 91ހ=S7ȹw̒Hg/Lyύǹ?º&)E05IzI?Tpewc(O~Rϩ=֗[,1guڎ7NHG >=cM6Ivv7Ns^=9~d k ^)<}@X./]ujجȗ:E|G;yY#GHT4H@Hdr)?J&#ՂNp 8?k_Z|;jBDG{ @8;.E-mos _3~bƝn0}Q[z@7Rc\w}9aHԮI[hdGր;\cBٯ^iVk؍qfR@ݎwڏ;XZ^v7As]PD8ns|?WZ\2tJ$pm;a _ jsF2tpqW|I u4f]ZibN]PXIo"x>xsZMgKFd˵BR\Pm`z;xÞWaEޱ}HPp>p}*ޗ2 Q#d(_6:V ״ˉb7frk`@4A8ޣm JA&h>=]Iic6I"::+9Ǩ8:qfs/Go5Ū<z^@>8f6Lsn׏lo$Z((((QEQEQEQE64hsKL QA8?gSRثgn~ j F@F=*Z~)~_f"dʺmAMUjs_%7WnƸo|,ѿrhׇ~gEzUV6w~ic=qy7}7sO{L88Ϧr35xkⷈ*5z~AMc%[dp >/h!(剾Hh-xUMB[\˪*M`b>gSԊܾ^CLbҥf|gi!˥Cb&`ت ϺZ|?qr-E5-@.?^k|K{ 7ҮZ[ϴDݸgl'98z45Kb.\1N?Z5-MS%XI[ y%iZiJs(%휟`k/TSO45״=H}czِ* і\b tXFJ&iĬF@M=ar(GYjWn|/Ǜem뽘T&E]#$:,Y[_6xk}_|sXYrZA$d,9'58UV,F 8$z)>JA3f(ANusI|iZpyFd|oq߃CxoZ/U?in¦W'czys?"ֵ_PV7OQZ?[Vk%k-@½u9`iNp {'?bPsDq‘k}¾>XV?-|l@lpH@bx&E|qn95x@*u9F@ ;mhh`Wni$𧉄-<6tn[n ^NjXzt~kլ #;;@7>ڢנ)ok2`rsbzO^&W(1۳NMA/Q[ ΙĆH=^{Ŀ<5,ܪl2C!Bux%7 2z/#/$ZY"xD=0%M}_!cF`1q'Y:/>eIX>d3JI B`I'5wI5٭C)O1,@=+߄z &EÀpvNJ}kKŪZY{5٘yl<8FJˍ'}}?<1?!rFy'ڀjʬ 2wVRTC_Y/IԈ#|;{<- te)E k_7_&[;qt j>RO5,i >:,aHgp=$}  _+^ǦxcB"*V;P$ʌ0=z'Ɵqe8qyPQ@ W!N6*G@T*m-nT(˙B v߅3L{Gw;y5ٖPגE񟊴o6]"ibBHҺFpEzEyw?Y[dPWd b,oknu{7(򠄱3lx_ xY,xd{3]^)8]MZKi#[^ <`Aރ;NP_Iѓh(Xǘp399~=׵ϴ_4P|6kR-QI#Nk64w1hquO$N3p]T2pIS dͧ:_yA|T2I[* :KVIH傰a;H0x xTi7~#}hdilsX99~8ZkW\oDc83kH(.uKM2YbPcd@`x8~k ;8C^]t`b!C ;d ).KQ6Lw7l8< -Z/-6'g#uZƈ GB)@0d<ao7-|9Y9${Kx@.;PWfvݵ@h:p{|UC^e\߼Uϧ=y¯گ.,gٱ~sGXwwTk'ZEU(T)ہ@6>ƉiW*RNk}32#l0@p[[0t(C>;d FrNѸߕƫkևK”, qpQAh9 I~-WPve!$JܟN ĺn59|k3VϏֻ+Z߇E[s$723 8\Ђ $PU`:I=[]\x:+{w Ygt=jÚZOneVO:2Σ=jY?LcboPqU~O=΍t.es@Q#I# &6֩lp*+ "#o@hׂAkm-ճd-$RA#מ0k韆&n'4S2nZ;`[s 9?־c%ktJGⷾx)H.R|v>մ+U X[q `d.N ޾X/xJ%퍝䲵{fW O,}8>$Ky0K_ip%N#hc1laV> T5(.)R ~废5v{)}[NkADP n=:ڃ:֥Ց4O%ZA 9$|Ua~9ٜ|=]|]:xBP$nxtFeg?'\ss]\?db 91Fy ? |L7wy6,%:o]o=]̀:A'[_4O']8\8Bns1~xgZ|'mr-:h.Vw둟gP׾Z5`sGT`NCdPƱ_tTF҅1]w~5xg&о#K\m6{k]2$1<{DS3p<\{(q@MO#49cր[oho/-# гἧ+j2ǁ& gbIր;P(hPQKI@((((fJRi3HhQ@1Qnt,sRǽ|}#Z{m,Œ@2O^kKJլ崻dI;MymY`@ր>wkW.@ )bQy,p9|uRپ1@<]F0;_J ]C}q;[^\ӏ ןz*h(m{N^s  ן8~y~~|Ci/o!Ϧ^ o^߱4:A^&?z.!I~u5g{|K?ƀ=xJSBSw \࿲k<8z_i8ؿH|[>+δז6'WC͉\8ϭX?ՠ?z-O} Q#_Ю~6zz6}?ƀ;F|Y{kyzOg߿v_?xF\hn8~#q|01g:({?Z dig˒HՋ p dW3/Otqȿ?@xnMN61Gⶇ?!r&|41u?)?9;jM'7ף&QI Ƃ9ЎNoPH?7{tZ4ý~‡lץ D<}PAP|w9~…oG(]?=CAW6G~h?N_@<8: R먠(~ˆ?O@<6zj)R3+GnzOP'I|_#E7bGԐݬQ I|ԟ^<ⷍlQG?J1+~#-=$R~aKÖ ,Ϊsֽ&+T  (|(NG4IޖQ@Q@ EPEPEPEPhJZQF9.h#ӭ&03ޗ4O uj޵!P޴=hցҼ_ҴR'je0kn#M*j59:xrH۠+T7s^EwŨoBQPǖzmo #N}i'.Aq@ !14c4moQiހ@4moMƐ44^1H:ҜH:?ާMlSKi;&v!-G@ .ܵ5;Ը>RO>&& SIF'5CfHrZ^AV$ۙ X] xkzr+ ~,-Bm6Mڅu' |&:8aʜc[#ԽE&@?ޤf FZ9֓ZN}hvuZ^ԙN!(EQA((((QE%-PiPM%Q4҃Ab4b PKRQ@\Ӏɤx_R__wǦ;U?K=,>R{PPs6MX֟Օ7ƃ◃'3֑-'"|H~/6 ?<:SO?!?ұ[ ?K /?y(kCOccy /#|>_k _Z v(|`[—K[€5?jx3f?th?߬S].Zi?s~+8Y}Yۖ ,}c <Z]| 5wPٌ=1-DnC)Ր1_=^ 2tr۟`W^2D $D3[FM̽X#s\w/VEGGy_xC .GhӮ>(x:݊fu-^VmImt݌ҭšIZ'W?:O[oS9Z w)Z$W۟0|MS)Z\tA} e/R>)Z]R=581 C1.rQxLtO|!Vqꐟ<$)? C2AP?pL!aDqxS[ܷ X=p]KTpVCWAxOET}OXtbO:}_/o3gtp>~_׳ApQF:P):Қh-&h&h4x4f(%IEQE((HhQEQEQEQE ERb Z1EI(hQER@ AGjJM&+MIM"6~)q@ ~4QJ(6ҟkPF(7]@L3p]|)`"3.N1W$ v]x@9\?]߉u0^)Or{Q,h*1\<l|W~(H8h4lb&I1@ zQvIzbP&6AZ\MZ\P(M71@ 1Eii(-P@ ( ZJZ() -%:((((ZJZ))i(((RREPEQK@ EqA3v)m)!44"Rnb€ (ȥ> Bir(yx!Wv=pkЙx VM76sXJΌzckĀ%Uڇ z `^KdSq/L㨯|5HR0rc4 41HHp-.)7 M€&@ @+ yIiR @ KM))i((h()i)h(((((EQ@Q@Q@Q@Q@Q@b)hө()T撕x5k7s}GQ\gc lH D}@5w Gė䌜@N)A 3o}d JTw'pG8/- 0}' )=}r&Bg.? ?دzw?ր>?(?Q GY|WJO(‡_׭_دqltӁ?}j"G_|=Nk++g0>ԍ@~us}͖^ ŠybFsO<sxS#?G|O>OOSOo '+=OIڀ>_k_%zΌS_<,|}P>4xXuWh=Jw{΀>|)?u[zW$'}^>4x`Q} r|gyʣ.+ߥ0?}i>$Lp,"JWŷ#S0^S1H3q▊((J( ( ( ( ((((((QEQEQEQEQEQEQEQEQE-! JPh 55 zYn9&0WYho_7~8\Pe 6y\9zPw?@k+ωZmڐ S6yƸ5q]Յòu  2zV5]?DG^X?gm+ܹ9ΰG|+|Hk-b ;mwC,bKĵ32W6Ӏ21׎GM]4]."DQ)!2Z⌚_ƞ-«3~WY}&JݭuώEgwG9kb!Y#nydesp K־u -Jzmֵi($ǵT@KYxmic6坎 3c0(cȦ⿄E_ xNpT@l #+YdY~B ^(.NBF q2}HikWz %n4"7?dt s8 xy^xL^'axF5-X({#Ž0I "fa 0O$:Us U,8*z; 2=_r^,buΊRp eHȻ~Z6,ppM*iA917bh%tikuv'p|;6Kˣi廓+mjldrsڀ>}᛭GA涒GdrdKc>?ms[ö| '!#+""`0 ΄нh(r(QIN_Ez=7yF#_%|;>"ik\ ;ޖZC@RQ@Q@Q@Q@Q@Q@ E%.hh(((m&hJ(h((((((Z(RR.k-xY8ү?&!Ǭm!4߃:g2;EIM06@?6=q\Y࿇^,5yHe^8orz-s~#趰ht.FO`Ns9P:䚇 جbKqC. c$e*ܐs9-c-/iiyuHa6rsx|s R-,,෶HgߴBTfS%xߞh7ֶu7$̍ Ҷ8/(>'Q5&)m d>C8#\ֵ._i_—7~S6qy+Z4;x[1ݼ,ּC{suyX+(dN~`6A;GLYj MF-7LY*1 H>+V wb2t &U*A#1]֝aerhq<$/2|(|;Ga{lC"GO8E: i>.?Z+4V qtdW4PN/5[˨iEk a$P6Wj-Z2@ٜ|K@>نJDA:)g=9ғg ZuΥi [I2tQsOJC@ )K@ J%оL}_#8?PKozZ3EPEPEPEPEPEPEPEPEP(((eb\Q@((((((hiE!PmH]b t=akOq4BUaFS"qo MX%\uH3yls+}u_+&4M?Bu%34n7m=pߊ}_Z/״-R@}s^΀tm6/ /o?MTnuS֘MzDt7 ;)ջ}j[mkž90O(zzJ; ڥMJJm^E2FKkym#8xBЃȯ|_wt÷0YM;t9˺@A}*Ӽ]aZ6ʉ1p>'$g5z֍mŤj7vQN4k#FY&Ypqn3 γ7/-ߙg!%I9'#-@ :s]Uߛ(=v'X% Yp3k)i]B<_FjV1K,Bn#;(ĵ kY&oY,>)*-xQxz\l/8%q+|ew x\VX(浔cXI yn@`Kc )~4E|'y5Fi. a߆P<xDŽiivj7W<>Px^!\5-Hb+H~f IKondf\'#seAZ|M])Ⱬj6k9C,r)g=(x;-`Hdod`ֹxC^{W_, yH`tw'(5–Ki20@'8x?_,>dUb@}l#q5 xwm[,n H>TwASr$-ƏK*w0"%Ued,=As|5;O"^b?#zIjzVw׃6$!qz~1d|fpV؂GZ#0?| s?a|[juZt-5k<;H;FN;U )໱DV3d̂4#}1W|`[%ms,)܁(i|wJ֝<'j&T6!T?h23|okKmnŭLr2TGqbvp j hIIGbXrvZҀ;QtW\]3kE/zSE)C@ E%-QEQAJZ((((uQ@Q@Q@Q@ (((((((((h4RPJ)*?=F##iHN=M|Ia=L4BWHA!1׵k?35yot'+d Pg >ɠ xO4K64K]b !QW ~$Jdb :/PrAL^hFzRb=ǃ|[/|/q=%>!X@8GZMGaFoaqGNl1@gMuk#$UdtA'+īYGhv с 6p03 5I@ƽ#SXxcT#*XV$H}qX>1|" 1 f*.BMRAgqF(Ο!;O+xZvxږ#q "}#ʜ A7F^)D8d!Z >⋈goM԰Dc&s <{6ciXHٗjWKx L;]='mt 'CEhW\~AcPrk~44(& Aipۆ@Qskq-{4?tmkEMM8q$ci=OJ7ŧʳiW)so̙ xך(1GĖ7|@H#$Ӟ|YGS7b;hƔKH K31j>5xwQUtsx1o4Z8T 8#sHCI{X]G8pJ+x4`PU61|ŜA Ɓ&Upz+~0:/5_&&},w?mz~%G.OE Frqp O?=(ezPyq,, }x>译~F?cziOQ@ KEQERZC@Q@ EPEPEPEP(((mQ@Q@Q@Q@Q@PEQE%&iM6KMCBӨe^)#<5Zĺ@ImbYW @Y3P??URs@!^+>̃ԧh(ǶhOT+x?CCǬgG*t1C>D?g龏T>+h(!~ |a}o})q8?xtXC_c?(S,?JScŃoI_[`zff>JXGAI cŀȀ_ZtQW)t=/)_ _ZtFX-[i@)E&OE|> xxۏiO_>/n2iG=| Cylm}ejL / n<3|u=XFn@Z ^ QNZ@:Q@ Hh4QEQE%-%PKIK@Q@Q@Q@Q@((((QEQEQEQEQE% ZJ(ii()i(4Z7z\SI:iPQZ((%%PsF)hSJ1KFh1F)PbRњLRbLS%44PdOMJ1KE%RJ)i)hQ@ )h(ZZ( ( ( (EPEPEPEPV}H6iWCyW7q= ׄ?jaU>+uuG_g w5 k 3t τjaI τi?aXBL]BL]mstOERs?EV')м7G)м7@GTu?EV')м7G)м7@xCTu?EV)/' k 3t ׄ?jaG'^C_Ub› 3tBL]ms?EQ ׄjaXBL]BL]oxH(xm?Q C3i 4?E'?T]@hx#m?RG C]4 t?/YQ ??2ʻ7V?_G [D|_MRtG,ͧʽ7U_G WC|_MZ;jXx'QѡG>*8-^>%|QɤSCN'Ϝd8__Z+yqG`Bo崾fpJ+[xKD\7X״۬meg.SVNA].lRM@l##TsdsW|Q KuH[2u#N{Po?A+7/k v@}ЩmF/_N;졔F s6ϵbI 旕;shV'%oϡd}"$o>I7>v8]֥C6py\gj2T{Wzw)k{^ T \Ο O{RO ikqq6$-69l8>mKQW)$%eN Z>xj[{P)>֬k>j_ umipEr6; 𖥡hdm$B"Hr!.K6_Ҁ3gR3As2vEs~Vڹ /R{`n:W"aKۼHWLgoiF=\b4r7 : tҀb-L+>IjrC/x/-#l4/^Bg'ER?ÿ x;_N\&F#4WO(xYGb$Pq櫲 b5x[~kN-,,Tsu=to?A0]^9SۢM*r NC#^4O:݈-2:m$`+FNhRD|wK_z@Э.|59FO3 3 %԰eg,y 1=qסh,Y3^/omc 呤fGQncU%Gv^(񿇼Ij1`sA=;g84l5 39$KmR$O%;PhK+x"K(ԯP>aV<s4K40K'G6qy8q@xA.45MF;wԟe*̲μ5TfZݙ|VcisF3@x^֤M"HKævHNh0]PI3"`RD*y=z{ho,xFPkkSm8O91OOj7~=:[dO52ܘآv1V/{^cT9/ (Uꄀr hj:?=*{R㝡hw A18aѳWmC—ZZx'pM4dm9snqlV-h4UWA'j쨮OWVJke1FQWto~ .m*mCyb`B#i'OJߥpS|^M,ɪ}>UHx,ru87NڣbI\z:+go{bfpNWxǺ44o4F feHJ$dpyݲ񷇯+'a* |JA <1AEtWA݄V̀)\Yl0$qֽ ( ( ( JZJ(Z( ( ( ( ( (EPEPEPEPh(((+~$jZ /Otki|=^BU^2xw}YvFyr7 53i |Iۋ{U F[#8 (д7Zm+pVN 1M:~ -bY.l#Q(('8xo>'ľ"F~m!Xdq@FA#R|;%JXO,CL`sj!M6*]\Yq@tns^>B!] V׈~ëjl7:py[  c<>>8z,̒L{zc#ր9OczWmOHV징cٰ;HIAv𶡡M?pYadbFz׀uG(߈yw Cwth1¨ }WPKsmnۈ"2r(',O-GsҖn ;9)'=ՕoMekmRݡwQH=IncY`9#qF# ךi? W[7Þ96SH76 3`<3@ƂBhD%V+7Vס#EOZE HbMKIxbY% gny% ;9 /=;Dkp֑2suO1KSy#Gh,o5W#\N x [0x cMzg|0|c ] SpPJo t|;5+^$ZOdXBps9kڀr'*Bbeh$A(j8$} /\,I>X#c]nj20ֈmh #ҩ{xĂ*0K Ǔ.eh5|=j4WWEn{MIm#'?3VLX6P7o/O'V4φn"&tFn6Pp9jͷ·.uVҼQm^M$m`%8`rŰ;؀1S-7FN2=G } VO|]}\Qo8Pӵp*鬭KgejhmCQ)09;꼟MKz;[k+D12R7p2xͮG;Sѵ klQ 01I'[^oYe1sp6,1|^sק\oK|7KkԴԜ Cg#;>b eIf[FAc fb=k+bgwWWWz%tkk+@0@8Z6Ȯ  1n;W5?|1-@_Lgei&. Z0S#HX92x>j |$ڃXh.Nឫ1@|_U8jW}~^Z[HC`3F zpq]]o|kssqEFOz9^$\^"9xНfbP=][VZ.0LtPև!+Mu\c*ŧ/YT{4Ӥi px$s4QD LG3?i{q%"kI769GB*UzxW7 1,dS9o~?9{*n]ۼy~N:P!j3׆ΟA{>lm, (b@Uj%j$Ve 7ry u{-4mWzKo䢼23+zHƃ{Wi hrD<#'9ꨢ((((((((((uQ@Q@Q@Q@ (((((((((((hJ( ( J((((((((((((((((((((((QEQEQEQE٠F`"A7(86 JeJFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz0DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` \O  Ob$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhy 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppLAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4   \|(  \D \ C A1IiP \ s *޽h ?"` 333380___PPT10.݆r '?  ;)tM( / 00DArialngs- w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( )(4QEQEQFhQE-PIE-%f )3K@ E%Z)((((Z(Pf((((()(hQEQEQEQEQEQEQEQEQEQK((%QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQ\hb55[yq,jG#hCJ뿘dcL>ϊ??5gPWEs/A?o"X~ 7@=dI?a_/\,? FO?" 7@=_&)`c/Q\, Eo"X,EtW- ‚q|WpǮ6 C MvTW!/JX/,wn^G'ri C MvTW1mC1M^>ǧOLUM'CFޢ7 / "_4h0 + Ѣ/*N<%CNޢ8 :' "_40 + Ӣ/*N<%CNޢ8 ' "_4h0 +.zF[]kNZ+`AȭfxHdI#n?EQEQEQERRPEPE-REh@ 1Fh.(&h@ 1I4b3Fhhs@(.i3@(&(.i3@)1KLZL@ZJ((() -%PKIE-Q@Q@Q@REQ@Q@Q@Q@ E%f((((((((((((((((((((m+ u_mQ'M''p:߲R`޸Ht?xPEPEPEPEPEPEPEPEPEPEPEPEPEPrCI;D,lpHK1D4q"4Bv> O1ƃqvMiI#w{H3I#j | fV6ғ>!o*dk/FA#`"u \r5iP푘yq*BΉ鷰+ .yϓLcQ@}kh#ƫ@'ɞV)Ldge? ʰCYy<\3ێkv^ZE9ȹO@hbOA:ϢrOEsƒrj i:6?@G|j&fp1ZϣUI.m/S#UF| H'szGY}y*ix]zG/?ihg.W7^P`V_ڮ7@`VIԟkIY@z/?ϦhWhߵfu Gh[ciKZgKZ=-|^ \q?Jz+-hM Ym5x nx&N IsCh%сVV2Oq᛹ .-Z d>e u禊X@H!V+:P-, ϛ/ s/ ;K-=ASW9(yotk#Ps<.brŠ'b@yýb+^U!֞屹 ܑ:vq_رeՅ:g.mͺ>Uv# pMqׅuzmՄǪg^0w҃4эݷeW=~+^ C ݮ2<0a]Iakڢ_ZEu2FLєI (ǪΝ#ũIH#+)R`^G>i>og`n}&Pۥ&E.(7Z7ZR)1@I⢹Kingc$2H*$@.פ.on'hva9a?wvus*K 9+޾Xm;Y'umwO-JoȕGO3_REoip`m+,qgRSٟf{Y/4os^fG?+{zs\QfkBC ݮ2>@w 8Fԭd"W+brBq8=_~ >kmwo캌#cx|𚗉NmkPiQpHDmw󂡔 =pZa\hVܮ9B,c3e)bIoј}09"y}"|9>AstdWu-:ݝKLT7w\6GP)FrI{}KŷM>)ѝ$@"|S~c]8^ k:GҼ>>$ЕZpke 87IF9LjVr$dH`z|'Jկ-Ө>ƿXOFz6My'JR,m6׏M!BF'б8P6PX-8j{U<yzڝ8ec񪄮ri#Jwƀ.GZK$+NkeBzXYwrM:q@?,԰Tw gTyoWiVrΌS3Mݻi Qq\,iR'Oa :RHE*#A Qmn;qP0vǭPUU$:67{.6dVpdT?YgtTE h)s  ;@Izr)DDAlvy {k/T;A:+(<7[\io>vX))_#t<3Fj7[J2,ȇ*FA ((((((((((((((((((( ?&H?xWo~&t 3DSIo>J>j¬~'N|~q/]OaS]tp'chKeQC$ Ni://Kd"\;r|0'o\ f/\h&M}05ݼep?}Z;_9 O$`C`qR+KM.O Ok4ؠ>2JLz;Vshm̆Yd\˹8+ūi >Ѐi㕷glqsxpό{G0JpndbLc}vЦ:l;)!bF;aם'{MZWc5$9RV_l.|uѥ[-L|1& A'H뷶A mUDŽ=Mb ft%YAc;S~+]K3xL7c$}K3XGoZf>7t٥:mG* 3V:w! Dw1us#T~)M gqΉ|K{o] }MT˶LPW޼ϊ,>Murz+KMmgWZI+q>|wcwV(:ocRjۊ*?@|._D_][#y7NP Crs<6uWOc4SʰǔvaO ze =9]U{X.*`XОq_]w:FJkHPr_08?{5?|;7&5) Sv9dN'c+) Ԋ%~?5ҷ@es 5ef`H!W'zPϊ?<@|omo Nl{y@*Xs9x⯂4HԡeI<8AJs@_Z|c♠m2+8*@<pk ~ 42 o/b0 7pXP{^'* -wNd\DyXe^d`W\o\5"?[TkɢiRdG!v>:ýcO[C  R2<'#ӝƝ6W׬R(?pUb8$qր:[7|9=cYҚ-?vOi$JFќ MǍEPCfE,[)Ls;^<ž2A{ 5nm2uf$~\to~Ehf1Mr{vv(#?5OlVWQZ2"|;° d1vZ;i,5+m: IKV<./"jZ4gGwW6kIqI+˸rG?=\k)-^]Dug. ,F0~s(oxX!]ysܥӹJ :sX蚴Px%Kr|!ʖ^zWa{|uB]NƙlI07@Ƕ+C״ zƩ=F<[> 4pvgWH+xSu.D#CYվ1N֥tNi80cR9ʓ $^;3Wslobayd .7c(dF (YEwO0:Brz=HHwĞ{d n~PA_0+;7_k;t| $_ K@gk叆;_Qeez*bp5_5~О/{A{w"Okr?Fٽq6/<7K, 'fV=2xT EoGq%!w.pJ \tW[o4:v'עItk63);zC*38?ItZ_K[}竇(P3IڷI<{'n?wP\ H܃^JIҰuOW#v/d9Ys=:(9~Bc׈팑D䵘1 m1rF=^!U'S,b˳KI3 &.״˝6M|ȏ==ҽI5)tiI/܄V?q=}*ε]jX-/ PzG^S ukR* #!EB731!GԂ{}a5w6"r?Nm>?*%[j(9'޹>n.幻beF<^'_@>Z? O B#Lr U? #A+k?iJy֌̿wIxjs;pC^g?Js?%p9on`Y?8D?&*J?1_I"i_%|e;\wu+O4Sk1VÅW$Fs@?g C,z}̒nP3ǹf J׮MvUcK2Sd ^5Kz>s .,1` O5Oc}J-?!,"ܦ*m8^(|=;V؆ X/uO]h^jݘyx p BKs7; ]rkM]>AVvi}ܜzm#Hlo5mIet%ی|L tBYӯuHu^:N*Fܑ0 Oi-᫸#hV | 9*x~(V.Ӽ? 2[6[Ř( xO }b3)Kcd㨥<x768m\ (Ͻqo=cXn43\I`I%Nd+^_vG{vV++`\xM+!cqkZrd׿F$UFI? Wᾇ5mI "gS*=xXi%K򩴖Vܓzuïjڻ궭ku -`N?tep7n۷oL99w'Cд)u GSmo+e#q\Qas߉4w֬5 k_K-sx#99o=oIk{J(mD6%AI _c<\{WXo|7q ymE $W'V_<;.omk{zVrAXá Nzi%%5XE ?!XZou{l?NV0P!)pG JdoT&ty|=[+Cc8I'@ś/n4_]jcB?\c g~o>KoD뎙^wjw!Tn~R}/YMAMp~D|g,@-hZTTS `Z| c+I8kHƣl$Ӥ.>9dٶܜ20w ОߋtSGŤx-.R;@fߑTbԵ6wTӼVh89Œ>xk=WT{gZ?h Qw rqpki5 \.t;!3d@ ASߞçp*玴:]bXaO@vdOuv|C$}Zޏ4$XcRI%rI=Ś_m-k=: $R1p{@,>5C'Ft!Vn]OCXg-.nzigU؏q/U_@1?%oApxNלbe^fW'|1`tO5+4-BI|73闹E+7t,sh~/^US,YĐ:5_'ÏFvj۔8d\t8#5ïg,vkV9 pNpB:$Z))h(((((((((((((( ,.#h|'zH?xWk.?k)$C%gu-ֺƟ-RJ\& Mp}UiqgˍS=vS PIoq5<$w( 8vQhќtbO,Q̅%$C]r*(,,mm$1`U?ϤGfei>7+az&P%2&/1TX1n<=SWH*,$zG:r.u=M(A-ͤr0Qe8unOOL!.NN5|) Ꚕ۪+*'s+  h:]^i&it5FpR]hZ=yX_AɹH˵$t5EEsko{m%Oo*)P2 EfSÖYU_4t0qz _­c !=#ز;L{PhDr.Ųy6gzqZTPXsx/·<ѥF.=LJI(^j + 6FGn-TO*ï [G _\[b@28Q@L"X=:49Te }@`jCkoQH8Ppb ^nuyYiѥ05y_08| ] :V (c[ZePYU%6r./}%O &"GBrhz[IaۢŌ@z2á9@آ(((>>)΃ !MbfdgM^HJpp:O|s|M6gaP[%#~"#iË㻨!`/Gϸc~Q[VFOZVߙy?C߲ޅZ1>M/Mfz~c'j'+A|==懬}Ro&KiG$qcb>w]f&sY_`r;sӭ{ ^+"t4(@vom= gG"209C/B\FLn#'8"9?i֚E+B'd}]_EijhU}xʾ񟊭<[fklSP~<@ _I!ѿwsr$BŹ8>ԯ>#r2IA 䞀dMzMS~*5ϵyhϗ7@{?.1>^U~+XII,i9[U3t3ֳ\{^^[Z*ƓIjz׬LזxC )k:soaDr41s# d'<>xW~8ʱM|%9כFڗӴt$啐G/b[AN߃|WjWfu}6d([DՁ;m?R|SHI}Rb Xtܣ {.|?N KH4xI?v~8) hh>[ Y=ȯ&ocd)4 O"|ށx8'Ezkx‹wt??jط.-h$H2ph˯tOĺ\ޗoh6WId\4&H9U6k'þvG!" {ϵBr~##^ l%:6=cD19<ڻ7zFMbvNn!Sui滥}Lg srTr Mg zӴ;Y4{*!sJ 3_w|7W19Fxm%6Ağ a6[LPI{9}@@>'AH? o|;!Iߝq8ͷ-6_?e o4Dr&O=~_bI@Ds[:! ~98&|)v\ ?^ފ'uh -WGe՞YP9e /\t ~ x_j.a ,|#;zv};ėnfĈCnx6UU"(UQ>M%RC 4 ?ød1| >:T?3ҼB-|+{;|2yVB8eQが$Uj&k9HxfI@(Gs??Kmfg<)ivaGv@\^wDQWb8**a&(< ]5F5)ZM6h"+^ai%E<>S {d)ǰ@leymd&a<Ҭ5?<5 h#$+d\Xr3\WIP,#R@ۀMw)%t95mA&x6B8 F}zi:֏g]³ |nppHy_:v:v|I|VGGE`A 0;ޛ_Ś-sټ2FXw@Ll4 3=V}9I4"cUqVtKXteV\r 񌃞2(|_3VjP]ʳ-XA^Ciֺcou Maa5x{NZ;(P*vāO|:ӭ4χ"Y"Y⸓:+3sMt)mG4yu'J3exW-ˁ=x<$r~--n ,4 |g㣐; ߼<*J["ǔp}5@5W\^!bԭ<[-1\۶VKy 9SA o_Ho>& ՜`p:3,uqaUK9$x'OQ9Iڹsq؂K_0Hq|.!Tˉl;Õ+V^ЬukPD7$ȤWpӎ2:q@^<^* iv慏SpGwzM%K=SOC9 Ќ{+z>'|4Ɨ-1-)i18 ݱ=7@J諸((+W?<9\?ux*܍4(ONk۟[}DqƄpq ki+wj-^Z- vԌQ־2w? .kx#\-ޑOqs:@ЛՖ0Ulv.G@'Q%:pFHUsw:zu>&;JB9GC \}F1KKoĖ6nR{uPKHl:}j_MmoӺ2Ev0r1{_Ğu->9=IFQ6 d>6|WTDIhNePUO$q@//y> $^ɞX )a?/ {x_PEr=i.>ɶ[fa&`R@* OxQtiYyT睿Rs3^I6kv\Q8_w|G;לּE?&˙8QobO''>"¾{o2qUVࣞ+Ů-~x.70cXfMS8\zC1xjH|Opd ixI? )9Oj?ft,F hD%y8{QEQEQE [q5milؒ#nF##n$zuVRAqYEudc#WCc #kQEQEQEQIK@Q@e?7o9K jqr2y9qБ\m|^ukpK#Zr>lTa}A;/E$,$K31$&P0 (2ئba4bh=j ҪM?|0:C*ֈQ U# 8qW/R#Ppo.%r;3@ go''iExÿxM_Gwi;;olq9gI~?vpW|ON"\^IPs _9?p '?@ꫩi:ń:WV1 '?@i3\?./E<>?";;q\G-x,Ezg(o3^@jZ)q辎~0 I.OYE̜o;mG}GO'UZk6w4;+W6}R uAzkjh~0ik0ֶ D$TuvA*{T>jo|/ճe@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@u/Mr_,S:v#+Կw\A5|2ះMI)'>4EQEQET3[]7KP]׆+tEĶ >b3jsim{k%ռSȻ^P20 EMESӴ7Gk}/OGk ĥHPp>«_xg@^P۹Ḅ$HVv֐EK8@ y?zсV uj-t+{;u$XׅU%𷇓R]K[0gy9-ݞsֵxE֞7t ulW<'x8SXmꋮ#nJ٢9#-A/ $Kqp}=}kVAﯣln/"*cD*rb20I#5E5dFGPXd\1Lj>ěacd>\{c(l6Zۯ݊(X(((zޓovV !"3up#7EVluKipge" Ѓ՚+\#WHufwc8Lrќ`FKXZ^@7p:O)jW/]&W׍߄# K> ԯÖFg9fLa @Ͻ|]Z~|Ac}ZݥWfB121ȯ/йm$|&$3$Br2=A$x7^ _h;ۯ_G7&o v,BQa3\Tzo _G4^B/W¢ O*T^r:] ?!½\E?-Uy4VB/R+M> _T^r\TZP^hvLHHɤ #P2`.9 瓞B^vIP ~+7(@#8#I#d&!K <ޜǽzC/mU/*йo$etiZG;Nww>=q 4U_Xt1?;ge'Me*|;IJ8h->%ҵ /*#'~OC|zUG# 01w8C »f;vʋ ϰ~>=7Xf @|ÏֺR^ۏ9K O ;q(AxOWW O ;q('7l;Y 1D01_h ?Z1?I={'n?нr9Oh/ ?Z1?ᠼ'@k+'“yBN?|'@k+~&|J[ڵjѬ$cy9J|={'n?Mkw1GؙYOYʑE'Y>hQFaUvS*5UU*vEQERQ@ \o xo5}W` АFsEq BݯU2_~69nH K@|2cˉ$8N?<mG<\L N^+&hO_?߀6HljODC#wPضyK[G {q1otR^ۏ9J> ={'n?z&h'㔇vWKR^ۏ9K W ;q+)hJ|={'n?нrJI<{'n?')?/4“{BN?I={'n?zhȠ>)㔿~нr4~нr_ ^喁 ·($OwʊLb((c?o>o<82eI7k?Oa(+ׄ岉;rg$=ޫ_ Tr7RU{9d^3׆"խʘ1 H0HpAC†O-jV[Y7{y\m~7sb;o<H֎DW8p&>Т__YNNCV((4QEQEQEQEQEQEQEQEQEQEQEWR]p-n%Źe]oǚnk)BI 'Hp  ~J袊(((((((((((((+ƞ:% {8ac T=xXs_bhȁI[*U'S↞ld]IMl;&18=@_xLkmRUbGT`>/þ/tmǶq]U EaRF0n}An-+y):~AWo<Y<5<]䭹?vb'sxVJ+IZ[/:ā8 緦M W0Iȥ7PF vD57WGzi:n{]úRKy N_[?*1'dvj %-%QE-Q@ E&h4PqE:ZJ)h4-:A\QE64QEQE-%%-!)i((((ZJ)i(^(&)hbuI@Q(IN" ZJ3@ EPERR@&#| ;xq?e#?o>o<82QEQE/JŚD`YNUXP;1 B{+ĶR$V#c@6|Ð~U 8$spEO꺊GWA#;q+t;G6eXԱ8jEP&+$xXeRG"WR0A\E6w[K1[-rg)N@cHC2C4k$R)GF zP÷^x?X{;͡^ۙFZCGVZޕsj0,(c6=gڵצ5K;\z'5W'^kZmKkLi8xۂJG gYEbWĖ*aKiUI[L\p3[TQEQEQERE;4Pb(((%Q@ IEQEQEQERbLQKE%PEPEPEPIE-%r/Xqu$~dv^G\>ugqf~T?ߨ0~=4g/9@ ^6Hnl]̍B:yW~0B8' f=#Yq#*WIrF~d~7oj3Uӷ[iyd׿niv섛YPY'j7UVe,9l[V ը3U ۉR Ɂke6F>]ؠ 7U_?ܙб3qTs4OP)?aѣ?5hQ )1Z33qTw4UUb ":?/)2*ᩡ('Q_G24=%IZ)(g?o>o<82i 3/ß*!?ҸI@=b(((~'ov[  g!"8$dum+S&[jR7XaAk~'3񽄗ݵ%0w9 rw ߞ?pxB>vȵ{@oIz_;⺴| a]Wemp8܇ :( ( ( ( )sI@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@%폊4Yxf^Q!OEe;[s+˴]w :WW\<-&*ZxLαa\&91$=sQEse4"mDZ; Ԏ 9WA@u!;hYaT*[NNpHn'$Ez !  i֚qBZ!I#p {מ;xW[iW}"طm4cq;d(((J((((((((((((((((((~;T+[+/?|4?+kV9#ƞЭ|}+6-;FloZր>ⅽ**޵wEE^h~IG40)+HGwv9@R W?ω'S,nw~8FS+>(j#Vm >\ Z\˻vݧh\K\cv{Pj,^Y|^ԼE.뫙$)Gam~99⾍-6gܫN$'o2Qw@Y7?:o\_ E7[ apwm'nw#']&nu&%& npǀ0s@Fr?tJۉ2_$Mۋ")ċ"(E,2C9Wv~J$ݱ` O9(J(h(((((((((((((((((((((((((((8񏇮/'=;tX >Hf3A]晩klsͥXC{yjyx8 kS@>Br,OÚ:>"xfOxJk{Wjwfr|U}Fy\{=][PpLWV^u28^eKo' vEUr '@yzmQEQEQEQEQEQEQEZ(((Z(()s@ E.i(((((4@&v\!r?p5a[_v\!`xGL~!T_XڙIcdކU Aڀ>yO]覯$Uj4}N]6]J=:";dXć ÿq@A~!NOz'?ℾ**q@撖W|2 /_̄cס8sP@$z 4).~G~1e:N-umUͻߞW oEÞ$_C+%I\}L{]ޙS s@G?HԴx5ѩivfY!1~QY7eZ.fWIbeYW̓$a#cׯҴ+M:]BxSr[C8CYv ǀ-fHz2MnXr,y^kZ׉V8#SKr9xS|!/NN[X~v0m׊km3Bn%Ӵd%aJ~`%ӗ%Pb O@C Ǐ)֟OCXZX`+ev$ "8`=h幼+MzfVwYY }}FG46wy3SF(eM|ޏ?{wOx~Lq9M|@֍?$ѱ9'{7|3M}=K8^xMhcrFF5/?B[:A!w|hsNO:ujV֚ms܌C?vPӇ>C_U>C_U| S ;o(+ 7'{(frWuͨhWڭVC'$a>?5h0ա/*c+ 㔟>!пr>6il.-㐨k[߅:lcw61':u,%[+]_T+o#eQg \4-|~ڄ8AtuN!cuF)uglUb3@QE [̭ \*c)  dqֶ𦻢^w\5WA{G-exaBkr>('y>ħφ>y_4kRFڳCqm.Wx7QjZ/h&kTV8`x#V()h ( ( ( ( (%Z(((((((((((((((((((((*YM֙@Z\c=ǡA@5r+麴 I- hD\$y5; k l_ӯwC'X=8xG1xL.X- vɀ E{^k{mppG|6ܡcEwh>.NI]ޑ6F>dyun9FGapp0U]7PմMF]BD`aۭZ((((((E-P( ( 3Ef((((((((@%v\!u~'O2&*ddp"$<?/B~;U Pv}tTQO+jmq5XA<}Hxrnx⾡r:|Gݷ`1ZCr訫+?g''^ eqk~&Y[orXs0;W>v8# XxKF]+MiH zc_ljHUk8x]f(L01؀[kzjPZ;}6'-5$Ycsu} qyx>}Eq.)U5׈YxcI`0c`288+WӢG6f{D+&L .Hr<ɷռX%(k߬2/RC6B2FN{mÏYfBqs/L[@׎MU?|;eI %ȗG˟ x#< }:$V]Ee.ExW' zc>}\5G[ḓ4p:נh |5 \fw{1z m_ 閚;Tݧ FNA(t= R.t.VYgL@LA|8ݟQ/ѕzװX(}3Z2Sۃ)7 rW'=#&$^|}I?ѼK jF,#FmP9,6drA\p0k_o Zx~&Yw.;* =]P6\Mt)nb#qN@:>J$A5OIo>J-b} J׭^8I g>F(¼Y;Z]xZ>27d'P1!yKųZM?T&)`]NF?B;f^׆ jvཕ\n CX {pyI^>/ݶs=Gj+ʃ} M"GSQKHhExw_mwxI3B"Et:@<`׸fT |Kx?\6:hy 8\`8?}]_%|_{^hĴ/QF{s]Eoi-zg߼Eatm B;3q\v垟izTRiP:F؞z`y"k3xĬ_hRR' F: 4h((4Q@Q@Q@.i3EfR ((((((((((((((((((((((xNH )uܬG1L!AHb3(((3@fEPE4QFh(((QEQEQEQEQEQEQE-QJ P@Cj&m?RX^thu# p| էԭeVM݈Ȋan#r9ZWߤf1>c= #OE|.I8Ӡ RT?U} })v/hhO Cҟ#T?]}K}(hڨ_ ]e{o݌/iTS <qO`LK@E?)oJ#?]N7orɼqڦeiWZmbieltP3ǩx{O0krIycK ઻' ~6X'ÒXO]R7auQyJ͋F?._ QCie_y!?o _Atc_v JPmܨ_'O* xv69H|)6 oh7_#Mz+޼KPCb-P 1k⏌cMu"-lq#s:,p;+Vha1S÷\*`8 6a5SR(4QEsx& !G[x&>J|$CN |<>a9B(hCIKI@5|v~N|Sz]*~l¶3~lCuvv՛˛1MX6䞹q Wk:=]Z"[[nFz=*.{^hOg.DpeqAw>[MFՄ7hld8'z ]\W!? xUxk:U/Nx,##-?QMͬdBY"ݎ)YY89׋|_ G@7 R660w$[r#gbAKK,$,E2Q}W-դ+;K&eCBw|X ~-i,NIY'^_#|G֖$Bp) }f$'Kvjҝ(JZGGj4ޔ6ij0yҀ'%D%>gIFj/0QPj=ҜPhu( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( [yC*) w2?-=\+Xgc$'8Rc/]~,nD1`u,$jޯ? ~0ܘF4~j[OV.q صIu`|GA'q@9H,omce?z"UAӀz@^a>kw0%ޭF6 vk<Չ?-ƺ=mH앀 * `vWGk4]4+n.p4*| >ے u1Fhh1E.hZ\PqE;J)h\Q@ E-)h((((((((EdP(4h4t&hk> t֑W׃M>u2`ઑϭy퍅AoiC[c1e=0+J>Zmz|6QM4B Ӿ Ԁ098$o4PF( ( њ(Q@4Q@ @QKI3@&#| [|'%6̓);Jɟoq[x&> !G@Q@RRS %yQxN}:kVp2 $!6Gr]& ˢ[Y\#eຑW sy-:' %W{6H\ |8Ws+LBrz c'q●ǀE8{Uv/eeɔrž5kL YǂQa]jui`m͏CP^O l=>9]K(gىkdzh[H{egHK~։sW@Gw^h?q#ހG|tW??Nu:*`J>aH ׯtѯO|"W:ك'zİJ;)Y]H wv~r=|'^5):>fguų:Y^t/ 9=}SG/ 쯿I@I;At?^>ox^߿|ϻԐC%V4HgbpI@Jz+w h((((()3N=)s@ ( ( ( ( ( ( ( ( ( ( ( ( ( ( JZJ^Qi78bdka.8\s@;W .^qZ7pWȘɸ g=++ývh.b#ehQRvhx-X:pjj;ZPxU$? <:"؅#$I$s@UI n(@ 4mmu(@3F\PsFiv6fmiq@ 3K1@ Lm4EERPQKE&))i(h(((Z(@ K)A74fLPK2(b#֌n+WW;>﹣4bm&isF\PfE&(P\b@ 1PEJ1J(6ZLP1I7k-?|I7k#?|EJ(i(&hx[CEklJ9@9\a޵@0|D'n5}F-ρy p2gMy!'8>+˧.-`@YTW#xu >FG_4Q_Jx$R$R.t9VuQҎ=)P_EźKS.ŵ3%ҾԴ}o/ XpL.rNz;O>xa,e\!=~jPM{\6gc$7d >RIN |5湫xDʎ gsž$ZQjVk Bi/9el`yw鶾Gu9u]iDL&H@z.F ד[ >A}pYˑ-؀H gg.#y|;Mq8L"V'*N1|9l 'Qɒ PR2~lF3SF/"ӵGu]_hh1$y~2~R SɎScP>xO6zd7LWq{XbVʆXcx֟%ג&F#q׍0@ G>Z{ fIqA#]3 |#xA gm&U cc"9{/|_ڇ4K+PAq C!`W#|bwNîWS$.C~lڢ/EQEQEQEP(BAS1@(((((((((((((((JZ(E׬oOQ@L`1VcjU=[@'h7λ8w+0V6O*6>"/ ,( @'=WVM^L_&IጸG88pG=9q#Df |nǮx<:s2iד[;IpHU*}8##}Z\V6r BgzG=+K@F*AE~TGۯXSjtՍ= 3{,[lyQTZv<ԿjqT948S M ~s<U w.OH}Z헟?_4O܎G5/O"(RQT}թ?RguG7@7cqT}B}Q+SjڶkcCuEyWNfB0@.ya< 4f\EQEQEQEQER撒*Cj7q~e{wb=G\| D$-*Jz0\ j_36&HJ( y} _1~jko8 +Pgܰ~=kcE}ܺ0sFA1gʼvstvI;r{n c^Puʗu*=sҀ//ۡUփJooaU@F=#w/i o٤sc_sJ=)~OJl~}/Z;=)Cڀ4~}?Z1QP4gCښș@?oԿmfҗˏ zެԍ c61@ >rk#@ch?Q^gOWͥGuOgҨT&G T^hف5R,$}IFhu5mzXcqN^TF?gs|t|C;IK@%- \.(R8=ǿh"wԎfcE}/F?#mWǂt?>uGGVLo3gʹTi9,V<;zдbU*R39lf9lͷjhuEXH&/t-[OƕyC3KfrNY=1 ij xVXNA*KppH5 5Kٯm{nm˫I53O1Cy4%1 {D1rr8Vt_V[ڭ'(޳/XZ[?ߎ4Hc ÞмYxf]6sh716$c,*S:d}Wʋk$,lmNF9u-ljl'>a%?skڃj]ܾs$ :*; A2M dt8e#A X kgauqpiYx]_)mΧ^n-7>f\䎴MYCF + (((((((((((((((((((((((y?W* {A4};9=**VOr4BZ [կV Wd0G̼w+|#?)mV>aM)ERzP3Ky~#~7ƺDhCłg#a^q6U |~-w$mev#E%!}@;O|EEK$Y6W`ǘ Rn"t^u(;YInW${.gۭxt_o ukyaU2.p0:6skmcT2D6P++o'yd(3N;IL3GJJ$05Sž3D=k6:]\#+QW5ۙ!Eiʸ{XM *e{ _<;i\z j|7NR v>Xaxm{źMAn @FB2^1sgHC+l{%vuKJ9'q?44RG PN LPKF(HEP_QxOھ%> C(o'm_?B>'Bݾ7N9IޝJ)i(EQEQEQExKkk+{>EBdٿ#<[Ҁ>M%RC |o4 kX&ԭ7WS"[+// VF{?^]3J-3K Rc+0QWɠ9r jY3"ZǸFn$\ g j8;y/Zy-gė} \F9lӀ:Ηqriqm&`/<}-9G}|_J =/V|AP1ň$qxS:?#Ma&;-NMMM|m`ƀ=I22NE8UA߉}:[[ *0YIASԐB(=sм+_)+3J%$@HO'b=gE׵-OWm/4 >c29+tw*1xa辱GGh NF\? 69l xYX87p;Ⲵ/ NZxJ56C8យIQk1۲Dٱ71Q- "s-KO_k%Ʃ bY@#.N2pFr92تW>'}65J;A)}`nH$Zh/1A]2>Flg8uK CKcwon`KZܕr;O SV_6"?GG?$:($\h(((E:A@=0jG_37&?_ёW̾ǵ{'Wu VIZ2.G{.:ڹ/g|c{ ߎ9tv>[GS` ԓhEoߋI k܅YԒI5֣)R9dhLU@'+YC7['lu9OwYᏈfXo5kNcYv' udo5YCU0.Fq^k7~ ?3r-Mn}=@;9gдQiR"A L:_ kq|CO Eoj+mn 7 o.06Z+oxmiѤY7cw Tӵۻuڗ.2AIR8P[h4N.bCxl  R$$g뢚L|]֓]SDם#PVnji6ܩ#9xcZK?i.K%55@5+ۨԣgER)V۴ydd(A< V,mMakjm6$RI#=zҀ<~1E}EPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPTo׼ OV={žvE퍭̊Z3y#"A rƾ?W~un$yʐ8(cg?U?|ȲF̎2GpkO]:6q) 0G#E_$,H'PEGFH)|ƚ`Yv3ӢҾ(h6QjVl=f\b'~7|KBkD٨ι6#tf'?xs–5hƦ4h1IyȤH8U =*LQ@$\ui3AΕ# ``n#\$;@' Dk1RQ @\JpE'Zy9m)sM;Rb48.hq@ ";m4٠ qo'm_.;cIgL.wRJżx3\ [Wϟ^!@2xٿ' O7p4Wyɿ3k3I@ 767om2o5^Exg+<djWxɿ{ O Q 77s<3o-?2o5G+;UO-#\Gmݖ EpAa9@sIf\CZ >;-™H[s=kۋk;D6gq('k䏉gOIA*I~|cρ/XJN*|+ʾHݨERqÌtR)$$~!~^Tsv&©;GSw> ejuKN5!5ޝ'k H ʎGhҼ5h7:ucpā˷LuCdӇLD|5ejs{mupΌ\l|x=+оjIGZ{uZfy#;y[G+ ?&P͹1| rk)&M@޷۶:ǟ{cSMcx59.DG{!\8KWwMz^j:Dr*H`2Qxs]08P- CC:2ѭJ&dYd 3\6sZRsIKu,SYx9l\khTey>&[%o&yb\*#|2|m. mg $6NvFњʏº$^(ĉe^d%ǚq;z(;T~Z[yWz+I3ys }j92o hޣjuIڿU UzW|aa7m;|`V-7?⼰d6Z8v? F@NiKZ!V(@$Z> "GKIn>:> "G@Q@Q@RPJ(6ԌJO?2*k_J$sw#Q_?\|G_cΞ.T庮qqw3M&3{zVY>"xv( c*Wu _5Z߉i4oh֏6,p9(Pt/|M,7ُ>M~4Kd>W#!=LWb|wE{(xg'or4Wa|w`v=oO[n.kĿ>:zU>:K?ހ=i3v=o[-?~:4W`uzchn.pqqoǿ4&8_ˑtNVه«#$xLPxI><<r37beq-9@Xh_x~>c7\>=/okg\|<*W|z_Vfmga1_ O5{}Mh6Rzrf=l-:JZJ((Q@ EPRRLӍ47K+"H%IbvD`pTA}{HԾ>DcdpG~|ϧjVҢNѕKCЂ=x4׊vAO>k&6po#mPDQWst^GӼ;q?I$jݲXzcӝhm; כBPs!x4>TAR7wO~N?3C+Sn~}+¦uɝGˎ:Jh]?ntyg^緥{B)@x6w7aY~J?Whm8nkҘ PZ]{VJZZ2+O ?iw49>r1>짭>A hM+wi҈"{.b-x^գJZmWC_I ՠc#v? F]Kк`h7l;CLpqWֳ7Ƒ-"؀qz,p9'0>İur_*CkEgn0SPh_-s|t|E_Ha=((((%(4i’8=)7P:N;Rn74PRiE-'GK(:oH~(Ҕ)E>3GE.}ŠZ(((((((((((((((((((((((((()1KK@ J8RJ)i(&(sKbu&hI1F(wQLR ѸQLPQڌP(z%Q(ZJJ\QJ)qI@ E&hњQ@ U+=KԯXm-2K#v۹x [WѼ}NQ7$wbXI$ O7_K[mo%̪-a8,9PAI.u6R¶O12@9 [=+I42;[8lqF8I_x~ #|,I1>xSI@Zf-{IV',$RJ4/J2k ɟ5\$û<3dƝ==T~<">tP}@+Zvh0? HA Rk'G+ 8?1Er3@P/U' qUb'G qUbP1UxgWOErxgQ?Uu(]KI4y&P8:kW(PQEjGGGƯ$zWIm|QER(():(IN(4f(3Ef(3Fh њ(PEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPKIE- ( (((((3I((4 Nh]Tri7@41AE?4RMRBg9 UeaK(4Ph٪חZwq H!FIOLw>&6pcm" x$u-KWFОN .B '8lG}WBK}NIcR"ـvs_H|.u=piw~ry&FUL#h u> +Kʶw坻+S&x,?(^iǭ.@ IќրPQ@ 3EP3IE.isM3I()(PEPIn>:> #GGƿ$Z)$C%wQE- JZ())h)(h((4QEQEQEQE4PEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQERQ@Q@Q@Q@Q@-%Q@Ph3_,L⛯jz]>cavg!̻瓷8Fkjg.+uZN_CV?; Z %>P崅d}r[gQ{Ɵ 5Pj匩5ۈكf*0 h dE#Nqץ}_lCpm|?_l-D]E]XFGQ ep~1#o@ni٠/䠟~oLx\{҂Ԡh2߾y`0nk?\O=Rȃob;u#›v}w&#H"{9L֑Hndث6ۇz͜7Z+4 :e=28=qNHJTPcHbHE4P0—aяNdh?(΀t'?Zq4t479pS4rhui,0p-*xC :QK7d] XG=kxWDTd5p Q  QEZ((RPQZ()h ( (8HwSIo>J>5"?GGO$Z((%RR (% Z((1EQEQEQEQEQEQEQ@ )h((((((((((((((((((((((((((((((((((+/B/nkW۵x·_5fk}`JqٯC{GhG~FU}B%p8_Sb>]E|Rk(ĚEZU꺄Fu\[B>ޤ(]ִ~?>6\w)?xC_mc:* O4ZxI>ZήۄPtlpqW3Ě=cM%k DE f1̘8}oď_Z8Kib|.8<E{LjGimV&x"*  $c$֮i:i .IUYC | o4SU4e]M©G7{铹sm|I:MBR`zg tWY:2NAMB_+O3*W[ڌF7V91ۿ,{F\l] {kZUƿ#Fƀ(he?8tK}"ABҶ2oʨ؟)msgq]|i{P៲u6Y{y4ؔbz 61XͬjڶkJ ir|0>@ӎN_1Qx=#3k3>3fFO*X11]t(w>:藒%O6ZPr0 gxՔSR -mcon淵Ӓۖ%[#=1G-o(,Z5}Kھ['?KP&(APQE%-%(((((()q@ E-=?|=?|QEQEQEQEQEQEQEf(((((((((((((((((((((((((((((((((((((((((1K@ E.)(-WŞ(➿-]ZKіG0d/B/nkP| #k-ԁ; G LVǍa"LԮ.`\*e|ڼSoętJ ӳܶs&S?nލRG[Z7k$*OpI![90W07uCOcc,}en`< q>҉ǰx_WzjlG#h2q@bxWLmf6g [@Ph_K2J'g'U_ʳx~^9丽y^tM``j2h<~ TC-Ս-m mNO;淣Xi˧[NdDut$ȱQ.$R,7c8^wmė9͛$y<'<溙AE%4hsRFz(?j5ׁM_Q@E-%-RJZ((J( (((_=s|t|G%k=?|QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEP(L P_|Mzۭ!u{5 É#yk񕾅s=F?q/F=wnۀ2I@/.5 ۹L74YׯXiDw_99s?]/?]x^:vm%8rǯ$$Vk[$8_ٺW,Oݴl5:o3 ^$?g @ؿ]!u3b#ti ׉PC9߃#Z#t=s^+ [Ppq^/甆ȑjȻ\- ~Sht~/Y2>VH#  #hL );T SvcWvv6B2I@N)⼂/,OORHtWsJ>E$CW9wy#<!AI=;PyZW#nO+mEYYO#ӵ5> 㫅c 0Ňf8b[s@øf E{xPHU I+ɠH .ᄦk"ܓ :esUgoRm5`;q ?hH5 }E;Z9XdzՂ/j\h) yZ G$##z}!@4QE3FhfJ(3@fZ(PEPIn>:> "GGƿ$Z+$C%wQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQK@(JJv)RPfPf;&(8SqKqUu >[BJTN'zVGPT 5+gvo96kM.^Gkiޑ$ +5g4@=7OKZPˠ4aYI<y&/ <[ëi2eY$B7Tq["hMwh+/7],{G.>57 2+$ O~/E_wh@ni>y#@ۅ&Y_h_7ߋ4G_^~/3[]ᎨF-qq{5u_ھd;k{nXPf,201Zkluk+;նfxB#?+q iE,đF`HTTP:;P9c%Z4@pf^5gpsu٣>v:_ lȬܠJ5vϋq9 9 JZ(((b4Q((sFkϾ&|P} `qB` rx|\Xt@e?R>?Ѿ/n~%㴟ў/v~%E7#5^7vX"9+ܧG#7,t/.ik_ 8oi ֡= MmdRdV'ڵiM$?C@\Q+.`M;7aKXh$ɦG&6(+Zw?wuo|(+7ǤKCzA|(cş{Ihc"5CGuB~hc4y Iu -qp݁)iJ($\>:> #|]KWU 8*SHC}ӭW+$C>J諸(((((((((((((((((((((((((((((((((((((())i(3JѲאׯ~ѿP?coo0dS9Ҁ:)>+ "D]Qۻ>g~ujRUpGÄw7 4Z!..R6#W 3IܿҼ/|@OOP-&gPZ%\f8'xe% RXۣQRak*Կ'it$Jq2gI=h׊T}B9dY"])Hםf>h~-}BƎ!XrH Hvb:hxg%T6E;sW¿=iV0ׅq#G&'n_v~QԞxE4{hmUvXH 4njO]YjziHQ-V,PpF7~$x xLM*NKp2 z[NQ2%' 8#r?07z土eJ`H+6[D mB+AK3}8EzH4b2x^Zմ&٨ӣ|[5|>0u۴>Z\bKK1@2M7igj<7y>?G%#K~\-#!ĞvЌE} ^HMxuţh ) 8#޶↻MxSZUI8G|IT8<d=T)WUo 隞e5pmld`d <W]ç$Q)Ӵxito.Ċ`ҋ*^qq>KoS4_j\AnT! 3{u{k~ 3lqMwͺ.iPP{w3O("ڀ$f<׌~RI~)9Y c^̼vm%zJX_f4c3CoרfiR:yoVIqyIm2!Z -v!@LWfbs^C\t#v<ݸrsA+;Xlm EH`bEU*' ZJZ1IKE%Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@ IEQEQEQE% Qkɭ7P N bRA~~ ^6+g g)_P#^$!yOmGN6{[uVN9sQխdcKvVv]8{'$*OE{DT?ږ'b0ŏ^R$ᶤڅ֗WXWz=p}궥_x{cEpݽƧ8ª۸ AiЎO E}Bvז:)C&}4mrچy>F\I`1|S|kt-B\=}?^+g̍7\WhAպ۟Z%(Ӆ;h:S! ۣjzNoIշF|2'ksVVYr[kmJA 1<@k܈QGoH~4⚯u[y|tx-2;ZmOUek<3}s<4qIP-7:F6;zWH&m.Mxg0yrgjq7'=@X=Γ5|]$lq5gTWnʢ{ˀ"xpO8{z&+@^%u3Ti3(d,02K'#aZk_W6A'ڥ;$B;i>.LIRJ)~= (L4<׊~ o$j⟴Aͮ(ѾzU]);(KPT]`A?Sk<;>"vjqwEXk|~~Ty.Q^e⟎vl> b(iT(Lu#{qb/̎׺̪ kC yw12\67/#8.Ķ8{PT~k^! {V ';cOQڊJ( (IEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE% Qkk+P>M,1YYlaD7 zr28GKF ޛ1O"+;K d$7.~ּz>?5cL[2G9I Wu}};:XY,(Ԍ?@_j|>nBErӗ w:Ddtw#9hMzb_q8q deW dz+6M74ⴛh=;^ޝ&,uF5'8}ƕʂ ĕw#a׼9NŧmD@c'2ʐ{VtsMO㺴` P}P/↚k\LFK !fͿ2 3޲ / a Askrx߽{? xja>[:3fI#i?/u_xM:\f+ lndux|?cMҴ.L%SXF[Xrp͡xҵi-&ȊKJzWi <%j6:By6!by91ZVωNƮYyYJvބ~~'[arI9yoXob/9N/}Z1.$UDK1eEڠ8pat\G3ΑnUw琋qye;~7V&Z'0V0cC/;xn;QN6Fi.*+Fql(8@ů3'cJ1/)&p7 OGei֍gE Ef(9;Sx#Z0|SՋ󌍀>m c y+MfLwbС$p+; _F~n+j(V(G(4m<.( 2"h##Ѳ!xhǶ@J鑃OK@Cx? K['|5`_PIKI@ KIEQEQEQEQ@0ѿPGe?/|uK|@x#цI;sH Km6׌P%ҭ4!{:ZN:2c#<:|}j>;SU4_.Vg% nX𨙆rF:n?6?g}eGDg}^̠^A>[H4-fᕄR\ SsDzm#NQ(+<$d20)zTE|k\x'E񯁦w7R#_,f_0s~E} ⵇax+[#K#oFO8F,F1fv݌1޽_Rx7vu c#,A(rԃ w| cֲY%fpoN:f |CR##&hkM/ͅVJ8T ?[ 4PϿgq/ͅ:8h]YJ1{#_@f+&ѕ <|ג tW?Qk)X w{H+3Fh~V}?r%xJjX@7L7N;Q)^7Y+fdz#Wt@<W|hu_Cb,PhuG%?]o| _Ə[U} QP?huG%?^oX+B^J3мׯhOƇFUdBAǑ2q\d !x\yotsp滾`9$A8+밠vSѴmKH쭣G~B}PQKE%QEQEQEOQ,5{7l໶a0yCxψgKx%,Imx)FH`K9la(4iB7#0FNq:%|mw& Pv~ äi:F~]'=XՉ4*kV iO >zx=@|Q@ &nm!P@ u|ߎV @ V&0v,N*~aL=c=,K16<8ƟF}2F(C,t#zނ,?N}Xd2hacx)KGbls9ǷLqҾ4ٿh?[ pWњ~›bHX(PYXzrOrh|AG@sI@?y?'W94PO  @sH+j}j%YJp!b:kjPh/z~ޟE)lX0\lvJZ(((((((((((((((((((oN>} d`H+B$QTWF2@.0g?Jje쭙Z%<қ>P %qud+d+{CI\?u=$?v:o:oqWn]`+7]N@_GN@_@g.00];p9!`c qd+d+OE~&I?y' xua7#kg'M}_'M}_ oX~ H?a7#kJÚB+N6Z}pG^MS*/a7#h4 O  h*/a7#h4 O  h*/a7#h4 O  h*/a3#h4 O  h*.a3#jdׄd@!ڏA|!B?  hO4hM*._Ы/& h>/*M'CFUP7Q8'\pOR9# Xn$:4h0 Ѣ/*SxO?SxO4h0 Ѣ/*SxO?SxO4h0 Ѣ/*SxO?SxO4h0 Ѣ/*SxO?SxO4h0 Ѣ/*SxO?SxOx-IC$l]H #I\g*oзi}? -O4ٚJSxOƢn#r vW>x f2AY 5_vPQ^ S ;q()4W“yBN_R?_ۏ9@%p?нrvPK^ O ;q('“yBN?I<'n?zmty۝5 ;~TS~I<>q>(OۖFemJ=)|@ q3[v;.WF~ nUb~:PfחGQ 3/@3^] 3/G(oEzhy(oE4 P/oEt P%y(~#)?F~#(sIQGQ 7@߈9 Z7/K 3/@Ey(oE'(oEz}0HFOjkz]m_BUmc^4WAD#p|vvg9|Ӗ]5?c;#hiq^{'K9ž/w?%ٵRK'OxI¸!RxQb.FXzwW m-o3>Nb;x uEpm`m@4f;H |hbZh^AlƄ?&Ɵ4?Mz&ikοVMC?h?VMC?hZJUO&UO&=UO&UsO&=d?d?C\?\?C\?\?C\?\?C\?\?C\?\?C\?\?D\?\P8;7iOL4@k)#YH3('>־8i"t4/.m0@H?$(3؞1h(5]vvQ>sks"c =1GoQ>!A?}j7+.I+'^TzzEWS{cKͲJp.Ӵ7#qk>)Lֶ(cK1b-1(+Ͼ/x>zcKTnL{8Sy/JmJP6H #meKGԣtK Rh⽶u ~kEW'SKwi2,vԌ| +EmsƗ%Z1=ג(@CG<{QEQEQEQEQEQEQEQEQEQEQEQE%Pb(((((((Q@Q@Q@R@ E-QKEQEQEQEQEQEPERJ((PK(4bQE%PQKFh(4PEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEPEP ѢI&$*q{T8H5*ut'q@ x9>{cgZ=Vc|3<@?:;[;xH@ak#ICmQPs\ͷ%x#\֢eΑf]@w|Up9_Fj:>ıjzuj.`Y<'5xĉsG P HA )vSr:d|s ;Axl{+:C n  _5?h/v=y@!9OO6{{O hB#xF1lǀ\:+ֵF6X^d?x;^0tB+kh㉞ 7$&F;H˒=1T7ZΊW,>lc#|7[SDl5KT_ S늚Eҭ5m2n,N'$Ϡ~$Y]i_dP{ /yL(<*F?W^v|@%61Mo$ 2F/$;G$c:a'vW8>T4k>[M"iW,}bHîo_o+Gek_o}e'Gx?4[:k[|@_k[];"/!vY.Р}yK;hnm^:0 k3F"-cF,bQ@5߀] !ndCO\#x iVUC`|8z>lj5$5}&;A8 u&мQ=/>ϻwc=_ 4Ȓ1";F8yXy((((((((((((((( %Q@Q@isIE-Q@Q@Q@Q((((((((((()i)h4QEfF(4Q(((((((((((((((((((((((((((((:/x4|C4V(3!A+[<Ӽ)}sUZZǵSRyό{^]#PxxE4ۼew,E83׽Q~%kv>J\A*Y8,X#z:Ǐ| Cvķx0CAHf C_ľ0o>' ~6/nmRSs#m;Sylz_j+\Lq[$fH%Fv8>Jűx+WZ& $I#O`hc~=< 5ơ:/6ySFv2F+F|G{[yX}.Knh!{ &}WĿ|+ඛR͜bHNLE7aÍ{do|ak.eajB&Sq;;`rHtUP_aZNo!;.ghW?2&xNvqpQu8du8*ЏC֕yk[oC7صweJ&T \Wpg;٣ңI&p dZEyEާ÷^'u'G=š\Z+" Kv=G+6xwRt׵Hm-?0Ĝ>XtSjzȶo)Rw0Q Uu5t9V x!]b?ɣ6"k] o]…eVǾ ѼsWF쯿4DѲ Sqrpph2Լ[ /i#DoWyLT۰PEmŞx/ʹMけQ^?aox(f]ĚU)S30SJuލkH&Լ9$1l X|#ۼwҀ=:M*?֏u#O}Ae/, XddQA'oW֚bki H #j3ԀR+xDOi3YSqw  u`rl>_C}c6gmWRw137`!9FsN9 kMsK sB7g6׉;o]Ú[P-i5mUwn6X'@Exoo'Gki^Zv2TP 䓐1uuAd5ftLA$if`zm ^p DW jL1[O>ʷkJR Eu|1 89M^N7Ë}$YwhB\ 3~Cs@Y?4x]eޥɴ 1:JXBu(ն0,qtxgkkxc7a*  @{Բ O,ƊYݎԓTVW֚wv7P][IA tl0ƓW;Yg> 铻i)\h<C/Wkehdgӧ$8@Q^s?_i7Jt;{LZiRjI+h&n3g'zU3BƒogF0ӡ1!\$ v.!.˥߽\"S 08OKOoizxm)7G1aυ׮ZAvBXeW{2Fx8qwW'4SFnt/5V=w6Ü3xƞ(]K^ p_c^ăO͞(9վ,E |FtwkyVnܥqG!J'FxN*B[iaW8W23{Wx&m h-#_0.y Kwhq^GZY݆a8l`F<)I|Egtnt9ͽͤ+`ʲ9 7}ҷ(((1@bPEPEPEPEPEPEPEPEPEPEPEPEb (1F(Q((((((((((((((((((((((((((ϋ.}Km;y|{:8X<`\gox=Я"0E`5@uoj qgvz=iwNȱ]ĬB T0`+>*,`4jv3"Muk9?guJ5-'?-eK*W2| {Y|-!]2g&vGl.{5Q>j6V\YJi+w`/#=xU^u52^y?|wtS'װ@xׁ58n\7\{-"Di-crr1{ n- J3,BMMY ]9gM_ڏ5u,.kupTJP3ml{ŭ6nkvdB g<1LW<%P"YSԭPn<8}"`u/Oj|LK:HQt<ϻ ϐ@@^EyA|K<5 ݛSPH_˶5l$ zdU :[ڷW2m-i2y*mN={uW|5MŶe Ϋ+Ct񱍝Y! pgҬ>![)I籴Yb)$ʉ% +k ~|9\6Š߼9ߜ`(|u-\Bn%q#J^`pylV%'o歮r>Zt FqEy|[xE3薚}L@oݢ7޿PO'h|<~ ZOu}֐ŬE&\iBSx@a^<oqK RHPF AJ_O !ۋyc tx䍃+Aw2Bר@5t65ܒi`"S>2R} ݚB lQ;Kc%t]o}wA}"Fݎ'o4.l9=a{溑U@,3Y^9׮di[ėY㹴@e F(AE#{ĶOR299f8' գilm ʸd\ &>vMu6o)Hկ3~,` 0} vԬ?zgċRYP͏o!9 ;{x(bPTP0^{O7OCh?Xghbi1A .<>9X<=*<7%.HO|sQx,Zo &'ĺ5$\XL[%NE)@}r+[oV.Zwom۸l>f!F>Py_kAn~ӨmB#`t`N(-?P\Yiewq,W:Y/n;!l<׫|dVG]c@ , GqȡC>+]Bom|nhã`2PFӿho Goo%啂6aOs֬jk=g 𞸨Ez|E9!S\CJӵx KO[zs ȡF@`y?.9_o 拧\El\ 5:ĸj>Qz < CkݾZI |)ۅ뜐A@ӵM[Ouu0[}go)|یc%v֐EooڑDG@QEQER撊Z)((((((((((((Z( (%-4f\њJ(sIEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@``  `Q  _b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pphAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4   `|(  `D ` C A2P ` s *޽h ?"` 333380___PPT10.ކ0#ɂrw)C? S)XEj ( / 00DAria      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]_`abcdefghijklmnopqrstuvwxy{|}~lngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` 80lZ   _b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppmAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, $CAdverse effects_Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. Patients should be tapered off of I-blocker therapy in order to avoid precipitation of arrhythmias.The I-blockers should be avoided in treating patients with asthma, congestive heart failure, and peripheral vascular disease. ``6lZ|$  d$(  dr d S t 0   t r d S $t 0  t H d 0޽h ? 333380___PPT10.ކr$  h$(  hr h S  $t 0   t r h S l,t 0  t H h 0޽h ? 333380___PPT10.߆P$  l$(  lr l S Tt 0   t r l S t 0  t H l 0޽h ? 333380___PPT10.7rE0f2h^j? pElG( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` 80lZ   _b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppJAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, $CAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. |$  l$(  lr l S Tt 0   t r l S t 0  t H l 0޽h ? 333380___PPT10.7rl? lI\!( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` @8p]   !_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppWAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, $CAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. |ACE INHIBITORS "Actions: The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility. These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II v@J  ' $  p$(  pr p S (KS 0   S r p S FS 0  S H p 0޽h ? 333380___PPT10.pٴr? a!( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` H@t`   !"_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, $CAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. |ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin IIH  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.$[3$  p$(  pr p S (KS 0   S r p S FS 0  S H p 0޽h ? 333380___PPT10.pٴ$   t$(  tr t S aS 0   S r t S vt 0  t H t 0޽h ? 333380___PPT10. Tb\rQ B? -n#( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` PHxc   !"#_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses  Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combina- tion with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z Zrl$  0x$(  xr x S  0    r x S  0   H x 0޽h ? 333380___PPT10.r-r? #( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 RALLY-ACTING ADRENERGIC DRUGS actions õƬ 31test  õʾĸģ õƬ DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` PHxc   !"#_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 ppAnti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z $~ $  0x$(  xr x S  0    r x S  0   H x 0޽h ? 333380___PPT10.r-r "? $'( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` h`"l   !"#$%&_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp!Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. 6 M~$  @|$(  |r | S 5 0   5 r | S P5 0  5 H | 0޽h ? 333380___PPT10.j$  P$(  r  S 5 0   5 r  S p5 0  5 H  0޽h ? 333380___PPT10.Xs$  `$(  r  S L 0    r  S G 0   H  0޽h ? 333380___PPT10.P:2r-%0M?OkQ?  %S ,( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` x0%u!   !"#$%&'()_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp%Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. $ !"CENTRALLY-ACTING ADRENERGIC DRUGS " Clonidine  "actions Odiminishes central adrenergic outflow. Clonidine is used primarily for the treatment of mild to moderate hypertension that has not responded adequately to treatment with diuretics alone. does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment of hypertension complicated by renal disease. PP6'  c#  Clonidine is absorbed well after oral administration and is excreted by the kidney. Because it causes sodium and water retention, clonidine is usually administered in combination with a diuretic. Z6 z 9$  p$(  r  S P 0    r  S  0   H  0޽h ? 333380___PPT10.p|-$  $(  r  S % 0    r  S ( 0   H  0޽h ? 333380___PPT10.JҦ$  $(  r  S J 0    r  S `d5 0  5 H  0޽h ? 333380___PPT10.p1rS!0A? Sm#,( / 00DArialngs-0z[ 0D[SOalngs-0z[ 0 DTahomags-0z[ 00DWingdings-0z[ 0 A .  @n?" dd@  @@`` 8&x"   !"#$%&'()*_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp&Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. $ !"CENTRALLY-ACTING ADRENERGIC DRUGS " Clonidine  "actionsOdiminishes central adrenergic outflow. Clonidine is used primarily for the treatment of mild to moderate hypertension that has not responded adequately to treatment with diuretics alone. does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment of hypertension complicated by renal disease. PP6'  c#  Clonidine is absorbed well after oral administration and is excreted by the kidney. Because it causes sodium and water retention, clonidine is usually administered in combination with a diuretic. Z6 z 9$testMWhy are Levodopa (L-dopa) and carbidopa applied cooperately to treat PD? (6) P  $  $(  r  S 4 0    r  S  ~ 0   H  0޽h ? 333380___PPT10.`.r$? ε$n.( / 00DArialngs-0z[ 0"D[SOalngs-0z[ 0 DTahomags-0z[ 0"0DWingdings-0z[ 0 A .  @n?" dd@  @@`` 8&x"   !"#$%&'()*_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp!(Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. $ !"CENTRALLY-ACTING ADRENERGIC DRUGS " Clonidine  "actionsOdiminishes central adrenergic outflow. Clonidine is used primarily for the treatment of mild to moderate hypertension that has not responded adequately to treatment with diuretics alone. does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment of hypertension complicated by renal disease. PP6'  c#  Clonidine is absorbed well after oral administration and is excreted by the kidney. Because it causes sodium and water retention, clonidine is usually administered in combination with a diuretic. Z6 z 9$testWhy are Levodopa (L-dopa) and carbidopa applied cooperately to treat PD? (6) What is mode of action of benzodiazepines? (4) According to opioid s action? Why was it thought to be a  catholicon at 19 s century? (6)ZZ  NE$  $(  r  S 4 0    r  S  ~ 0   H  0޽h ? 333380___PPT10.`.r $? $.( / 00DArialngs-0z[ 0"D[SOalngs-0z[ 0 DTahomags-0z[ 0"0DWingdings-0z[ 0 A .  @n?" dd@  @@`` 8&x"   !"#$%&'()*_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp3(Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. $ !"CENTRALLY-ACTING ADRENERGIC DRUGS " Clonidine  "actionsOdiminishes central adrenergic outflow. Clonidine is used primarily for the treatment of mild to moderate hypertension that has not responded adequately to treatment with diuretics alone. does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment of hypertension complicated by renal disease. PP6'  c#  Clonidine is absorbed well after oral administration and is excreted by the kidney. Because it causes sodium and water retention, clonidine is usually administered in combination with a diuretic. Z6 z 9$testWhy are Levodopa (L-dopa) and carbidopa applied cooperately to treat PD? (6) What is mode of action of benzodiazepines? (4) According to opioid s action? Why was it thought to be a  catholicon at 19 s century? (6)Zl  N1$  $(  r  S 4 0    r  S  ~ 0   H  0޽h ? 333380___PPT10.`.r$p? $.( / 00DArialngs-0z[ 0"D[SOalngs-0z[ 0 DTahomags-0z[ 0"0DWingdings-0z[ 0 A .  @n?" dd@  @@`` 8&x"   !"#$%&'()*_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp3(Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  '      Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. $ !"CENTRALLY-ACTING ADRENERGIC DRUGS " Clonidine  "actionsOdiminishes central adrenergic outflow. Clonidine is used primarily for the treatment of mild to moderate hypertension that has not responded adequately to treatment with diuretics alone. does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment of hypertension complicated by renal disease. PP6'  c#  Clonidine is absorbed well after oral administration and is excreted by the kidney. Because it causes sodium and water retention, clonidine is usually administered in combination with a diuretic. Z6 z 9$testWhy are Levodopa (L-dopa) and carbidopa applied cooperately to treat PD? (6) What is mode of action of benzodiazepines? (4) According to opioid s action? Why was it thought to be a  catholicon at 19 s century? (6)Zl  N1r? `F$.( / 00DArialngs-0z[ 0"D[SOalngs-0z[ 0 DTahomags-0z[ 0"0DWingdings-0z[ 0 A .  @n?" dd@  @@`` 8&x"   !"#$%&'()*_b$;枚"pD0 2$$i,cn 2$*[,<3@*?UR$KȝHfBMhyR$A7(86 Jeh"8 0AA@8  3ʚ;ʚ;g4[d[d z[ 0ppp@ <4ddddL 0- 80___PPT10 pp3(Anti hypertensive Drugs   OVERVIEW Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg).   jcan lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. O ETIOLOGY OF HYPERTENSION (more than 90% of patients have essential hypertension, a disorder of unknown origin affecting the blood pressure-regulating mechanism. Inheritance factors Environmental factors such as a stressful lifestyle, high dietary intake of sodium, obesity, *MECHANISMS FOR CONTROLLING BLOOD PRESSURE +) (In both normal and hypertensive individuals, cardiac output and peripheral resistance are controlled mainly by two overlapping control mechanisms: the baroreflexes mediated by the sym- pathetic nervous system, and the renin-angiotensin-aldosterone system, 7 TREATMENT STRATEGIES iMild hypertension can often be controlled with a single drug. More severe hypertension may require treatment with several drugs that are selected to minimize adverse effects of the combined regimen. Treatment is initiated with any of four drugs depending on the individual patient: a diuretic, a beta-blocker, an ACE inhibitor, or a calcium channel blocker. TjZ1 7 N   DIURETICS Diuretics are currently recommended as the first-line drug therapy for hypertension. Low-dose diuretic therapy is safe and effective in preventing stroke, myocardial infarction, congestive heart failure and total mortality.  Thiazide diuretics  ~All oral diuretic drugs are effective in the treatment of hypertension, but the thiazides have found the most widespread use. .P     %   Actions7hydrochlorothiazide lower blood pressure, initially by increasing sodium and water excretion. This causes a decrease in extracellular volume, resulting in a decrease in cardiac output and renal blood flow. With long-term treatment, plasma volume approaches a normal value, but peripheral resistance decreases. 88x  Therapeutic usesin both the supine and standing positions; postural hypotension is rarely observed. useful in combination therapy with a variety of other antihypertensive agents including beta-blockers and ACE inhibitors. are particularly useful in the treatment of black or elderly patients, and in those with chronic renal disease. Thiazide diuretics are not effective in patients with inadequate kidney functionZ?I PharmacokineticsThiazide diuretics can be administered orally. They induce considerable disturbances in electrolyte balance. For example, blood levels of K + and Mg ++ are reduced, and Ca ++ is retained by the body HAdverse effects3induce hypokalemia and hyperuricemia in 70% of patients, and hyperglycemia in 10% of patients. Serum potassium levels should be monitored closely in patients who are predisposed to cardiac arrhythmias Diuretics should be avoided in the treatment of hypertensive diabetics or patients with hyperlipidemia. 44>  "beta-ADRENOCEPTOR BLOCKING AGENTS beta-Blockers and/or diuretics are currently recommended as first-line drug therapy for hypertension. These drugs are efficacious but have some contraindications. Actions The beta-blockers reduce blood pressure primarily by decreasing cardiac output. They may also decrease sympathetic outflow from the CNS and inhibit the release of renin from the kidneys, thus decreasing the formation of angiotensin II and secretion of aldosterone. >4  Therapeutic uses Subsets of the hypertensive population: The beta-blockers are more effective for treating hypertension in white than in black patients, and in young patients compared to the elderly. Conditions that discourage the use of beta-blockers (for example, severe chronic obstructive lung disease, chronic congestive heart failure, severe symptomatic occlusive peripheral vascular disease) are more commonly found in the elderly and in diabetics.] ZTherapeutic usesHypertensive patients with concomitant diseases: The beta-blockers are useful in treating conditions that may coexist with hypertension, such as supraventricular tachyarrhythmia, previous myocardial infarction, angina pectoris, DAdverse effects|Drug withdrawal: Abrupt withdrawal may cause rebound hypertension, probably as a result of up-regulation of beta-receptors. ACE INHIBITORS These drugs block the angiotensin converting enzyme that cleaves angiotensin I to form the potent vasoconstrictor, angiotensin II>  ' Actions:The ACE inhibitors lower blood pressure by reducing peripheral vascular resistance without reflexly increasing cardiac output, rate, or contractility.[4Therapeutic uses Like beta-blockers, ACE inhibitors are most effective in hypertensive patients who are white and young. However, when used in combination with a diuretic, the effectiveness of ACE inhibitors is similar in white and black hypertensive patients. Unlike beta-blockers, ACE inhibitors are effective in the management of patients with chronic congestive heart failure. ACE inhibitors are now a standard in the care of a patient following a myocardial infarction. Therapy is started 24 hours after the end of the infarction.  Z CALCIUM CHANNEL BLOCKERS ;Diphenylalkylamines: Benzothiazepines: Dihydropyridines: @Actions Calcium channel antagonists block the inward movement of calcium by binding to L-type calcium channels in the heart and in smooth-muscle of the coronary and peripheral vasculature. This causes vascular smooth muscle to relax, dilating mainly arterioles. &"   Therapeutic useshave an intrinsic natriuretic effect; therefore, they do not usually require the addition of a diuretic. are useful in the treatment of hypertensive patients who also have asthma, diabetes, angina, and/or peripheral vascular disease. $ !"CENTRALLY-ACTING ADRENERGIC DRUGS " Clonidine  "actionsOdiminishes central adrenergic outflow. Clonidine is used primarily for the treatment of mild to moderate hypertension that has not responded adequately to treatment with diuretics alone. does not decrease renal blood flow or glomerular filtration and therefore is useful in the treatment of hypertension complicated by renal disease. PP6'  c#  Clonidine is absorbed well after oral administration and is excreted by the kidney. Because it causes sodium and water retention, clonidine is usually administered in combination with a diuretic. Z6 z 9$testWhy are Levodopa (L-dopa) and carbidopa applied cooperately to treat PD? (6) What is mode of action of benzodiazepines? (4) According to opioid s action? Why was it thought to be a  catholicon at 19 s century? (6)Zl  N1rF? pFu$Root EntrydO)@{DPicturesZCurrent User 8SummaryInformation(ZC     ^      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]_`abcdefghijklmnopqrstuvwxy{|}~|"R OD PRESSURE õƬ 7TREATMENT STRATEGIES õƬ 9 DIURETICS Thiazide diuretics õƬ 12ActionsTherapeutic usesPharmacokineticsAdverse effects _,u΢û_o(u7b#beta-ADRENOCEPTOR BLOCKING AGENTS Actions õƬ 19Therapeutic uses Therapeutic usesAdverse effectsACE INHIBITORS Actions:Therapeutic uses CALCIUM CHANNEL BLOCKERS Actions Therapeutic uses#CENT